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CHAPTER ONE
Introduction
1.1 Historical aspects
“This is arterial blood: I  cannot be deceived by its colour. It is my death 
warrant. ”
John Keats (Cook, 1995)
On a winter evening in London in 1818, the Romantic poet John Keats coughed 
up blood on his pillow. As a qualified doctor, he knew what it meant. In February 23, 
1821, after hopeless treatments, Keats was pronounced dead.
Tuberculosis (TB) is one of the most historically important diseases. A number 
of characteristic and pathognomonic lesions in prehistoric skeletons and in Egyptian 
mummies have been attributed to it (Zink, 2003). A slowly but inexorably 
progressive and debilitating disease called pthisis (a Greek word; the lay equivalent 
would be “consumption”) was certainly known to Hippocrates and his circle. Roman 
doctors described terminal tuberculosis with accuracy. The Black Death of the 
fifteenth century is said to have wiped out a third of Europe’s population and Cholera 
epidemics and other diseases still killed more than tuberculosis. But TB was unlike 
any of these. It was a killer but it also transformed the lives of its victims; it became a 
formative influence in art, music and literature (Dormandy, 1999), it challenges 
doctors, governments and society from antiquity well into our days.
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Tuberculosis was one great engine pushing the Romantic Movement in the 
eighteenth and nineteenth century. It seemed to single out the young, talented and 
famous -  writers, poets and playwrighters; artists; musicians; courtesans; society 
beauties and scientists. The list of famous people who died from TB is long: from 
Renee Laennec to Edward Trudeau; from Moliere to Chekov; Dostoyevsky; the 
Bronte family; Modigliani; writers like Franz Kafka, D.H. Lawrence and George 
Orwell (Reichman & Tanne, 2001). Although TB picked out and killed a few princes, 
it slaughtered the poor by the million. Overcrowding, poverty and malnutrition were 
all found together during the Industrial Revolution. It is not surprising that especially 
during this period, death toll by tuberculosis had a massive increase, particularly 
between the young and poor in England (Dormandy, 1999). The phenomenon is 
transposable, with the appropriate adjustments, to other countries. In America, TB 
became epidemic closely after the arrival of industrialisation. Tuberculosis spreads 
more easily when people are in close contact with an infected person. Men, women 
and children working packed against each other into poorly ventilated factories (“the 
dark satanic mills”, as the poet William Blake used to call them), were the perfect 
breeding site for TB (Reichman & Tanne, 2001).
Escape from illness by moving to another place is probably as ancient as hope. In 
Europe, the pilgrimage of consumptives initially started to leave the northern fog for 
more gentle skies in Italy or the south of France. Following this, the sanatorium 
movement arrived, which combined the features of a hospital with those of a luxury 
hotel, in towns situated at high altitude. The beginning of this movement (between 
other reasons) could have its origins from a mistaken belief that tuberculosis was 
caused by a weakened heart and that reduced atmospheric pressure could help 
(Dormandy, 1999). As expected, sanatoriums, with its regimen of an intended 
healthy lifestyle, good nutrition and gradually increasing exercise (sometimes too
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forceful on TB sufferers) became very fashionable on the 19th and first half of the 20th 
century. The Magic Mountain (1927), a novel written by the 1929s Nobel Prize 
winner Thomas Mann, described this lifestyle superbly. By 1923, there were 656 
sanatoriums with 66.000 beds in the United States alone. However, the sanatoriums, 
with its draconian demands, had absolutely no effect in curing TB (Reichman & 
Tanne, 2001), although the effects of direct sunlight, more specifically ultraviolet 
rays, are fatal for TB bacteria (some forms of skin tuberculosis were even cured by a 
special lamp in the 19th century), the death rate in and out of the sanatoriums were 
about the same (Reichman & Tanne, 2001). In reality, perspectives of cure and 
prevention of this terrible disease looked distant and were yet to come.
1.2 The causative agent: Mycobacterium tuberculosis
Mycobacterium tuberculosis (MTB) is a bacterium and causes tuberculosis. 
However this concept has only been known for 122 years. Before, tuberculosis was 
commonly attributed to several causes, from heredity to “dampness of the soil”, but 
few believed it would be contagious and caused by a microbe. However the past is 
punctuated with clues. The Italian physician Girolamo Fracastoro postulated in 1546 
that diseases such as phtisis were transmitted by invisible particles that could survive 
outside the body and still infect. Jean Antoine Villemin (1827-1892), a French army 
doctor performed a series of convincing and controlled experiments on the infectious 
nature of tuberculosis in animals. However, the medical establishment at the time 
could not accept such “heretic ideas” (Dormandy, 1999). It came to Robert Koch, a 
brilliant 38-year-old German physician, to present to a stunned audience on March 
24, 1882, that through an elegant four-step procedure (the “Koch-Henle postulates”),
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tuberculosis was indeed an infectious disease caused by a bacterium. He won the 
Nobel Prize for medicine and physiology in 1905 (Kaufmann, 2001).
The genus Mycobacterium, belonging to the order Actimicetales and to the 
Mycobacteriaceae family, consists of members of the Mycobacterium tuberculosis 
complex and more than 80 species of non-tuberculous mycobacteria, including 
pathogenic, opportunistic, and non-pathogenic species (Soini & Musser, 2001). M. 
tuberculosis and M. leprae (causing leprosy) are the human pathogens of most 
notable significance in this genus. In the tissues, M. tuberculosis are non-motile 
straight rods, measuring 0.4 X 3 micrometers, which do not sporulate. They are 
characterised by a resistance to destaining by 95% ethanol, 3% hydrochloric acid 
(acid-fast stain), a feature that depends on the thick and complex cell envelope, an 
additional layer after the peptidoglycan, rich in lipids and glycolipids. M. tuberculosis 
is a slow-growing organism (average generation time of 24h) and is considered a 
Gram-positive bacteria since they possess a single cytoplasmic membrane (Black, 
2001). The M. tuberculosis complex comprises M. tuberculosis together with M. 
africanum, M. bovis, M. canettii and M. microti. The subspecies are very alike 
(99.9% similarity at the nucleotide level) and can only be distinguished by a limited 
number of phenotypic or genotypic characteristics, but differ remarkably with respect 
to host range and pathogenicity; whereas M. microti is an almost exclusive rodent 
pathogen, M. bovis infects a variety of species including humans (Brosch, 2001).
It has been said that M. tuberculosis has evolved from M. bovis (which causes 
bovine TB) by adaptation of the animal pathogen to the human host (Stead, 1995), 
approximately 10,000 years ago, when people first settled down to tend their cattle. In 
a comparative genomic analysis between the M. tuberculosis H37Rv genome (see 
below) with the partially sequenced M. bovis genome, Brosch and colleagues (2002) 
have proposed that M. bovis has undergone several deletions relative to MTB; in fact,
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it is the final member of a separate lineage inside of the MTB complex that branched 
from a progenitor of MTB isolates (Brosch, 2002). Whether this progenitor, at the 
time of branching of MTB strains and M. africanum —» M  bovis lineage, was already 
a human pathogen is subject to speculation. Complete sequencing of the M. bovis 
genome has confirmed these predictions (Gamier, 2003).
The completion of the whole-genome sequence for M. tuberculosis H37Rv 
strain (Cole, 1998) is a hallmark in tuberculosis research. The annotated sequence has 
revealed a 4.41 megabase genome with regions of higher than average G (guanine) + 
C (cytosine) content. Few organisms display the extensive array of genes for 
lipophilic molecules identified in MTB (Cole, 1998). The genome of MTB is rather 
stable, single-nucleotide polymorphisms are rare; insertion and deletion events 
(InDels) are the principal source of genome plasticity (Brosch, 2001). However, a 
recent study (Fleischmann, 2002) comparing whole genomes in silico of laboratory 
strain H37Rv and clinical isolate CDC1551 has identified frequent polymorphisms 
and suggests that these may be not so rare between MTB strains.
The MTB genome sequencing also brought to light two large families 
(roughly 10% of the genome) of novel glycine-rich proteins; they were characterised 
by a conserved amino-terminal segment with either a proline-glutamic acid (PE) or a 
proline-proline-glutamic acid (PPE) motif; some were combined with a carboxy- 
terminal domain comprising varying numbers of short repetitive motifs (PE-PGRS or 
PPE-MPTR). These proteins are highly polymorphic and were suggested to be a 
source of antigenic diversity in the bacillus (Cole, 1998; Banu, 2002). In addition, 
members of this family have been implicated in the pathogenesis of M. tuberculosis 
(Camacho, 1999), M. marinum (Ramakrishnan, 2000) and M. bovis BCG (Brennan,
2001). The Gly-Ala-rich domain (PGRS) present in some PE proteins may influence
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proper antigen presentation to the host and may prevent the development of an 
effective cellular immune response (Delogu, 2001).
1.3 The disease: notes on diagnostic, treatment and epidemiology
In the nineteenth century, health officials prohibited the act of spitting in 
public; they thought erroneously that it was a major cause of tuberculosis infection 
(Reichman & Tanne, 2001). However, virtually all M. tuberculosis is transmitted by 
airborne particles that are 1 to 5 pm in diameter (fig. 1.1). Usually, only the 
pulmonary form of tuberculosis is transmissible. Transmission is greatly influenced 
by characteristics of the source case (number of bacteria excreted, etc.) and the nature 
of the encounter (such as the duration and closeness of exposure). However, 
regardless of these factors, infection can result when as few as one to five bacteria are 
deposited in a terminal alveolus (Small & Fujiwara, 2001).
After infection, a precarious balance is struck between the host and the 
pathogen. In about 5 percent of persons, the infection progresses from a latent form to 
active disease within two years after infection, and an additional 5 percent have active 
disease at some later point in their lives (Small and Fujiwara, 2001). Although less 
common, exogenous reinfection instead of reactivation can occur, especially in 
individuals who are highly exposed or HIV-infected (van Rie, 1999).
A subgroup of infected people may develop primary tuberculosis, which in 
most cases is a self-limited, mild pneumonic illness that generally goes undiagnosed. 
Briefly, at the site of the bacilli, there is an alveolitis with arrival of monocytes and 
polymorphonuclear cells. The tubercle is then organised with histiocytes, surrounded 
by epithelioid cells. These are differentiated macrophages with large endoplasmic 
reticulum. They fuse to form giant multinucleated Langerhans cells (Roitt, 2001). At
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Figure 1.1 Transmission of tuberculosis and progression from latent infection 
to reactivated disease. Approximately 10% of infected, HIV-seronegative 
individuals will develop tuberculosis at some point in their lives. In five percent of 
people with latent infection, active disease will develop within two years, and in an 
additional 5%, progression to active disease will occur later. The rate of progression 
to active disease is dramatically increased among people co-infected with HIV. 
Modified from Small and Fujiwara (2001).
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the periphery, there are lymphocytes and fibroblasts. The centre of the tubercle may 
suffer caseous necrosis (caseification). The described structure is called a tuberculous 
granuloma and is a hallmark of tuberculosis (Robbins, 1986). From this structure, the 
bacilli may be drained to the regional lymph nodes where other granulomas may also 
form. The complete structure is called the primary complex (Ghon’s complex). Often, 
the infection is aborted at this stage without further significance; a calcified nodule is 
eventually observed in a x-ray of the area. Nonetheless, viable bacilli may persist for 
years (Tarantino, 2002).
Again, in a small proportion of the infected, usually children, there is 
progression of the primary disease. Exudative infiltration with variable degree of 
consolidation can be seen in the pulmonary parenchyma. If caseation is present, the 
progression of the disease is faster and the prognosis is worse. Miliary dissemination 
can occur; the term “miliary TB” refers to the small, discrete granulomatous lesions 
in lungs and other organs that result when blood-borne tubercle bacilli seed many 
tissues (Fanning, 1999). Pathology of pulmonary lymph nodes during the primary 
disease is a frequent finding in children. An increase in volume of the hilar- 
paratracheal nodes can seriously compress the bronchi and restrict airflow (Tarantino, 
2002).
There are clinical and experimental evidence that M. tuberculosis can persist 
in tissues for months to decades without replicating, yet with the ability to resume 
growth and activate disease, a characteristic named “dormancy” or “nonreplicating 
persistence (NRP)” (Wayne & Sohaskey, 2001). Post-mortem examination of tissues 
from asymptomatic individuals living in high-incidence areas and that died from 
causes unrelated to tuberculosis frequently reveals the bacillus in culture (Young,
2002). With time to adapt, the tubercle bacilli can survive on microaerophilic or 
anaerobic environments, restrictive conditions found inside granulomas and necrotic
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tissues in vivo; in these conditions of hypoxia, genes coding for regulatory functions 
are activated (Wayne & Sohaskey, 2001). In response to alternative energy sources, 
the NRP bacilli increase expression of isocitrate lyase, an enzyme from the glyoxylate 
cycle that allows the bacteria to use acetate or fatty acids as the sole carbon source 
(McKinney, 2000). Changing the cell wall architecture seems also important for the 
persistence of MTB in vivo (Seiler, 2003). In such cases of latent tuberculosis, the 
host mounts a strong immune response that frequently contains but does not eliminate 
the infection; disruption of immune mechanisms can lead to reactivation of the 
disease in both humans and animals (North & Jung, 2004).
Secondary tuberculosis could start with an early exudative-inflammatory 
process with pneumonic characteristics. The lesion, as seen in x-rays, shows 1-2 cm 
of diameter. With progression, classical symptoms may appear: cough, fever, and 
expectoration, sometimes with traces of blood; anorexia, night sweats and weight 
loss. Caseation and cavitation can be present in the lungs, frequently in the upper 
lobes. The dissemination of caseous material can spread the infection to other regions 
of the lung. If this process develops in an acute form it can result in caseous 
pneumonia with extensive consolidation areas or caseous bronchopneumonia, both 
being very serious forms of TB. When the early infiltrate is driven to chronicity, the 
process can stabilise and fibrosis develops (Tarantino, 2002). The person with the 
disease can live for many years, however periodic episodes of haemoptisis are not 
uncommon and can be life-threatening.
Besides its preference for the lung, the tubercle bacillus can ultimately infect 
and cause disease in any human organ (Tarantino, 2002). The extrapulmonary forms 
of tuberculosis are again raising in frequency nowadays, an event particularly linked 
to the AIDS epidemic. Extrapulmonary TB accounts for 62% of cases in HIV- 
infected people compared to 20% in non-HIV-infected (Fanning, 1999). The most
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commonly affected extrapulmonary site is the lymph node. TB meningitis has the 
highest rates of mortality (Fanning, 1999).
Definitive diagnosis of mycobacterial disease usually involves the isolation 
and identification of the infecting organism in the laboratory. The recommended 
procedure for clinical specimens involves decontamination and solubilisation of the 
material, microscopic examination for the presence of acid-fast bacilli, isolation by 
culture, identification and drug susceptibility testing. However, because of the slow 
growth rate of the organism, these procedures can take several weeks (Hale, 2001). 
Recently, several molecular methods have been developed to reduce diagnostic time. 
Nucleic-acid amplification (NAA) with genus-specific primers based on the 16S 
ribosomal RNA gene (Amplicor; Roche Diagnostic Systems, Branchburg, NJ) can 
detect specifically M. tuberculosis complex bacteria directly from smear-positive 
clinical specimens in a few hours (Watterson & Droboniewski, 2000). Another NAA 
kit, the Enhanced Mycobacterium Tuberculosis Direct Test (E-MTD, Genprobe, San 
Diego, CA), based on isothermal amplification of reverse transcribed ribosomal RNA 
from mycobacteria, has been approved by the FDA to aid the diagnosis of smear- 
negative specimens (Soini & Musser, 2001). Culture of mycobacteria in liquid and 
solid media is still required because of its higher sensitivity, growth of the organism 
for precise species identification and drug susceptibility testing. In this regard, the use 
of nucleic-acid probes (AccuProbe®, Gen-Probe Inc) allows differentiation between 
tuberculous and non-tuberculous bacteria such as M. avium complex (Hale, 2001). 
Identification of species within the M. tuberculosis complex is a difficult task. High- 
performance liquid chromatography (HPLC), for the analysis of mycolic acid esters, 
allows differentiation of BCG from M. tuberculosis and M. bovis (Floyd, 1992). 
Although imperfect (cross-reactivity with BCG and environmental bacteria), the 
tuberculin skin test, an intradermal injection of purified protein derivative in the
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surface of the forearm, remains the gold standard for the diagnosis of latent 
tuberculosis (Small & Fujiwara, 2001). A significant induration at the site, measured 
in millimeters, 48-72 hours after injection, when correlated with the medical history 
of the patient, can frequently indicate a long-standing infection.
Tuberculosis cases must be reported to public health authorities; besides 
treating the patient, protection of the community is essential. Five first-line 
antimicrobial agents (isoniazid, rifampin, pyrazinamide, ethambutol and 
streptomycin), form the basis of the currently recommended anti-tuberculosis therapy. 
The recommended protocol include initial treatment with three or four drugs for two 
months, followed by a four-month continuation phase in which two drugs are 
administered (Small & Fujiwara, 2001).
Second-line medications (capreomycin, ciprofloxacin and others) could be 
less effective and more toxic than first-line drugs; only patients who cannot tolerate 
first-line drugs or are infected with organisms that are resistant to them should use 
second-line drugs. HIV-infected persons with full compliance to standard treatment 
for tuberculosis do not have increased risk of treatment failure (Small & Fujiwara, 
2001). In addition, anti-tuberculous chemoprophylaxis has been shown to reduce the 
incidence of tuberculosis in HIV-infected patients (Maartens, 2002). Preventive 
therapy of immunocompetent adults with latent tuberculosis infection has a protective 
efficacy in the range of 60-80% (Borgdorff, 2002).
If untreated, TB is frequently lethal. Modem chemotherapy is highly 
successful provided a well-designed drug regimen is taken as planned. Programs of 
directly observed therapy (DOT) where an individual is assigned to assure 
compliance of TB patients to chemotherapy have been devised. A review of ten years 
of trials has concluded that, if well implemented, such programs are indeed superior 
to unsupervised pill taking (Hill, 2002). DOTS, an acronym used since 1995,
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originally stood for directly observed therapy short course, but actually, as developed 
by the International Union against Tuberculosis and Lung Disease (IUATLD), 
consists of a menu of five specific elements: a national TB control program, 
laboratory monitoring, directly observed therapy, a constant supply of first-line anti- 
mycobacterial drugs, and good recording and reporting. It represents the current 
World Health Organisation (WHO) TB control strategy (Elzinga, 2004).
Multidrug-resistant tuberculosis (MDR-TB) is defined as infection with 
strains resistant to at least isoniazide and rifampicin. Rifampicin is bactericidal to 
mycobacteria and the most important anti-tuberculous drug. It inhibits the synthesis 
and function of mycobacterial DNA-dependent RNA polymerase (Sefton, 2002). A 
mutation in a region of the mycobacterial rpoB gene that encodes the p-subunit of 
RNA polymerase leads to an alteration of the rifampicin-binding site and resistance 
(Hirano, 1999). Isoniazide resistance is most commonly associated with missense or 
null mutations in the katG gene, which codes for a catalase-peroxidase enzyme that 
converts isoniazide into its bioactive form (Pym, 2002). MDR-TB strains with 
resistance up to twelve anti-mycobacterial drugs at the same time have been found in 
patients from a study in Peru (Mitnick, 2003). Nonetheless, MDR-TB is curable, but 
therapy is complex. A community-based method to treat MDR-TB named DOTS-plus 
has been reported to attain high rates of treatment success (Mitnick, 2003). Second- 
line drugs are used and the regimen includes two or more drugs to which the isolate is 
susceptible, including one drug given parenterally for six months. The duration of this 
observed treatment is 18-24 months (Sterling, 2003).
Pathogens from the M. tuberculosis complex cause epidemics that run over 
centuries (Dye, 2002). A consensus statement by a panel of experts from the WHO 
estimated that in the year of 1997, there were 7.96 million new cases of TB in the 
world with around 2 million deaths and 1.86 billion people infected (Dye, 1999). TB
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is the most frequent cause of death due to a single pathogen. It is a leading killer 
between people with HIV/AIDS. Comments such as “TB is arguably the most 
successful pathogen on the planet” (Jacobs, W. R., in Enserink, 2001) are not out of 
place. In the later 1980s, after decades of steady declining, TB was considered a 
disease of the past in first-world countries. However, the synergistic combination of a 
deteriorating public health infrastructure, inadequate institutional control, urban 
crowding, the epidemic of HIV infection, and immigration resulted in the resurgence 
of tuberculosis in the United States between 1985 and 1992 (Small & Fujiwara, 
2001). A highly infectious MDR strain (strain W), invariably unbeatable with five 
anti-mycobacterial drugs, was identified and disseminated rapidly in New York City, 
an epidemic epicenter (Bifani, 2002). In this scenario, molecular techniques, like 
DNA-fingerprinting, have been important to study pathways of TB transmission. The 
transposable element IS6110 is the most used marker; it varies both in copy number 
and location inside the genome (Bifani, 2002).
The perceived threat of pandemic drug-resistant TB is enormous, with the 
potential to destabilise society. However, MDR-TB is at critical levels only in 
specific regions of the world. Highest rates of MDR strains have been observed 
mainly in Eastern Europe and in some provinces of China (Espinal, 2003). Most of 
the cases are generated by poor treatment protocols with first-line drugs.
1.4 Thl-Th2 immune responses
The immune response has primarily evolved to defend the host against 
pathogens and to avoid reactivity to self. Thymus-derived lymphocytes (T cells) are 
the prime conductors of this response and they vary in type and function. By the early 
1970s, it was commonly accepted that T cells could be divided into two distinct
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subsets on the basis of their cell-surface markers: CD4+ (Lyt 1) T cells that could 
“help antibody synthesis” (therefore, helper T cells) and CD8+ T cells (Lyt 2), which 
lysed pathogen-infected target cells on direct contact (Liew, 2002). Evidences 
suggesting that helper CD4+ T cells were heterogeneous were confirmed in 1986 
when Mosmann, Coffman and colleagues characterised two distinct types of CD4+ T 
cells from a panel of murine T helper (Th) cell clones, according to patterns of 
cytokine production (Mosmann, 1986). Adopting an earlier nomenclature (Tada, 
1978), they named T h l the T cell clone producing interleukin-2 (IL-2), interferon- 
gamma (IFN-y), granulocyte-macrophage colony stimulating factor (GM-CSF) and 
IL-3 in response to antigen presented by antigen-presenting cells (APCs). Type 2 T 
helper cells (Th2) on the other hand, produced a B-cell stimulating factor (identified 
later as IL-4), mast-cell growth factor (IL-5) and IL-3 (Mosmann, 1986). In addition, 
the Th2 clone had the ability to enhance the production of immunoglobulin (Ig) E and 
IgGl by lypopolysaccharide (LPS)-induced B cells. Thl cells are responsible for the 
induction of IgG2a switching by B cells (Stevens, 1988).
These findings were confirmed later in humans with the characterisation of 
specific clones producing either IFN-y or IL-4/IL-5 in response to M. tuberculosis or 
Toxocara canis, respectively (Romagnani, 1991). After encountering antigen, i.e., 
engagement of the T cell receptor (TCR) by the appropriate peptide-major 
histocompatibility complex (MHC) molecule, which triggers clonal expansion, naive 
Th cells rapidly undergo programmed differentiation to become effector Thl or Th2 
cells. The products of these lymphocytes can act as autocrine growth factors to 
promote further expansion of these cells, as well as reciprocal inhibitory agents for 
the opposite cell type (fig. 1.2). In general terms, IL-4 can help the clonal expansion 
of Th2 population and limit the proliferation of Thl cells; conversely, IFN-y 
enhanced Thl-cell growth and inhibits Th2-cell development (Liew, 2002).
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Figure 1.2 Schematic representation of induction and regulation of Thl and 
Th2 cells. The Th-precursor (ThP) cell can differentiate into T-helper (Th)l, Th2 or 
ThO cells depending on factors such as the cytokine microenvironment. Interleukin 
(IL)-12 drives Thl cells, and IL-4 can promote Th2 cells. ThO cells differentiate in 
neutral conditions with optional IL-2. Interferon-y (IFN-y) and IL-4, produced by Thl 
and Th2, respectively, can also act as autocrine growth factors as well as inhibitory 
factors for the opposite subset. Functionally, Thl mediate the destruction of 
intracellular pathogens and organ-specific autoimmunity. Th2 cells are anti­
helminthic and increase allergic reaction through IL-4, IL-5 and IgE. IL-4R, IL-4 
receptor; NKT, natural killer cells; TCR, T-cell receptor. Modified from Liew (2002).
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In addition to TCR engagement, IL-12 produced by macrophages and 
dendritic cells, has been shown to be a major factor in the production of IFN-y and the 
development of the Thl phenotype (Hsieh, 1993; Robinson & O’Garra, 2002). On the 
other hand, IL-4, which besides T cells, is produced by different cell types such as 
natural killer T cells and mast cells, has been shown to be essential for Th2 cell 
development (Seder, 1992), although inducible Th2 responses in vivo, have been 
reported in absence of IL-4 (Fallon, 2002). Therefore, Thl/Th2 T cell populations 
may share a common precursor and at the onset of the response, the cytokine milieu 
is primordial in lineage decision. Nonetheless, antigen dose and affinity, MHC 
haplotypes and co-stimulators may have crucial roles in determining the dominance 
of a Th response (Liew, 2002; Murphy & Reiner, 2002; Szabo, 2003). This is actually 
an area of intense investigation and lively controversy.
The Th2 cells are typically involved in optimal antibody production, non- 
phagocytic immunity (protection against extracellular invaders such as helminthes) 
and in inappropriate immune responses generated in atopic diseases and asthma. 
Cross-linking of IgE bound to its receptor results in degranulation of mast cells, 
basophils and eosinophils (Roitt, 2001). Besides IL-4 and IL-5, Th2 cells often 
produce IL-6, IL-9, IL-10 and IL-13 cytokines, and this cytokine network can operate 
redundantly to sustain a Th2 response even in the lack of one or more key cytokines 
(Fallon, 2002). The binding of IL-4 to the IL-4 receptor in the surface of naive Th- 
cells activates STAT6 (signal transducer and activation of transcription 6) protein, 
which efficiently increases the expression of a zinc-finger transcription factor called 
GATA3 (Zheng & Flavell, 1997). GAT A3 is crucial to some key attributes of Th2 
cells (Pai, 2004), acting directly on certain cytokine promoters, or indirectly trough 
cis elements, to instruct the cell to revert chromatin-based loci repression of Th2 
cytokines (Murphy & Reiner, 2002). The IL-4/STAT6 signalling pathway can
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mediate selective proliferation of Th2 cells by inducing a new transcription factor, the 
growth factor-independent 1 (Gfi-1) (Zhu, 2002).
Appropriate induction of a Thl response is required for effective control of 
intracellular pathogens; in contrast, disproportionate Thl responses could ultimately 
lead to immunopathology and organ-specific autoimmunity (Robinson & O’Garra,
2002). Thl cells produce IL-2, lymphotoxin-a3 and IFN-y (Roitt, 2001), the latter 
being essential for activity and maintenance of Thl responses. Transcription factor 
T-bet has been identified as a Thl-specific transcriptional regulator that could induce 
production of IFN-y even by Th2 cells (Szabo, 2000). T-bet is strongly induced in 
naive T cells by IFN-y signalling trough STAT1 and can promote expression of IL-12 
receptor p2-subunit in such cells (Afkarian, 2002; Szabo, 2003). An onset scenario 
for Thl responses would involve, between other factors, the engagement of the TCR 
by antigen in a milieu of IFN-y produced by natural killer (NK) cells, favouring T-bet 
expression and initiation of Thl cell-differentiation.
Other cytokines are also reportedly involved in the development of the Thl 
responses. IL-18, a cytokine produced by both immune and non-immune cells, is an 
important later player in Thl development, synergizing with IL-12 for the 
enhancement of IFN-y secretion by Thl cells and NK cells, even in the absence of 
TCR engagement (Robinson, 1997; Nakanishi, 2001). IL-18 KO mice are less 
resistant to infection by M. tuberculosis than wild type (Sugawara, 1999). IL-23, 
another pro-inflammatory cytokine, is composed of the specific p l9  subunit (IL-23a) 
attached to the p40 subunit of IL-12 (Oppmann, 2000). IL-23 induces secretion of 
IFN-y in memory T cells, dendritic cells and macrophages (Cua, 2003). A recently 
discovered cytokine, IL-27 (Pflanz, 2002), acts together with IL-12 to induce early 
IFN-y production and proliferation of naive but not memory CD4+ T cells and also
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help Thl development. IL-27 has been detected in human tuberculous granulomas 
(Larousserie, 2004).
Polarised Thl and Th2 responses are also seen in vivo, after chronic 
immunisation or disease. In acute immune responses particularly, distinct bipartition 
is not always found; clones making simultaneously type 1 and type 2 cytokines (ThO 
clones) can be seen in vivo (Polakos, 2001). Th3-CD4+ lymphocytes, are regulatory 
T cells producing transforming growth factor-p (TGF-P) and involved in mechanisms 
of oral tolerance (Weiner, 2001).
Dendritic cells (DC) are the initiators, the modulators, the major antigen- 
presenting cell generating adaptive immune responses. They perform multiple tasks 
with high efficiency, and may determine the specificity, magnitude and nature (Thl 
versus Th2) of the immune response (Moser & Murphy, 2000).
At an immature stage of development, DCs have higher phagocytic capacity. 
They also perform receptor-mediated adsorptive endocytosis and macropinocytosis 
(Banchereau & Steinman, 1998). DCs act as sentinels in peripheral tissues, 
continuously sampling the antigenic environment. Encounter with microbial products 
initiates the migration and the activation of DCs. There is up-regulation of co­
stimulatory and MHC molecules coupled with increased processing of peptides for 
presentation for T cells and effective initiation of immune responses. (Moser & 
Murphy, 2000). Dendritic cells can also cross-present antigens to T cells, and this 
could be important in generating cytotoxic responses (Kaufmann, 2001; Schaible,
2003). Matured DCs usually express moderate to high levels of MHC-II, which 
become very stable complexes with peptide in the surface of these cells (Shortman & 
Liu, 2002). DC maturation also triggers production of cytokines such as IL-12 and 
IL-10 and they play important roles in the polarisation of T cell responses (Reis e 
Sousa, 2001). Maturing DCs produce under tight regulation, the bioactive p70 form
of IL-12 (p40 and p35 components), which is a potent inducer of Thl responses as 
explained before (Moser & Murphy, 2000). IL-12 signalling is mutually antagonistic 
with GATA3 expression, providing a mechanism of regulation on lineage fate 
decision (Ouyang, 1998). IL-10 down-regulates the production of IL-12 by murine 
and human DCs (Maldonado-Lopez & Moser, 2001).
DCs can be subdivided in different subsets according to patterns of expression 
of surface molecules such as CD1 lb, CD8a and CD4 and by cytokines they produce. 
A number of studies have suggested that different DC subsets induce T cells to 
differentiate either into Thl or Th2 (Maldonado-Lopez & Moser, 2001; Szabo, 2003). 
Other reports show dendritic cells to be quite flexible in driving either Thl or Th2 
responses (Boonstra, 2003). TLRs on DCs provide the link between the innate and 
adaptive immune responses (Medzhitov, 1997). These conserved, germline encoded 
co-receptors expressed in macrophages and DCs, recognise specific microbial 
products such as LPS, peptidoglycan, hypomethylated CpG motifs and double­
stranded RNA (Barton & Medzhitov, 2002). Besides up-regulation of MHC and co­
stimulatory molecules and the secretion of proinflammatory cytokines TNF-a, IL-1 
and IL-6, TLR signalling also lead to high IL-12 production by some DCs, driving 
differentiation of T cells to Thl pattern (Barton & Medzhitov, 2002). TLR receptor- 
signalling pathways controlling Th2 responses are less well characterised (Schnare, 
2001; Jankovic, 2002).
1.5 Tuberculosis immunity: of mice and man
Pathogenic Mycobacterium spp. survives within the macrophages of their host, 
contrasting with the accepted view that these cells afford an effective initial barrier to 
bacterial infection. Multiple receptor molecules can mediate the uptake of
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mycobacteria into macrophages (fig. 1.3). Complement receptors (CR1 and CR3) are 
among the most widely used receptors for mycobacteria, for both opsonized and non­
opsonized entry (Hu, 2000). Although in some cases not altering significantly the 
outcome of infection in vivo (Hu, 2000), triggering of complement receptors leads to 
the activation of Rho, a member of the small GTPases family, and this pathway 
downregulates bactericidal mechanisms in macrophages (Pieters & Gatfield, 2002). 
Mannose receptor (Kang & Schlesinger, 1998), transferrin receptor, CD 14 scavenger 
receptor, fibronectin (Pasula, 2002) and leukosialin CD43 (Fratazzi, 2000), all 
promote the attachment of mycobacterial ligands to the macrophage surface and may 
be involved in bacterial uptake. Interestingly, cholesterol appears to be important for 
the mycobacterial invasion, since cholesterol-depleted macrophages are unable to 
specifically internalise mycobacteria (Gatfield & Pieters, 2000). In summary, it 
appears that the bacilli can gain entry into the cell through ligation of many 
phagocytic receptors. Mycobacteria can also be phagocytosed by other cell types such 
as dendritic cells (Bodnar, 2001). Both human and murine dendritic cells have a 
bacteriostatic but not bactericidal activity against mycobacteria in vivo (Bodnar, 
2001; Jiao, 2002). In DCs, M. tuberculosis targets the dendritic cell-specific C-type 
lectin DC-SIGN (DC-specific intercellular-adhesion-molecule-3-grabbing- 
nonintegrin), leading to inhibition of immunostimulatory function by the DC and, 
hence, promoting pathogen survival (Tailleux, 2003).
As early as 1971, Armstrong and D’Arcy Hart discovered that phagosomes 
containing live M. tuberculosis do not fuse with lysosomes. By contrast, dead 
mycobacteria were readily transported to lysosomes (Armstrong & Hart, 1971). 
Pathogenic mycobacteria have evolved a strategy to arrest the normal maturation 
process of phagosomes after uptake by macrophages, living in a vacuole with 
characteristics of an early endosome (Russell, 2001). How the bacillus achieves this
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Figure 1.3 Intracellular pathways for M. tuberculosis. Macrophages can 
promote phagocytosis of large particles. Both endosomal and phagosomal pathways 
undergo interconnected maturation processes that merge at a later stage, prior to 
lysosomal fusion. Various receptors interact with MTB at the surface of the 
macrophage. Cholesterol serves as a docking site, facilitating the interactions between 
mycobacteria and surface receptors (Gatfield & Pieters, 2000). Once inside, MTB 
ends up in a phagosome, the maturation of which is arrested at an early stage. 
Infected, the organelle characteristically retains TACO, which apparently prevents its 
further maturation (Ferrari, 1999). MTB inhibits phagosomal acidification (Russel, 
2001) and prevents fusion with the endosomal pathway. This last arrest is incomplete, 
and some phagosomes mature to form phagolysosomes, particularly in activated 
macrophages. LAMP-1 and Cathepsin D are lysosomal markers. TLR, Toll-like 
receptor; CR, complement receptor; MR, mannose receptor; TACO, tryptophane, 
aspartate-containing coat protein; LAMP-1, lysosomal-associated membrane protein 
1. Modified from Kaufmann (2001).
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effect is still unclear. A molecule termed tryptophan-aspartate-containing coat protein 
(TACO) has been found in phagosomes harbouring living mycobacteria and seems to 
prevent lysosomal fusion by a yet unknown mechanism (Ferrari, 1999). There are 
also evidence to suggest that Mycobacterium spp. survive in phagolysosomes within 
macrophages in granulomas (Cosma, 2003). Mycobacteria-containing vacuoles are 
less acidic than their neighbouring lysosomes (Russell, 2001); mycobacterial porins 
could contribute in setting a favourable pH within the vacuole (Raynaud, 2002).
In professional APCs, MHC-II molecules bind peptides derived from soluble 
proteins, particulate antigens, and microbes that are internalised by endocytosis or 
phagocytosis and degraded in the endocytic pathway. In both human and murine 
systems, the MHC-II antigen processing machinery is inhibited in M. tuberculosis- 
infected APCs, by either reduced synthesis of MHC-II molecules or by sequestering 
these molecules intracellularly in an immature state (Ramachandra, 1999). In 
contrast, antigens present in the cytosol are degraded to antigenic peptides by 
proteasomes and enter the endoplasmic reticulum via the transporter for antigen 
presentation (TAP) to bind MHC-I molecules. It has been recognised that CD8+ T 
cells play an important role in immunity to tuberculosis (Tascon, 1998; Lewinsohn,
1998); uptake of mycobacterial antigen from extracellular vesicles from apoptotic 
cells by APCs resulting in MHC-I presentation has been reported (Schaible, 2003) 
and is important in the process of specific anti-mycobacterial CD8+ T cell priming.
In the initial steps of infection, a fine-tuned interaction between innate and 
adaptive mechanisms of immunity would be essential for the host response. 
Mycobacterial antigens such as 19-kDa lipoprotein and lipoarabinomannan (LAM), a 
glycolipid that dominates the mycobacterial cell wall, are recognised by TLR2 with 
induction of TNF-a and nitric oxide (NO) production (Brightbill, 1999; Means,
1999). Whereas most purified mycobacterial ligands activate macrophages via TLR2,
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whole killed or live mycobacteria seem to interact with TLR2, TLR4 and other 
unknown TLRs (Stenger & Modlin, 2002). Only a high-dose aerosol challenge with 
MTB was able to show defective responses in TLR2’7' mice (Reiling, 2002). Recent 
work in C3H/HeJ, a strain of mice mutant in the tlr4 locus, demonstrated that TLR4 
might not be critical for MTB control in mice (Kamath, 2004). Finally, MyD88- 
deficient mice, which are unable to signal internally through TLRs, failed to control 
mycobacterial replication and showed a definitive participation of a TLR (or a 
combination of TLRs) in the immune response against the tubercle bacilli (Scanga,
2004).
M. tuberculosis induces the up-regulation of several important host genes in 
the process of initial resistance to the bacteria; most are chemokines, others are 
cytokines such as IL-ip and TNF-a (Ragno, 2001). Recruitment of macrophages and 
T cells to the infection site is essential for protection. Chemokines are potent 
leukocyte activators and chemoattractants, and are important in granuloma formation 
in vivo (Van Crevel, 2002). The p-chemokines macrophage inflammatory protein-l-P 
(MIP-lp) and RANTES (regulated upon activation, normal T cell expressed and 
secreted) are induced by and can suppress intracellular M. tuberculosis growth 
(Saukkonen, 2002). Significantly, C-C chemokine receptor 2 (CCR2) deficient mice 
are very susceptible to MTB infection (Peters, 2001). Cellular migration to MTB 
invasion sites in the lung is also affected in intracellular adhesion molecule 1 (ICAM- 
1) deleted mice, which do not form granulomas (Johnson, 1998). Interestingly, 
protective immunity against MTB infection is not affected in this model, although 
long-term survival of the host may ultimately depends upon the production of a stable 
mononuclear granuloma (Saunders, 1999).
TNF (TNF-a) is a pleiotropic cytokine produced by monocytes and 
macrophages after M. tuberculosis infection and Thl T cells (Giacomini, 2001). This
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cytokine synergizes with IFN-y to activate murine infected macrophages (fig. 1.4), and 
is essential for the protection against murine tuberculosis (Flynn, 1995). A critical 
role in humans has been demonstrated by reactivation of tuberculosis in patients 
treated with anti-TNF antibodies (Keane, 2001). Neutralisation of TNF in a low-dose 
latent disease model induces death with severe histopathological changes, suggesting 
a role for TNF in ameliorating pathology of mycobacterial disease (Mohan, 2001). 
This cytokine also has a pathological facet. TNF appears to be linked to cachexia and 
increased multiplication of virulent bacilli in human macrophages (Engele, 2002). 
Absence of synergizing effects of TNF and IFN-y has been observed in infected 
human monocytes (Engele, 2002). A tentative explanation for these contrasting 
effects could be related to dose-dependency: low levels of TNF in vivo mediating 
protection, whereas high levels provoking tissue damage (Bekker, 2000). In mice, 
TNF is crucial for the formation of tuberculous granulomas (Roach, 2002).
Although not intensively investigated, natural killer (NK) cells and T cells 
that express the gamma-delta (yS) TCR may play significant roles in TB immunity. 
Killing of intracellular M. tuberculosis by unstimulated human NK cells is not 
mediated by granule exocytosis or Fas/Fas ligand interaction but by an unknown 
apoptotic mechanism (Brill, 2001). In mice, y5 T cells have been shown to protect 
partially against a high but not low inocula of MTB and are involved in granuloma 
formation (Kaufmann, 2001). Human y5 T cells are stimulated by a unique group of 
non-proteinaceous antigens that contains phosphate and they express a specific 
combination of TCR variable chains (Vy252); these cells appear to contribute to 
control mycobacterial infections in non-human primates (Kaufmann, 2001; Shen,
2002). As described before, IL-12 is a critical cytokine connecting innate with the 
adaptive host response to mycobacteria (van Crevel, 2002).
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Figure 1.4 Host defenses against tuberculosis. In most cases, M. tuberculosis is 
initially contained and disease develops later. The granuloma can be the site of 
infection, persistence, pathology and protection. Effector T cells (conventional CD4+ 
and CD8+ T cells and unconventional T cells, such as yS T cells, double-negative
and CD 1-restricted cells) and macrophages participate in the control of tuberculosis. 
IFN-y and TNF-_ are important macrophage activators. Macrophage activation
permits phagosomal maturation and the production of antimicrobial molecules such 
as reactive nitrogen intermediates (RNI) and reactive oxygen intermediates (ROI). 
LT-_3, lymphotoxin-0C3. Modified from Kaufmann (2001).
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Mycobacteria are very strong IL-12 inducers; they can even skew the immune 
response to a secondary antigen towards a Thl phenotype (Flynn & Chan, 2001). It 
has been recently reported that IL-12 is induced after phagocytosis of mycobacteria 
by dendritic cells but not by resting macrophages (Hickman, 2002). This inhibitory 
effect on IL-12 production by macrophages is probably caused by MTB-induced IL- 
10 and is reversible with cell-activation by IFN-y (Giacomini, 2001; Hickman, 2002). 
Inappropriate IL-12 production or signalling is implicated in increased susceptibility 
to mycobacteria in mice and humans (Flynn & Chan, 2001; Casanova & Abel, 2002).
Cell-mediated immunity is of critical importance to combat tuberculosis; mice 
genetically deficient in ap-TCR T cells are highly susceptible to infection and 
succumb rapidly to acute tuberculosis infection (Mogues, 2001). The role of B cells 
in protection against tuberculous disease has been more difficult to demonstrate. 
Nonetheless, Teitelbaum and colleagues (1998) had reported increased survival in 
wild type and immunocompromised mice injected with a monoclonal antibody 
specific for surface arabinomannan and challenged with the tubercle bacilli.
Since M. tuberculosis resides primarily in a vacuole and mycobacterial 
antigen presentation by MHC class II molecules takes place, is not surprising that 
CD4+ T cells are the most important in protective responses against MTB. Murine 
studies with antibody depletion of CD4+ T cells, adoptive transfer and gene-disrupted 
mice support this concept (Flynn & Chan, 2001). MHC-II-/- (Tascon, 1998) and 
CD4-/- (Saunders, 2002) are very susceptible to infection, the former more than the 
latter. In humans, the importance of the CD4+ T cell subset is easily demonstrated 
with HIV infection, which increases the susceptibility to tuberculosis from an 
averaged 10% lifetime risk (PPD+ HIV- individuals) to a 10% annual risk in PPD+ 
HIV+ subjects (de Jong, 2004). The primary known effector function of CD4+ T cells 
would be to produce IFN-y to activate macrophages, which then can combat infection
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by M. tuberculosis (Flynn & Chan, 2001). However, other roles controlling 
tuberculosis have been also attributed to this subset; in CD4-/- mice infected with 
MTB, IFN-y production is eventually compensated by CD8+ and NK cells, but these 
animals show delayed, non-typical granulomas and ultimately succumb to infection 
(Saunders, 2002). Involvement in disease persistence is shown by depletion of CD4+ 
in a low dose latency mouse model, which results in reactivation of tuberculosis 
despite expression of IFN-y (Scanga, 2000). Structural integrity of granulomas is 
compromised in humans with HIV/TB co-infection (Raupach & Kaufmann, 2001). 
Granulysin is a molecule expressed by human T cells and other cell types which can 
direct kill intracellular M. tuberculosis (Stenger, 1998). Canaday and colleagues 
(2001) had reported a yet unknown mechanism of human CD4+ (and CD8+) T cell- 
mediated restriction of intracellular MTB growth that is perforin-, Fas/Fas-ligand- 
and granulysin-independent. CD4+ T cells are important for cytotoxic activity, and 
possibly to support memory functions of CD8+ T cells in the lungs of MTB infected 
mice (Serbina, 2001). CD4+ T cells also produce homotrimeric lymphotoxin-a3 
(LTa3) and this molecule has been found to be essential to control MTB infection in 
mice; in its absence, lymphocytes fail to migrate into infected tissues (Roach, 2001).
CD8+ T cells (Tascon, 1998) and macrophages (Frucht, 2001) also participate 
in IFN-y production. IFN-y knockout animals have demonstrated the critical need for 
this cytokine in the outcome of murine tuberculosis; in its absence, the animals died 
rapidly of disseminated disease with increased bacterial numbers and purulent 
necrotic granulomas (Flynn, 1993; Cooper, 1993; Cooper, 2002). Human mutations 
in either chain of the IFN-y receptor IFN-yRl and IFN-yR2 (Casanova & Abel, 2002), 
as well as mutations on the STAT1 IFN-y-signal transducer (Dupuis, 2001), can lead 
to partial or complete deficiency of response to the cytokine and these subjects show
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increased susceptibility to mycobacterial disease (Casanova & Abel, 2002). IFN-y is a 
major activator of macrophages and activated macrophages produce elevated reactive 
oxygen and nitrogen intermediates (fig. 1.4). The former has only a few contributory 
effects in controlling tuberculosis in mice (Cooper, 2000). The latter, however is 
essential for protection (Cooper, 2002). IFN-y activates expression of inducible nitric 
oxide synthase (NOS2), which produces NO' and other nitrosative intermediates from 
L-arginine; all major killer molecules for M. tuberculosis (Raupach & Kaufmann, 
2001). Of interest, as well as participating in granuloma formation, both IFN-y and 
NO' seem to be involved in limiting extensive inflammation in MTB lung sites 
(Cooper, 2002). Interestingly, mycobacteria are able to disrupt association of 
transcription activator STAT1 with CREB binding protein and p300, restricting 
macrophage activation (Ting, 1999).
On the other hand, IL-4 and other Thl-supressive cytokines could be playing 
a role in limiting the actions of IFN-y. However, a clear dichotomy in Thl/Th2 
responses is difficult to demonstrate in both murine and human models of 
tuberculosis; a depressed Thl response rather than a strong Th2 response is more 
likely seen (Flynn & Chan, 2001; Garcia, 2002). IL-4, IL-10, IL-4/IL-13, IL-4Ra or 
STAT6 KO mice are not more resistant to M. tuberculosis infection than wild type 
(North, 1998; Jung, 2002; North & Jung, 2004). IL-4 is not always detected in lung 
granulomas of human patients (Aung, 2000). However, IL-10 production may be 
important in both late/chronic stages of disease in mice (Turner, 2002a) and in 
regulating mycobacterial infections in humans (Weir, 2004; Demissie, 2004). TGF- 
p i, another pleiotropic cytokine, has been detected in patients with active TB (Toossi, 
1995; Bonecini-Almeida, 2004).
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In addition to MHC-II, MHC class-I restricted T cells contribute importantly 
to immunity against TB infection. Early adoptive-transfer experiments (Orme & 
Collins, 1984) and cell-depletion studies in vivo (Muller, 1987) have demonstrated 
that CD8+ T cells were involved in protective immunity against murine TB. Mice 
deficient in P2 -microglobulin (Flynn, 1992), a molecule that participates in the 
structure of MHC-I and other non-classical MHC molecules (Behar, 1999), show a 
rapid lethal outcome in response to MTB infection. CD8+ T cells could contribute to 
the immune response against MTB by at least three pathways: the release of IFN-y, 
lysis of infected targets, and direct antimicrobial activity. Tascon and colleagues
(1998) had demonstrated the importance of IFN-y production by CD8+ T cells to 
mediate partial protection of athymic mice. Mycobacterium-specific CD8+ cytotoxic 
T cell clones recognising defined specific antigens and producing IFN-y have been 
isolated from mice (Silva & Lowrie, 2000) and humans (Lalvani, 1998; Cho, 2000; 
Lewinsohn, 2001). Although not well defined, cytotoxicity mechanisms against 
MTB-infected cells by CD8+ T cells have been reported to be at least partially 
perforin-dependent in mice (Serbina, 2000; Sousa, 2000). CD95/CD95L also seem to 
participate later in control of murine chronic tuberculosis (Turner, 2001a); but in 
humans, alternative mechanisms of lysis by CD8+ T cells do exist (Canaday, 2001). 
Granulysin, a member of the saposin-like protein family, is present in human MHC 
class I-restricted CD8+ T cells and directly kills MTB (Stenger, 1998). Studies have 
shown that CD8+ T cells migrate to the lung with similar kinetics to CD4+ T cells in 
young but not in old mice (Serbina & Flynn, 1999; Turner, 2002b), and interestingly, 
infection in elderly mice seems to activate a phenotypically different CD8+ T cell 
population, expressing several NK markers (Turner, 2002b).
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CD8a- and MHC-I deficient mice are less susceptible to MTB infection than 
p2 -microglobulin (fcm) KO (Sousa, 2000; Mogues, 2001), therefore other p2m- 
dependent mechanisms of resistance are suspected. Interestingly, p2m is involved in 
iron metabolism, as it stabilises surface expression of a gene that regulates iron 
uptake (Kaufmann, 2001); P2m KO mice suffer from iron overload and correction of 
this imbalance by lactoferrin restored immunity to MTB infection to levels 
comparable to MHC-I KO mice (Schaible, 2002).
Evidence for the participation of unconventional subsets of T cells in the 
immune response to the tubercle bacillus is well supported. Formylation of proteins 
represents a characteristic feature of prokaryotic origin (Kaufmann, 2001) and a non- 
classical MHC class lb molecule (H2-M3) presenting N-formylated peptides from M. 
tuberculosis, elicited cytotoxic responses in C56BL/6 mice (Chun, 2001). In humans, 
a group of p2-microglobulin-associated, non-MHC locus-encoded proteins (CDla, 
CD lb, CDlc) were found to present hydrophobic lipids and glycolipids to T cells 
(Beckman, 1994). CD8+ and CD4-CD8- with specificity for mycobacterial 
glycolipids presented by CD1 molecules were demonstrated (Stenger, 1997). The 
CD 1-restricted CD8+ T cells appeared to specifically kill M. tuberculosis via the 
newly discovered granulysin (Stenger, 1998). Only homologous CD Id molecules are 
found in mice and natural killer T cells (NKT) are a subset of CD ld-restricted T cells 
(Chackerian, 2002). The absence of CD Id molecules did not impair survival of mice 
towards a challenge with MTB (Behar, 1999). However, activation of the NKT 
population with a-galactosylceramide, a heterologous antigen, has been reported to 
protect susceptible mice against infection with M. tuberculosis (Chackerian, 2002).
1.6 Vaccination against tuberculosis
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1.6.1 Bacillus Calmette-Guerin
In 1798, Edward Jenner, an English country doctor, employed effectively the 
concept of vaccination that would save millions. Robert Koch knew about 
vaccination and hoped to find a treatment against tuberculosis. In August 1890, he 
hinted he had found a promising substance (later called tuberculin), a solution 
prepared by killing MTB, then filtering and concentrating the liquid. In a published 
paper, Koch stated that tuberculin induced strong reactions in people with 
tuberculosis, protecting and helping to heal tubercles in the lungs of animals with TB 
(Reichman & Tanne, 2002). He was mistaken; clinical trials soon demonstrated the 
ineffectiveness of his therapy; nonetheless, the substance he discovered became the 
precursor of modem PPD (Kaufmann, 2001). The quest for a TB vaccine continued 
and in the beginning of the twentieth century, two French scientists, Albert Calmette 
and Camille Guerin, started passaging in culture a vimlent M. bovis strain. With 
astonishing dedication, they transferred the bacteria from one test tube to another 
during approximately thirteen years. After 231 passages, the bacillus was unable to 
infect but protected experimental animals (Reichman & Tanne, 2002). Called bacille 
Calmette-Guerin (BCG), it was given by the oral route to an infant with high risk of 
tuberculosis infection in 1921; the newborn remained healthy during its childhood 
(Reichman & Tanne, 2002).
The encouraging initial trials lead BCG vaccination to spread worldwide and 
it has been used for over six decades. More than three billion doses were 
administered. It is considered very safe (is usually administered to neonates). The risk 
of disseminated disease (BCG-itis) is about 1 in a million of vaccinees (Horwitz,
2000). Nonetheless, there is a progressive infection in BCG-vaccinated SCID (severe 
combined immunodeficiency) mice (Mills, 2001); hence, the vaccine is not
47
recommended for the immunocompromised or those with established HIV infection 
(Horwitz, 2000). WHO has included BCG on its expanded program of immunisation 
(WHO-EPI). For many years it was administered orally, but now is used 
intradermally, due to decreased side effects (Lagranderie, 2000). Several 
experimental studies for more efficient routes have been undertaken: aerosol 
(Goonetilleke, 2003), intragastric (Lagranderie, 2000), rectal (Lagranderie, 2002) and 
intravenous (Palendira, 2002a). However, a study in the mouse model has suggested 
the protective efficacy of BCG to be independent of the route of immunisation 
(Palendira, 2002a).
Mice usually show less susceptibility to tuberculosis than humans, but it is the 
animal of choice for initial vaccine testing and infection studies because it is less 
expensive and has a large research database (Orme, 2001; McMurray, 2001). BCG 
can protect BALB/c and C57BL/6 against TB, but the quality of the immune 
responses seems to be different. BALB/c strain shows decreased levels of IFN-y, IL- 
12 and TNF-a cytokines, low-magnitude cellular responses and atypical granulomas, 
in comparison with the C57BL/6 strain. In terms of colony counts, both strains 
control infection with BCG (Wakeham, 2000).
The classical animal model for mycobacterial infection is the guinea pig, 
because of its exquisite susceptibility and some remarkable similarities with human 
infection (McMurray, 2001). Infected guinea pigs commonly present similar DTH 
reactions to humans and also caseous necrosis in its granulomas (Orme, 2001). 
Vaccination of guinea pigs with BCG increases resistance to MTB challenge; after 
vaccination, increased levels of CD8+ T cells have been noted in the spleen (Kliinner, 
2001).
BCG is the only vaccine available against human tuberculosis. It performs 
very well in animal models and remains the “gold-standard” against which candidate
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TB vaccines with improved efficacy are measured. It is strikingly efficient in 
protecting children against early and severe forms of tuberculosis such as miliary and 
tuberculous meningitis, as well as extrapulmonary forms and glandular tuberculosis 
(Jason, 2002). It exerts excellent levels of heterologous protection against leprosy 
(Fine, 1995). Nonetheless, BCG has produced more than acceptable variance in 
protection against pulmonary TB, as seen in several human trials (Fine, 1995). A 
famous major trial in schoolchildren from the United Kingdom, run by the Medical 
Research Council (MRC), showed more than 75% of protection, on a twenty-years 
follow-up (Hart & Sutherland, 1977). In remarkable contrast, trials in Georgia and 
Alabama (USA) and Puerto Rico, all demonstrated levels of protection below 30% 
(Fine, 1995). Even worse, 0% protection to infection has been found in trials in South 
India/Chingleput (Fine, 1995) and Malawi (Ponnighaus, 1992). Even in successful 
trials, the efficacy of BCG was predicted to wane over time, imparting protection for 
a decade or so (Sterne, 1998). Although human trials are underway (Dourado, 2003), 
there is no clear evidence that BCG revaccination would improve protection and this 
procedure is not recommended by the WHO (WHO-Global Tuberculosis Programme 
and Global Programme on Vaccines, 1995).
Several hypotheses have been proposed to explain the observed failures in 
BCG vaccination; genetic variability in the population and vaccination of previously 
infected individuals are possibilities (Fine, 1995; Andersen, 2001). There have also 
been suggestions of over-attenuation of BCG substrains (Behr & Small, 1997). After 
1921, cultures of BCG were delivered for propagation in laboratories all over the 
globe (Oettinger, 1999). Continuous passage in different ways of culturing may have 
lead the original BCG strain to a profusion of phenotypically and genotypically 
different daughter strains. Work by Mahairas and colleagues (1996) have found that 
BCG was missing blocks of DNA from its genome in comparison to M. tuberculosis.
The deletions were called regions of difference (RD): RD1 and RD3 were missing 
from all substrains of BCG examined and contained virulence-associated genes such 
as ESAT-6 and CFP10; RD2 contained, between others, the mycobacterial protein 
tuberculosis 64 (MPT64) gene (Mahairas, 1996) and affected BCG substrains 
obtained from Institut Pasteur after 1926 (Oettinger, 1999). In comparison with M. 
bovis, all BCG vaccines lack RD1, which may indicate it was lost during the 1908- 
1921 attenuation (Behr, 1999). Knock-in studies have shown that RD1 contributes 
importantly to the loss of virulence observed in BCG (Pym, 2002). Reintroduction of 
this region made BCG a more effective vaccine against MTB in mice (Pym, 2003). 
Loss of virulence in BCG appears specifically linked to the lack of cytolytic activity 
and tissue invasiveness mediated by secreted ESAT-6 (Hsu, 2003). In addition, by 
using microarray technology, Behr and collaborators (1999) have found further 
deletions and named them RD1-RD16, four of them (RD2, RD8, RDM, RD16) 
deleted only in specific substrains. Besides these major deletions and other less 
conspicuous changes (Behr, 2000), there is little evidence that certain strains would 
be more immunogenic than others (Oettinger, 1999), and the same vaccine substrain 
has also been found to provide good protection in one region while performing badly 
in another (Fine, 1995).
A prevailing hypothesis to explain the variation in BCG efficacy has been 
related with the heterologous infection of the host with environmental mycobacteria. 
In animals, a recent study (Brandt, 2002) has complemented previous observations 
initiated by Palmer & Long (1966). In this study, two strains of the M. avium 
complex, isolated from the Karonga district in Malawi (absence of BCG protection), 
were found to block BCG activity; prior sensitisation with M. avium resulted in a 
broad immune response which controlled the multiplication of BCG and avoided 
protective immunity to MTB in mice (Brandt, 2002). Evidences in humans:
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correlation of strong efficacy of BCG in trials in which skin-test positive individuals 
were excluded (Hart & Sutherland, 1977); the success of BCG in neonates, before 
sensitisation with non-tuberculous mycobacteria occurs (Colditz, 1995). Importantly, 
poor IFN-y and DTH responses are associated with no protection by BCG in 
individuals from areas rich in environmental mycobacteria (Malawi) when compared 
with individuals living in areas with good records of BCG efficacy and less exposure 
to atypical mycobacteria (Black, 2002).
Independent of this variation, researchers have tried to improve upon the 
immunogenicity of BCG with some success (Dietrich, 2003; Pym, 2003; Horwitz, 
2003). Expression of cytokines (IL-2, IFN-y, GM-CSF) has been attempted (Murray, 
1996; Biet, 2002). By overexpressing the extracellular antigen 85B in BCG, Horwitz 
and colleagues (2000) have obtained for the first time a recombinant bacterium that 
was better than the original in reducing significantly organ associated pathology in 
the guinea pig model of tuberculosis infection. This vaccine (rBCG30) performed 
better than BCG in enhancing the survival of guinea pigs in long term infection 
studies and is being prepared to start human trials soon (Horwitz, 2003).
BCG has little or no effect on the predominant adult pulmonary disease and 
there is a pressing need for improved vaccines against tuberculosis (Young, 2003). M  
microti is a natural pathogen of wild voles and causes a progressive and lethal disease 
in these animals; however, other rodents and humans are relatively resistant even to 
high doses (Manabe, 2002). In the fifties, the MRC started a comparative trial to test 
M. microti as a better vaccine against tuberculosis (Hart & Sutherland, 1977). Over 
50000 children participated. A 20 year follow up showed 77% protective efficacy for 
both BCG and the vole bacillus (Hart & Sutherland, 1977). In mice, when given 
orally, M. microti was actually better protective than BCG given subcutaneously 
(Manabe, 2002). Although offering important advantages over BCG such as genomic
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stability (the bacillus can be maintained naturally in voles), M. microti was 
abandoned as a vaccine against tuberculosis for unclear reasons (Manabe, 2002). M. 
vaccae, an environmental mycobacteria, is being investigated in a heat-inactivated 
form as a TB preventive vaccine for HIV+ individuals (Vuola, 2003).
Attenuated strains of M. tuberculosis unable for long-term survival in the host 
have been generated (Hingley-Wilson, 2003). Given the genetic differences between 
BCG and MTB (Behr, 1999), one would predict that rationally attenuated M. 
tuberculosis would have a more relevant repertoire of species-specific antigens. The 
matter of safety is a primary concern: the tubercle bacillus must be non-reversibly 
attenuated and tested in immunocompromised animals (Hondalus, 2000). Along this 
line, an auxotrophic deletion created by allelic exchange disrupting a gene encoding 
isopropyl malate isomerase (leuD) of MTB generated a mutant dependent of leucine 
which cannot survive in immunodeficient SCID mice yet providing protection similar 
to BCG in a mouse challenge model (Hondalus, 2000). Pavelka and colleagues 
(2003) generated a lysine auxotrophic mutant of MTB able to induce protection 
equivalent to BCG in the aerosol mouse model of infection. Attenuated MTB mutants 
have been reported as being ready for phase I trials for safety and immunogenicity 
soon (Ginsberg, 2002).
Although exposure to certain mycobacteria can provide protection against 
pulmonary tuberculosis, this protection is not complete; human reactivation and 
reinfection emphasise that it may not be possible to induce more than about 80% of 
protection against MTB by exposure to natural mycobacterial antigens (Fine, 1995). 
Therefore, vaccinologists are left with the difficult task of designing an innovative 
vaccine, one that induces responses superior to the immune responses raised by the 
natural infection (Andersen, 2001).
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1.6.2 Current vaccine approaches against tuberculosis
The subunit and DNA vaccination approaches are based on the assumption 
that a few antigens are sufficient to induce and maintain a protective immune 
response. In addition, they have the advantage to be stable and safe even for 
immunocompromised individuals (Andersen, 2001). Attention to the vaccine 
potential of mycobacterial culture filtrate proteins (CFPs) came with the observation 
that compared to live bacilli, only marginal protection was observed in mice after 
vaccination with heat-killed tubercle bacilli (Weiss, 1955). Hubbard and colleagues 
(1992) were the first to show protection against an aerosol MTB challenge in mice 
immunised with fractionated CFP. Strong protection mediated by CFP plus 
incomplete Freund’s adjuvant was also obtained in the guinea pig model, with the 30- 
kDa fraction (Ag85B) (Horwitz, 1995).
Several subunit vaccine candidates are currently being tested in animal 
models. An interesting example is based on the fusion of two immunogenic 
tuberculosis proteins, Ag85B and ESAT-6; challenge assays in mice demonstrated 
that this recombinant fusion protein is capable of inducing strong IFN-y responses 
and protection levels comparable to BCG even thirty weeks after the last dose (Olsen,
2001). Coler and collaborators (2001) had described a low molecular weight-secreted 
protein, MTB8.4, which induces IFN-y production from cells of PPD+ donors and 
increased protection against MTB in mice when delivered either as a protein or in 
DNA format. Another fusion protein: recombinant Ag72f+/-Ag85, has been reported 
as being prepared for human testing soon (Ginsberg, 2002; Reed, 2003). Despite the 
encouraging results, there is a constant drawback due to the need of a suitable 
adjuvant to be used in humans to potentiate host responses towards these proteins.
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DNA vaccination was first introduced approximately 14 years ago. In his 
seminal paper, Wolff and colleagues (1990) demonstrated that naked plasmid DNA 
could be injected into the muscle and the foreign gene that it carried could be 
transferred and expressed in the muscle cells in vivo. Subsequently, Ulmer and 
colleagues (1993) were the first to report protection induced by a DNA vaccine 
against an infectious disease. Few years later, Tascon and collaborators (1996) and 
Huygen and colleagues (1996) simultaneously reported the protective effect of naked 
DNA vaccination against TB using plasmid DNA coding for a 65-kDa heat shock 
protein (HSP) from M. leprae and the 32-kDa mycolyl transferase or antigen 85A 
(Ag85A) from M. tuberculosis, respectively. Afterwards, the number of reports on the 
use of DNA vaccines for the immunoprophylaxis of mycobacterial diseases increased 
steadily; currently, there are several DNA-vaccine candidates under pre-clinical 
evaluation in the USA and other countries (Huygen, 2003).
The principle of naked DNA vaccination is simple, yet is surprisingly 
efficacious. Basically, a chosen gene is cloned into a plasmid vector and the purified 
plasmid injected into the tissue; expression of the coding information is driven by 
either a strong viral or eukaryotic promoter and the gene of interest is followed by a 
polyadenylation site for efficient protein production by the eucaryotic cell (Huygen,
2003). The cellular targets are usually myocytes (muscle injection) and keratinocytes 
(epidermal “gene gun” immunisation) and quantities of antigen produced in vivo are 
usually in the picogram to nanogram range (Gurunathan, 2000). Nonetheless, DNA 
vaccines trigger efficient humoral and cellular responses, particularly Thl type and 
strong activation of CD8+ T cells; both B and T cell memory responses are also 
generated (Gurunathan, 2000). The antigen encoded by the plasmid DNA may be 
processed and presented to the immune system by at least three mechanisms 
(Gurunathan, 2000; Akbari, 1999): (a) direct transfection and priming of somatic
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cells; (b) direct transfection and priming of dendritic cells; and (c) cross-priming, a 
process in which non-transfected dendritic cells take up antigens secreted 
extracellularly and/or derived from apoptotic bodies of DNA-transfected cells and 
present the processed peptides to CD4+ and CD8+ T cells. Dendritic cells are 
fundamental for DNA-induced immune responses (Akbari, 1999). Bacterial DNA has 
inherent adjuvant properties and can activate dendritic cells and trigger the production 
of co-stimulatory cytokines such as IL-12, IFN-a and -y and TNF-a (Gurunathan, 
2000), through interaction with the Toll-like receptor 9 (Hemmi, 2000). In one study, 
treatment of mice with unmethylated oligodeoxynucleotides could increase Thl 
responses and reduce MTB growth in the lungs, even if given to infected mice 
(Juffermans, 2002). However, there are contradictory results to the real protective 
effect of these oligodeoxynucleotides in tuberculosis (Hsieh, 2004).
After the initial reports on DNA vaccination against TB, a series of new 
antigens were tested as DNA vaccines with variable degrees of success in different 
animal models and researchers again concentrated efforts on secreted proteins (CFPs) 
(Orme, 1997). DNA vaccines based on the extracellular antigen 85 complex, a set of 
three mycolyl transferases (85A, B and C), had been seen as promising candidates 
since the initial protective results against MTB obtained by Huygen and colleagues 
(1996). Successful vaccination with Ag85B in both mice (Kamath, 1999a) and guinea 
pigs (Baldwin, 1998) was also demonstrated. Interestingly, the protective effect of 
Ag85A and B vaccines seem to be mediated in mice by CD4+ T cells only (D’Souza, 
2000) when administered by the intramuscular route of vaccination (Tanghe, 2000). 
Vaccination with MPT64 and ESAT-6 DNA also stimulated significant reductions in 
bacterial load of MTB in the lungs of mice, although not at the same level as BCG 
(Kamath, 1999a). MPT63, a 17-kDa secreted protein of MTB, conferred increased 
protection to a MTB challenge in mice when given in DNA form (Morris, 2000).
Potent T cell antigens are not exclusively seen in the CFP but also found in the 
cytoplasm of M. tuberculosis. Dillon and colleagues (1999) using a two-step 
immunoscreening of a genomic MTB library isolated MTB39, a cytoplasmatic 
protein containing the proline-proline-glutamic acid motif (PPE protein), showing 
increased protection in mice immunised with the DNA format. Yet another member 
of the PPE family, MTB41, induced protection comparable to BCG in mice (Skeiky,
2000). A complete and updated review of experimental DNA vaccines tested against 
TB can be seen in more detail elsewhere (Huygen, 2003).
Although powerful, DNA vaccines are still of limited efficacy and only rarely 
comparable to BCG. Several laboratories are testing different protocols to augment 
the efficiency of DNA vaccination and the prime-boost vaccination approach is one 
of the most promising strategies found (see below). Meanwhile, Kamath and 
collaborators (1999a) attempted multi-subunit vaccination with different vectors 
(MPT64, ESAT-6 and Ag85B), reporting better protection with simultaneous 
vaccination compared to single vaccines; similar results were obtained using different 
plasmid sets (Morris, 2000). Combinations up to ten plasmid vectors coding for 
different MTB antigens have been tested in mice, with improving rates of survival 
after infection, but still not better than BCG (Delogu, 2002). In this study, the authors 
fused the antigens either to the signal sequence of the human tissue plasminogen 
activator, for antigen secretion, or, to ubiquitin proteins, for increased MHC I 
processing (Delogu, 2002). Co-immunisation with DNA vaccines coding for Ag85B 
and MPT64 and plasmids expressing cytokines such as GM-CSF (Kamath, 1999b) or 
IL-12 (Palendira, 2002b) increased T cell immunity but results regarding protection 
in the murine-MTB challenge model were not very impressive. In addition, DNA 
coding for Ag85B has been also formulated in cationic lipids in order to improve 
immunogenicity and the targeting to APCs (D’Souza, 2002).
1.7 The prime-boost approach
Although versatile and being able to generate humoral immunity as well as 
CD4+ and CD8+ T cell responses, DNA vaccines have not shown impressive results 
in humans as compared to rodent models (Seder & Hill, 2000). In 1995, Leong and 
colleagues (Ramsay, 1999) have shown that consecutive immunisations, involving 
priming with DNA and boosting with poxvirus vectors, both encoding a common 
vaccine antigen, could generate unprecedented levels of specific immunity against a 
challenge with the native pathogen (Kent, 1998). This protocol could be defined as 
the heterologous prime-boost strategy. It involves giving two different vaccines, non- 
concomitantly, each encoding the same antigen (Li, 1993). Recombinant fowlpox 
viruses and attenuated vaccinia viruses such as modified Ankara strain (MVA) were 
considered safe for this protocol, because of their inability to replicate in mammalian 
cells (Ramsay, 1999). The superiority of this approach was evident against 
intracellular infections and tumours, enhancing CTL responses which are not easily 
induced by usual vaccines; Adrian Hill and colleagues at Oxford have obtained high 
numbers of specific IFN-y+ CD8+ T cells and protection against malarial challenge 
using prime-boost of DNA and MVA, encoding for pre-erythrocytic antigens of 
Plasmodium berghei in a murine model (Schneider, 1998). This regimen induced 
strong cellular responses (although no protection) in a non-human primate malaria 
model (Schneider, 2001) and partial protection in humans (McConckey, 2003). 
Interestingly, only the sequential administration of priming with DNA and boosting 
with MVA appears to induce protective responses (Schneider, 1999); although in 
terms of mucosal immunity, the reverse order of vaccination seems to work better 
(Eo, 2001).
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Effective results on the use of the prime-boost concept are available for 
several diseases: successful protection in experimental models is reported for viral 
diseases such as caused by Ebola virus (Sullivan, 2000) and hepatitis C (Matsui,
2003); protozoal Leishmania infantum (Ramiro, 2003) and tumours (Pasquini, 2002). 
Studies with immunodeficiency virus showed promising results in non-human 
primates (Amara, 2001; Wee, 2002) and in human phase I trials (Mwau, 2004). 
Prime-boost including proteins also worked in human papilloma (van der Burg, 2001) 
and dengue virus models (Simmons, 2001).
The mechanism that generates these high frequencies of CD8 T cells observed 
after prime-boost protocols still needs better clarification. Antigens carried by viral 
vectors and DNA vaccines are able to enter in both classical and alternative MHC-I 
processing pathways (Schneider, 1999). A potential mechanism is 
immunodominance, where a highly focused but moderate CD8+ T cell response to a 
few epitopes is induced after priming with DNA; the boost with the virus carrying the 
same antigen would again prime new cells but would enhance the previously primed 
“memory” CD8+ T cell population, which can react rapidly to the “danger signals” 
sent by the viral infection (Schneider, 1999; McShane, 2002). Ramsay and colleagues
(1999) had proposed that, because of the low amounts of antigen available, a high 
avidity CTL population would be preferentially generated.
McShane and collaborators (2001) were the first to report the use of the prime- 
boost concept against tuberculosis: levels of protection similar to BCG were obtained 
in a murine model using a polyprotein construct (containing ESAT-6 and MPT63 
antigens), cloned in a plasmid DNA vaccine and in MVA (McShane, 2001). 
Interestingly, in this protocol, IFN-y +CD4+ T cells were significantly boosted but no 
evidence of CD8+ T cells producing IFN-y was seen (McShane, 2001). Only partial 
protection to MTB infection was seen when using DNA-ESAT-6 plus recombinant
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Salmonella typhimurium, instead of MVA as a booster (Mollenkopf, 2001). A DNA- 
protein prime-boost approach using antigen 85 A and B has been able to increase Thl 
responses and protection significantly although not equally to BCG in a MTB model 
(Tanghe, 2001). Similarly, Vordermeier and colleagues (2003) reported significantly 
better Thl responses (both humoral and cellular) in a cattle model of tuberculosis, 
with heterologous DNA prime-protein boost using mycobacterial HSP65 
(Vordermeier, 2003); lack of protection in cattle was reported when employing a 
similar strategy using MPB70 DNA-prime protein-boosting (Wedlock, 2003).
A few studies have evaluated prime-boost strategies including BCG. In a M. 
avium mouse model, prime-boost with recombinant BCG overexpressing the 
immunodominant 35-kD protein was not more efficient in terms of immune response 
or protection than the DNA vaccine alone (Martin, 2001). Priming with a DNA 
vaccine expressing antigen 85B and boosting with BCG improved the protective 
efficacy of BCG in the murine-MTB aerosol challenge model and depletion of CD8+ 
T cells clearly impaired the protection reported in this study (Feng, 2001). Finally, 
boosting BCG-primed mice with purified antigen 85A has significantly improved 
levels of protection against MTB aerosol challenge when the animals were elderly 
(Brooks, 2001).
1.8 Immunodominant antigens for vaccination against tuberculosis
1.8.1 Mycobacterial HSP65 and HSP70
Approximately forty years ago, someone inadvertently turned up the 
temperature of an incubator full of fruit flies; the salivary gland chromosomes from 
the flies, thus heat-shocked, showed the characteristic puffs, indicative of
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transcriptional activity at discrete loci. These loci came later to be known to encode 
heat shock proteins (HSPs), which were gradually identified in all species tested 
(Srivastava, 2002a). HSPs are expressed in all cells, in all forms of life and in a 
variety of intracellular locations: from the cytosol of prokaryotes to several 
compartments of the eukaryotic cell. They constitute the single most abundant group 
of proteins inside cells and their expression can be powerfully induced as a result of 
heat shock and other forms of stress including toxins, oxidative stress and glucose 
deprivation. A collection of functions such as folding, unfolding and degradation of 
proteins, assembly of multi-subunit complexes, thermotolerance and others, have 
been attributed to HSPs (Srivastava, 2002a). These proteins can be classified into ten 
families; each consisting of one to five closely related proteins (Srivastava, 2002b). 
There is little homology between families but all families are present in every 
organism (Srivastava, 2002b).
In the 1980s, it was observed that homogeneous preparations of certain HSPs 
that were isolated from cancer cells elicited immunity and specific protection, 
whereas corresponding preparations from normal tissues did not (Srivastava, 1998). 
The immunogenicity of tumour-derived HSPs resulted from the non-covalent 
association of molecules such as gp96, HSP70, HSP90, calreticulin and GRP 170 with 
peptides generated by the degradation of proteins expressed by tumour-cells 
(Srivastava, 2002b). HSP-peptide complexes were also reported to be protective for 
infectious diseases such as tuberculosis (Ziigel, 2001). Further clarification of these 
effects came in subsequent studies: stripped of chaperoned peptides, HSP70 was 
ineffective in immunising against cancer cells (Udono, 1993). Exogenously 
administered HSP-peptide complexes behaved as adjuvants, inducing CD8 + T cell 
responses (Blachere, 1997). A surface receptor for HSPs in macrophages and 
dendritic cells has been recently identified: CD91 (which also binds a2-
macroglobulin), binds several HSPs with different affinities (Basu, 2001). Interaction 
of HSP-complexes with CD91 facilitates the transport of the complex to the cytosol 
(a proportion of the HSP-peptide complex also ends in acidic compartments for 
MHC-II processing). Other receptors such as TLR2, TLR4, CD36 and CD 14 were 
suggested to be involved in different immunogenic functions induced by HSPs such 
as production of cytokines, chemokines and APC activation (Srivastava, 2002a; 
Srivastava, 2002b). Interestingly, mycobacterial but not human HSP70 bind to CD40 
and stimulate production of CC-chemokines M IP-la, MIP-lp and RANTES in 
human cell lines (Wang, 2001).
The M. tuberculosis HSP70 (MtbHSP70) is homologous to the DnaK protein 
from E. coli and was initially described in 1989 (Mehlert & Young, 1989). It was 
noticed that this protein had potential for immunomodulation; purified MtbHSP70 
plus a powerful adjuvant were able to induce high levels of protection in the guinea 
pig model (Horwitz, 1995). In the DNA format, mycobacterial HSP70 also elicited a 
significant prophylactic effect against MTB in outbred and BALB/c mice (Tascon, 
1997; Lowrie, 1997), although had lower efficacy when administered therapeutically 
to infected mice (Lowrie, 1999). Mycobacterial peptides complexed with MtbHSP70 
evoked increased DTH reaction in mice (Roman & Moreno, 1997). Interestingly, 
MtbHSP70 fused with human papilloma virus (HPV) E7 protein and administered in 
DNA format, improved protection against cervical cancer (Chen, 2000). Gene fusion 
with MtbHSP70 generates potent CD8 + CTL responses to the fusion partner, 
independent of CD4+ T cell help (Huang, 2000). Regarding M. tuberculosis, 
overexpression of HSP70 (and other HSPs) is not beneficial for survival of the bacilli, 
particularly in the chronic phase of infection (Stewart, 2001), supporting the idea of 
“danger signals”, whereby the host immune system recognise high levels of HSPs as
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a warning signal for the presence of pathogens (Lowrie, 1998; Colaco, 2001; 
Srivastava, 2002b).
A DNA vaccine encoding the 65-kDa-heat shock protein (HSP65) of M. 
leprae has demonstrated significant levels of protection against experimental 
infection with M. tuberculosis in mice (Tascon, 1996). The HSP65 protein from M. 
leprae shares 95% of homology with the M. tuberculosis protein (Tascon, 1996). 
Most bacteria encode only one chaperonin 60 (also known as GroEL in E. coli), 
however, in the MTB genome there are two genes: cpnLl, encoding the HSP60.1 and 
cpnL2 (encoding the known HSP65 or HSP60.2); HSP60.1 from M. tuberculosis has 
been found to be between 1 0 - to 1 0 0 -fold more active in inducing proinflammatory 
cytokine synthesis than its counterpart HSP65 (Lewthwaite, 2001). HSP65 DNA 
vaccine induced substantial protection against intravenous or intraperitoneal MTB 
challenge; animals immunised with several doses o f this antigen expressed 
significant reductions in bacterial load in target organs after challenge infection, with 
protection levels comparable to BCG (Tascon, 1996; Lowrie, 1997; Bonato, 1998). 
This effect appeared to be strictly dependent of the endogenous nature of the delivery 
process; HSP65 protein alone was ineffective but a murine tumour cell line 
transfected with the gene and injected in mice exhibited high degree of protection 
(Silva & Lowrie, 1994). Although HSP65 DNA induced both CD4+ and CD8 + T cell 
responses, the cell population most effective at transferring protection was associated 
with activated CD44hlgh CD8 + IFN-y+ T cells (Lowrie, 1997; Bonato, 1998; Silva & 
Lowrie, 2000). The HSP65 DNA vaccine was also administered to mice as an 
immunotherapeutic vaccine (Lowrie, 1999). However, lack of protection and 
autoimmune pathology has been also reported with the use of DNA vaccines in 
aerosol models of MTB infection, both in mice and guinea pigs (Turner, 2000;
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Taylor, 2003). HSP65 and Ag85A DNA, were also reported to induce failure or 
severe reactions in both prophylactic and immunotherapeutic modes (Repique, 2002).
1.8.2 MPT83 andMPT70
Mycobacterial protein 70 (MPB70) was initially isolated from culture filtrates 
of Mycobacterium bovis BCG (Nagai, 1981). MPT is used in similar designations for 
proteins purified from M. tuberculosis (Harboe, 1998). Cloning of this 22-kDa 
protein revealed the sequence of a polypeptide chain preceded by a signal peptide that 
is typical from secreted proteins and in addition, that this protein was soluble and 
non-glycosylated (Harboe, 1998). MPB70 structure has been resolved recently (Carr, 
2003). There are no differences between M. bovis and M. tuberculosis in terms of 
amino acid sequences, for the proteins encoded by the mpb70/mpt70 genes (Wiker, 
1998). MPB70 is an important target for humoral and cellular immune responses 
during infection with bovine tubercle bacilli and has been exploited in the 
development of tests for diagnosis of bovine TB (Rhodes, 2000). Cellular in vitro 
immune responses to purified MPB70 were also prominent in human TB (Roche, 
1994; Al-Attiyah, 2003). When used as a DNA vaccine, MPT70 was able to induce 
CD4+ T cell based-proliferative responses in cattle (Vordermeier, 2001). Moreover, 
given as an immunotherapeutic DNA vaccine to MTB-infected Balb/c mice, MPT70 
was able to induce a very significant decline in bacterial counts in both lungs and 
spleen (Lowrie, 1999). However, vaccination of cattle with DNA coding for MPB70 
did not show protection against bovine tuberculosis (Wedlock, 2003).
MPT83 shares 61% homology with MPT70 at the amino acid level; the genes 
encoding these two proteins are arranged in an operon-like structure and are 
expressed under identical conditions (Hewinson, 1996; Juarez, 2001). The genes from
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M. bovis and M. tuberculosis are indistinguishable. Mature MPB83 differs from 
MPB70 by the presence of a typical lipoprotein consensus motif and also an insert of 
35 amino acids at its N-terminus with a putative glycosylation site; the 26-kDa form 
is an exported lipoprotein associated with the bacillary cell surface while the 23-kDa 
variant is secreted, glycosylated and non-lipoylated (Wiker, 1998; Harboe, 1998). 
MPT83 has no identifiable function; it is well recognised by T lymphocytes from M. 
bovis infected- but not BCG-vaccinated cattle, demonstrating potential as a diagnostic 
tool (Vordermeier, 1999; Vordermeier, 2001). Vaccination with plasmid encoding the 
MPT83 gene was found to protect mice to a certain extent against a challenge with M. 
bovis (Chambers, 2000) and M. tuberculosis (Morris, 2000), but was not able to 
provide protection against bovine tuberculosis in cattle (Wedlock, 2003). In a M. 
bovis infection model in guinea pigs, DNA vaccination with MPT83 slightly reduced 
lung pathology but not at the same level as BCG (Chambers, 2002).
1.8.3 Mycobacterial Apa protein
During a series of purification procedures on culture filtrates of M. 
tuberculosis, Nagai and colleagues (1991) identified and purified to homogeneity a 
secreted protein named by them as MPT32. When injected intradermally in Guinea 
pigs previously sensitised with dried cells of MTB, this protein induced a lower but 
quite distinct reactivity (Nagai, 1991). In an independent work, a fraction of 45/47- 
kDa bands was purified from culture filtrates of BCG (Romain, 1993); it interacted 
only with the sera from Guinea pigs injected with live but not dead BCG. This 
fraction showed to be forty times more potent in eliciting DTH responses in animals 
sensitised with live versus dead BCG, yet it represented less than 2% of the total 
material excreted by BCG (Romain, 1993).
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In 1995, the gene coding for the 45/47-kDa complex (or MPT32) of M. 
tuberculosis was cloned and sequenced (Laqueyrerie, 1995). The gene had an open 
reading frame of 975bp (base pairs), coding for a protein of 325 amino acids 
(predicted molecular mass of 28.7-kDa), with a N-terminal signal sequence for 
secretion of 39 amino acids; the gene, present as a single copy in the genome, was 
named as apa (alanine-proline-rich protein) due to the high percentages of proline 
(21.7%) and alanine (19%) in the purified protein (Laqueyrerie, 1995). The apparent 
high molecular mass as determined by SDS-PAGE could be explained from the 
increased rigidity of molecules due to the high content of proline residues. The 
function of Apa remains undetermined. Apa protein had sequence homology of 6 6 % 
with a fibronectin-binding protein of M. leprae (43L gene), but no specific consensus 
sites or motifs had been found to characterise the function of the molecule 
(Laqueyrerie, 1995). The apa gene [(named ModD, after the compilation of the M. 
tuberculosis genome (Cole, 1998)], was found in the same operon of a putative ABC 
transporter system highly similar to the molybdate importer system of E. coli 
(fig. 1.5); interestingly, this putative operon, encoded by three genes (modA-modB- 
modC), seems already functionally complete without the apa gene itself (Braibant, 
2000).
Protein glycosylation is an unusual finding in eubacteria. Initial evidence 
showed the Apa protein to react with Concanavalin A, demonstrating the presence of 
mannose (Dobos, 1995; Espitia, 1995). Further characterisation revealed universal O- 
glycosylation of threonine residues with a-D mannose units only; glycosylation sites 
were located at threonines 10 and 18 (mannobiose), 27 (single mannose) and 277 
(either mannose, mannobiose or mannotriose) (Dobos, 1996).
A more detailed study revealed that the 47-kDa glycoprotein purified from M. 
tuberculosis, M. bovis or BCG was composed of nine glycoforms; a small number of
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Figure 1.5 Schematic representation of the position of the apa gene in the 
recently annotated M. tuberculosis H37Rv genome (Cole, 1998). The apa gene is 
found in the same operon as the putative ABC molybdate transporter. The transporter 
is composed of a substrate binding protein (SBP-modA), two copies of a membrane 
spanning domain (MSD-rao*/#) and two copies of the nucleotide binding domain 
(NBD-mo^/C), according to the prokariotic prototype system in E. coli (Braibant, 
2000). Modified from Cole and collaborators (1998).
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molecules were non-glycosylated, whereas others had up to nine mannose residues 
per mole of protein (Romain, 1999; Horn, 1999). The 45-kDa band was found to be a 
COOH-terminal- truncated form of the native Apa (Romain, 1999; Horn, 1999). 
Interestingly, Apa molecules when deglycosylated, had a significant decrease in the 
capacity to induce DTH and were also less potent in stimulating in vitro proliferation 
of lymphocytes from BCG-vaccinated Guinea pigs (Romain, 1999; Horn, 1999).
In 1995, Espitia and collaborators presented the first evidences for the 
potential of Apa for diagnostic use. These authors reported that sera from 70% of 
individuals with pulmonary tuberculosis recognised the native protein specifically 
(Espitia, 1995). Using two-dimensional electrophoresis, Samanich and collaborators 
(1998) demonstrated the native form of Apa to have serodiagnostic potential, being 
recognised by sera from both early cavitary and non-cavitary TB patients. But further 
results were not as encouraging. HIV-positive-smear positive TB patients were poor 
reactors to Apa (Samanich, 2000). The recombinant form of the protein also had 
reduced reactivity to human TB sera (Samanich, 2000). In addition, tests on patients 
from Madagascar concluded that imunodiagnosis based on the Apa protein were not 
sufficiently predictive when compared to routine microscopy (Chanteau, 2000).
Immune responses to Apa protein were reported initially in Guinea pigs to be 
CD4+ but not CD8 + T cell-dependent (Romain, 1999; Horn, 1999). Besides 
induction of a significant amount of IFN-y, a DNA vaccine encoding the apa gene 
was not protective in mice against a challenge with M. tuberculosis (Morris, 2000). 
However, more recent results demonstrated partial protection levels after M. bovis 
BCG infection (Garapin, 2001). Recently, a prime-boost regimen using Apa as DNA 
vaccine plus live MVA-Apa as the booster, were claimed to be as protective as BCG 
in an intramuscular MTB infection model in Guinea pigs (Kumar, 2003). In the same 
article, the authors identified peripheral blood mononuclear cells (PBMC) from
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healthy PPD+ human donors proliferating and producing significant amounts of IFN- 
y to recombinant Apa in vitro, suggesting a role for this particular mycobacterial 
protein in the protective immunity against tuberculosis (Kumar, 2003).
1.9 Project aims
The aim of this thesis was to study new ways to obtain better protection 
against tuberculosis in a well-characterised model of infection. I first cloned and 
expressed the M. tuberculosis Apa antigen and then proceeded to investigate the 
immunogenicity of this antigen when used as DNA vaccine in mice. Importantly, I 
also tried to improve the efficacy of DNA vaccination against tuberculosis by using a 
DNA-prime BCG-boost vaccination strategy using different DNA plasmids 
expressing mycobacterial immunodominant antigens: Apa and other antigens such as 
HSP65, HSP70, MPT83 and MPT70 were tested alone or in various plasmid cocktail 
combinations and doses in two mice strains. Concomitantly, humoral and cellular 
responses with cytokine profiles were dissected, both before and after challenge with 
M. tuberculosis. Ultimately, the final aim of this project was to find a regimen 
capable of improving BCG protective abilities in mice.
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CHAPTER TWO
Material and Methods
2.1 Materials, media, solutions and buffers
All chemicals and reagents used were of analytical grade and were obtained from 
BDH Chemicals Ltd., Poole, UK, unless otherwise stated. Compositions of media, 
solutions and buffers are described when necessary in each technique.
2.2 Bacterial strains
2.2.1 Escherichia coli
E. coli One Shot™ TOP 10 competent strain (Invitrogen, Groningen, NL) was 
used as the host for pSecT2C.Apa and pCMV4.Apa vectors and also for the 
propagation of pHSP65 and pHSP70 vectors. Epicurian Coli™ Supercompetent E. 
coli XL 1-BLUE strain (Stratagene, La Jolla, CA) was used to propagate the 
pQE60.Apa vector. Bacteria were grown in Luria-Bertani (LB) medium (Sambrook, 
1989) containing lOOpg/ml of ampicillin at 37°C with rotation. E. coli M l5 strain 
(QIAgen, Sussex, UK) was transformed with pQE60.Apa for expression and 
purification of the recombinant Apa protein. The M l5 strain harbours a second 
plasmid, pREP4, expressing both a Lac-I regulator and a kanamycin resistance gene 
(see fig.3.3). The M l5 strain was grown at 37°C in LB medium containing lOOpg/ml 
ampicillin and 25pg/ml kanamycin.
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2.2.2 Mycobacterium bovis -  BCG
BCG-Glaxo (Glaxo-SmithKline, UK) vaccine strain was grown in Petri dishes 
of Middlebrook 7H11 Bacto-agar (Difco, Becton Dickinson, Oxford, UK) plus Bacto 
Middlebrook OADC (oleic acid, albumin, dextrose, catalase) enrichment (Difco), at 
37°C, Single colonies were inoculated and grown statically as a surface pellicule in 
Sauton’s media (for 1L, this medium contains 4g asparagine, 2g citric acid, 0.5g 
KH2PO4 , 0.5g MgS0 4 * 7  H2 O, 50mg iron (III) citrate, 1.4mg ZnSC>4 -7 H2 0 , and 57 mL 
glycerol; the pH is adjusted to 7.2 with NH4OH) or dispersed in Difco’s Dubos broth 
(Becton Dickinson) plus 0.2% glycerol and Dubos broth albumin (Difco), and was 
harvested at O . D . 5 0 0  of 0.5-0.8.
2.2.3 Mycobacterium tuberculosis
M. tuberculosis H37Rv and 1424 (streptomycin-resistant) strains were grown 
in rolling bottles under rotation at 37°C, containing Difco’s Dubos broth (Becton 
Dickinson) plus 0.2% glycerol and supplemented with Dubos broth albumin (Difco). 
MTB strains were harvested at O . D . 5 0 0  of 0.5. For colony counting, serial dilutions of 
organ homogenates from infected animals in saline were plated in 7H11 Petri dishes 
and grown for 2-3 weeks at 37°C.
2.3 Preparation of E, coli competent cells and bacterial transformation
E. coli M15 cells were grown in LB broth until O.D .6 0 0  reached 0.35 -  0.4. 
The cells were collected, cooled in ice for lOmin, centrifuged at 5000rpm for lOmin 
at 4°C and washed twice with 20ml of cold 0.1M CaCL with an incubation of 30
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minutes in ice between the washes. The bacterial pellet was finally resuspended in 
2ml of 0.1 M CaCh. 0.6ml of glycerol was added and this suspension was frozen in a 
dry-ice-ethanol mix. Aliquots were kept at -70°C. Transformations were performed 
by adding 50ng of plasmid to each aliquot of cells and heat-shocking it at 42°C 
(Sambrook, 1989). Cells were grown with shaking for one hour in SOC medium 
(0.5% yeast extract, 2% tryptone, lOmM NaCl, 2.5mM KC1, lOmM MgCh , 20mM 
MgSC>4 , 20mM glucose) and then plated in LB-agar containing the appropriate 
antibiotics for selection.
2.4 Eukariotic cell lines
2.4.1 CV1
CV1 cells (African green monkey kidney cells, a kind gift from Dr. Tony 
Magee, NIMR) were grown in Iscove’s modified DMEM medium (IMDM, Sigma) 
plus 4mM L-glutamine (Sigma), 80uM of 2-P-mercaptoethanol and 5% fetal calf 
serum (complete IMDM) in 5% CO2 at 37°C. Cells were passed by scraping when 50- 
70% confluent. These cells were used in transient transfections for in vitro expression 
of DNA vaccines.
2.4.2 THP-1
THP-1 cells (human acute monocytic leukaemia, ECACC No. 88081201) was 
maintained by dilution passage in RPMI 1640 medium (Invitrogen) plus 10% FCS, 
80pM p-mercaptoethanol and 2mM L-glutamine. This cell line was used for in vitro 
infection with MTB and RNA purification from the intracellular bacteria.
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2.4.3 RAW 264
This cell line (mouse monocyte-macrophage leukaemia, a kind gift from Dr. 
Ruth Aubrey, NIMR) was grown in complete IMDM. RAW264 cells were also used 
as host for infection with MTB.
2.4.4 EL-4
This cell line (ECACC No. 85023105) is lymphoblastic in morphology and 
resulted from a T cell lymphoma induced in C57BL/6. The cells were grown in 
suspension and were maintained by dilution passage in complete IMDM. This cell 
line was used to obtain stable transfectants expressing the apa gene and as labelled 
targets in the JAM cytotoxicity assay (Matzinger, 1991).
2.5 Quantification of DNA
DNA concentration and relative purity in solution were determined by 
measuring the absorbance at 260 and 280nm using a Unican UV/Vis 
spectrophotometer (A2 6 0  = 1-00 corresponds to a DNA concentration of 50pg/ml). A 
ratio A2 6 0 /A2 8 0  between 1.8 -  2.0 indicated low amounts of DNAse contamination.
2.6 Agarose gel electrophoresis
Fragments of DNA and RNA were separated by electrophoresis in molecular 
biology grade agarose (BioRad, Gottingen, The Netherlands) dissolved in TBE buffer 
(1-1.5% w/v in 89mM Tris-Borate, 2mM EDTA, pH 8.0). The gels contained
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0.5pg/ml of ethidium bromide (EtBr) for visualisation of the bands in UV light. 
Routinely, an lkb DNA-ladder (Invitrogen) was used. The samples were diluted in 
loading buffer solution containing 20% Ficoll 400 and O.lg Orange G.
2.7 Prim er design
Primers were designed based on the full-length apa gene (Rvl860) sequence 
(Acession no. x80268 from the NCBI Genbank Database 
(http://www.ncbi.nlm.nih.gov/)). Primers for the amplification of the entire coding 
sequence of Apa, including the N-terminal signal peptide, were constructed with a 
BamH I and a Not I site for directional cloning in both pSecT2C (Invitrogen) and 
pCMV4 (Tascon, 1997) vectors (Table 2.1).
pSecApa forward 5 ’-ATTGGATCCGGATGC ATCAGGTGGAC-3 ’
pSecApa reverse 5 ’-TATGCGGCCGCCCAGGCCGGTAAG-3 ’
pCMV4.Apa forward 5 ’-ATTGGATCCGCC ATGCATCAGGTGGAC-3 ’
pCMV4.Apa reverse 5 ’-TATGCGGCCGCCTC AGGCCGGTAAG-3 ’
Table 2.1: Primers used for amplification and cloning of apa in mammalian vectors.
For cloning into pQE60 vector (QIAgen), primers to amplify the entire coding 
sequence of the apa gene, including the N-terminal signal sequence, were designed to 
contain a BamH I and a Nco I sites (Table 2.2). All primers described were 
synthesised by Oswel (Southampton, UK).
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pQE60 forward 5-CATGCCATGGTACAGGTGGACCCCAACTTGACA-3'
pQE60 reverse: 5'- TTAGGATCCGGCCGGTAAGGTCCGCTGCGGTGT-3'
Table 2.2: Primers used for amplification and cloning of apa in pQE60 vector.
For use in Real-Time® reverse transcriptase (RT)-PCR, internal primers specific 
for the apa gene were constructed. In addition, an internal labelled probe specific for
TM
the apa gene containing both a fluorophore (FAM : 6-carboxy-fluorescein) and a 
quencher was also synthesised. Both were designed with the help of the Primer
TM
Express program (ABI-Prism, Applied Biosystems). Primers and probe were 
synthesised by Applied Biosystems (Foster City, USA). For the apa gene: forward 
primer, GGAAGCGCGTCGTATTACGA; reverse primer,
ATTACGCCCGTCCAGATCTG; FAM™-labelled probe,
CAAGTTCAGCGATCCGAGTAAGCCGAAC. For the control gene: sigA forward 
primer, TCGGTTCGCGCCTACCT; sigA reverse primer, 
TGGCTAGCTCGACCTCTTCCT; sigA FAM™-labelled probe,
TTGAGCAGCGCTACCTTGCCG.
2.8 Amplification of DNA by Polymerase Chain Reaction (PCR)
PCR reactions (50pl reaction) were performed using 32ng of genomic DNA of 
M. tuberculosis H37Rv diluted in PCR buffer [lOmM KC1, lOmM (NFL^SC^, 20mM 
Tris pH 8.74, 0.1% Triton 100, lOOpg/ml BSA]. Amplifications were done using 
0,5pi of 20pM primers plus 2.5U per reaction of high accuracy cloned Pfu DNA 
polymerase (Stratagene, La Jolla, USA). The annealing temperature was 55°C and
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extension time of 1.5min. For the construction of pQE60.Apa, PCR reactions were 
performed as described above but with an increase in the annealing temperature from 
55°C to 60°C. Amplification reactions were run in 0.5ml Eppendorf tubes in a 
CycleAmp PCR machine (Perkin-Elmer). The resulting PCR product was 
electrophoresed in agarose gels.
2.9 Isolation of mycobacterial RNA from infected mammalian cells
Bone marrow (BM) derived macrophages were isolated as described previously 
for BM-derived dendritic cells (Tascon, 2000) and reported in 2.24 of this thesis. 
Only adherent cells were selected. Approximately 5 x 107 cells were seeded to 
175cm2 culture flasks with 30 ml of medium. RAW 264 cells were adjusted at 1 x 108 
cells/175cm2 culture flasks. In both cases, to activate the cells, lOOU/ml of mouse 
recombinant IFN-y cytokine (Roche) was added to the flasks for 16 hours at 37°C. 
THP-1 cells were distributed at 5 x 107 cells in 175cm2 flasks containing 50ml of 
media. The cells were stimulated for 24 hours with 12ng/ml of PMA (Sigma), diluted 
in DMSO. When the cells were adherent, lOOU/ml of human recombinant IFN-y 
(Roche) was added and incubation proceeded for further 16 hours.
Infection with M. tuberculosis was carried out at 10:1 bacteria/cell ratio during 8 
hours of incubation at 37°C. BMDCs and THP-1 cells were infected with the 1424 
streptomycin-resistant MTB strain. RAW 264 cells were infected with the H37Rv 
reference strain. Afterwards, the cells were washed 3 times with cold and sterile PBS 
to remove extracellular bacteria. Lysis of the cells was induced by the addition of 
saponin (fig.2.1), diluted in media (final concentration of 1%), followed by a period 
of 40 minutes at RT. The saponin was eliminated by two washes with PBS by 
centrifugation at 3000rpm. RNA was extracted from the intracellular mycobacteria,
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Figure 2.1 Real-time PCR with in tracellu lar bacteria. Intracellular M. 
tuberculosis is partially separated from eukariotic cellular debris by centrifugation. 
Specific primers and probes for apa and sigA genes were used. The probes undergoes 
spontaneous fluorogenic conformational change if hybridised with the specific target 
but not in solution. Capture of fluorescence allows for the direct measurement of the 
amount of amplicons when PCR reaction is on logarithmic phase. Q, quencher 
molecule; p, primer; F, fluorophore.
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using a Hybaid RyboLyser apparatus in conjunction with a Hybaid Recovery Blue kit 
(Hybaid, Little Chalfont, UK), for lysing the cells and isolation of mycobacterial 
RNA, according with the manufacturer’s protocol. The resulting RNA was dissolved 
with 50pl of RNAse-free water and kept at -70°C until DNAase treatment was 
performed.
2.9.1 Dnase treatment
This RNA was treated twice with RNAse-free DNAse RQ1 (Promega) in order to 
avoid carrying contamination of genomic DNA. Briefly, the RNA dissolved in water 
was mixed with 6U of DNAse, 2pi of RNAsin inhibitor (Promega), 20mM MgSCU, 
lOOmM Sodium Acetate pH 5.2, in a final volume of 150pl. This mixture was 
initially incubated 1 hour at 37°C, and 6U of enzyme plus RNAse inhibitor added 
afterwards, followed by another hour of digestion at 37°C. The reaction contents were 
cleaned of protein contamination with the RNEasy mini kit (QIAgen Ltd, West 
Sussex, UK), according to the manufacturers protocol. RNA was finally eluted with 
50pl of RNAse-free water. A routine PCR reaction was performed using 
mycobacteria gene-specific primers and the processed RNA as the template, to assure 
the absence of DNA contamination.
2.10 Real-Time™ reverse transcriptase (RT) -  PCR
The mycobacterial RNA was reverse-transcribed to cDNA using specific 
reverse primers for the apa gene and sigA factor, the latter showing constitutive 
expression in M. tuberculosis, was considered a good candidate to be the internal
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control (Manganelli, 1999). The reverse transcription reaction was performed using 
Superscript RT II (Invitrogen) reverse transcriptase as described previously 
(Raynaud, 2002). The resulting cDNAs were used in a quantitative RT-PCR assay 
determined in real time using fluorescent molecular beacons: oligonucleotide probes 
homologous to central parts of the gene and coupled to a quenched fluorophore. The 
fluorescence is restored at the binding of the probe to the target, which in this case is 
the resulting PCR product (fig.2.1). The intensity of the fluorescence in each 
amplification step is a direct measure of amplicon concentration (Piatek, 1998). A 
standard curve was set using serial dilutions at pg/ml of mycobacterial DNA. Samples 
were assayed in duplicate and to increase the statistical significance of the results, 
several assays were run for the same sample. In all assays, the 25pi reactions 
consisted of 12.5pl of PCR master mix (Promega), 4pl of template, 5 picomoles of 
each primer and 2.5 picomol of the appropriate probe. Reactions were carried out in
J|y |
sealed tubes. The Real-Time PCR reaction was performed in a Taqman PCR 
machine (ABI-PRISM 7700 Sequence detector, Applied Biosystems, Foster City, 
USA). Results were analysed with the Sequence Detector program (ABI-PRISM, 
Applied Biosystems).
2.11 Cloning into plasmid vectors
2.11.1 Construction o f  pCMV4.Apa andpSecT2C.Apa vectors
A 1Kb DNA product was obtained by PCR using apa-specific primers, 
containing the restriction sites; the DNA product was gel-purified for further cloning 
using the QIAquick gel extraction kit (QIAgen). Vectors pCMV4 and pSecT2C and 
insert were digested with BamH I and Not I and gel-purified. The ligation reaction
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was performed using lp l of T4-DNA ligase in lOpl of ligation buffer (Boehringer- 
Mannheim, Sussex, UK) plus purified plasmids and PCR products at 1:2 molar ratio, 
respectively. A small aliquot of this mixture was used to transform E. coli One Shot 
TOP 10 supercompetent cells (Invitrogen). Selection was done in 100mm LB-agar 
Petri dishes containing lOOpg/ml of ampicillin. Colonies were selected at random and 
plasmids purified using the QIAprep spin miniprep kit (QIAgen). Restriction enzyme 
mapping identified the recombinant plasmids pCMV4.Apa and pSecT2C.Apa.
2.11.2 Construction o f pQE60,Apa vector
The bacterial expression vector pQE60 was obtained from QIAgen. This 
vector allows fusion of the cloned sequence with a 6xHis tag in the C-terminal part of 
the recombinant protein. The vector was also gel-purified and double-digested with 
BamH I and Nco I. PCR fragment and open vector were ligated using T4-DNA ligase 
in the same conditions described above. E. coli XL 1-BLUE cells were transformed 
with the ligation mixture. Recombinant colonies were selected in ampicillin plates 
and restriction enzyme analysis was used to identify positive clones.
2.12 Purification of plasmidial DNA for vaccination
Plasmids were purified using Endofree QLAfilter Plasmid Giga Kit (QIAgen), 
according to supplier’s protocol. However, in order to improve yields of plasmid 
DNA per starter culture, the QIAgen plasmid purification columns were re-used, 
according to a protocol developed by Gregory and colleagues (1999). Briefly, after 
the initial run, the columns were washed with 100ml of endotoxin-free water and 
equilibrated with 50ml of buffer QBT, supplied with the kit. The flow-through lysate
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from the previous run was saved and passed again on the regenerated column up to 
three times still yielding significant amounts of plasmid DNA. Volumes of starter 
bacterial cultures were typically two litres, with yields varying between 5-12mg of 
purified plasmid DNA per run. Plasmids were dissolved in low-endotoxin sterile 
saline (Sigma) and kept at -20°C.
2.12.1 Restriction endonuclease mapping
Plasmids Restriction enzymes
pCMV4.83 (MPT83) BamH I, Xho I
pCMV.70 (HSP70) Hind III, Pst I
pCMV4.65 (HSP65) Bgl II
pBT7 (MPT70) BamH I, Xba I
pCMV4.Apa (Apa) BamH I, Not I, Hind III
pCMV4 (vector) BamH I, Not I, Hind III
Table 2.3: Restriction enzymes used for restriction mapping in mammalian vectors.
To certify for the true type of plasmid being used, a diagnostic panel of 
restriction enzymes was used (Table 2.3). Digestions were monitored by agarose-gel 
electrophoresis. All plasmid batches were tested before use in animal vaccination. 
The enzymes were used according to the manufacturer’s protocol (New England 
Biolabs, Gibco-BRL and Roche).
2.12.2 Endotoxin determination
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Plasmids were tested for endotoxin levels with the limulus amebocyte lysate 
QCL-1000 assay (Biowhittaker, Walkersville, MD), according to the manufacturer’s 
instructions. This is a very sensitive chromogenic test to detect gram-negative 
bacterial endotoxin (LPS). Basically, the LPS catalyses the activation of a proenzyme 
in the limulus amoebocyte lysate (LAL) and the rate of activation is dependent on the 
concentration of LPS present. The activated enzyme catalyses the splitting of p- 
nitroaniline (pNA) from the colourless substrate supplied with the kit and the pNA is 
measured photometrically at 405nm in a EL312 microplate ELISA reader (Bio-Tek 
Instruments, Winooski, USA), after the reaction is stopped with 25% v/v glacial 
acetic acid in water. Samples were routinely tested in duplicate by the microplate 
method. Plasmids were used only when endotoxin levels were below 0.1 EU/pg of 
DNA. All plasmid DNA destined for injection and also, recombinant proteins for in 
vitro cell culture use were evaluated for endotoxin content by this assay.
2.13 DNA transfection
2.13.1 Transient
Transient transfections were performed to certify the ability of the plasmid 
constructs to express the encoding gene in mammalian cells and for purification of 
histidine-tagged recombinant Apa. Briefly, 180pg of endotoxin-free plasmids
TM
pCMV4.Apa or pSecT2C.Apa, diluted in 9ml of serum-free Optimem medium 
(Invitrogen), were incubated at RT for 45 minutes. 364pi of Lipofectin reagent 
(Gibco-BRL, Paisley, UK), was diluted in 3.64ml of the same media and also 
incubated at RT for 45 minutes. DNA and liposome solutions were mixed gently and 
left undisturbed at RT for further 15 minutes. At the end of this period, 28ml of media
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was added to the DNA-liposome mix and this solution transferred to one 175cm2 
bottle containing CV1 cells at 40-50% confluency in 15ml of Optimem®. At t = 16 
hours of incubation at 37°C, the cell monolayer was washed and new media added. 
Supernatants were recovered at t = 21hs and t = 48hs, filtered through 0.2pm 
membranes and concentrated by lyophilisation. The cells were grown for 48h before 
being collected for the preparation of a cell extract to test for specific protein 
expression.
For purification of recombinant Apa, transfection procedures were similar to 
what is described above, but the plasmid used was pSecTag2C.Apa and the number 
of 175cm2 flasks used increased to ten. Supernatants were concentrated by 
ultrafiltration and dialysed against sterile PBS buffer. A protease-inhibitor cocktail 
(Roche, Sussex, UK) was added to some batches. All procedures were done at 4°C. 
Concentrated samples were kept at -70°C until further purification by affinity 
chromatography.
2.13.2 Stable
For the generation of stable transfectants expressing the Apa antigen, EL-4 cells 
were plated at a density of 1 x 105 cells/well in a 24-wells plate containing 0.5ml of 
IMDM complete media. For one plate, 30pg of sterile endotoxin-free pCMV4.Apa 
was diluted in 1.5ml of IMDM media without fetal calf serum (FCS). 62.5pl of 
Lipofectamine 2000 reagent (Invitrogen) was also diluted in 1.5ml of media without 
FCS. These components were mixed gently but immediately and incubated at room 
temperature for 20 minutes. Afterwards, lOOpl of the DNA-cationic lipid mix were 
added per well, and the plate rocked gently. After 4 hours of incubation at 37°C,
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1.5ml of complete IMDM was added to each well. After 16 hours, the cells were 
collected, centrifuged and transferred with new media to 80cm Nunc flasks. After 48
TMhours, selection reagent Geneticin (G418-Gibco) was added to the transfected 
cultures at 0.8mg/ml. The cells were left incubating for two weeks and the media 
changed weekly. At the end of this period, survivor clones were selected by limiting 
dilution at less than 1 cell/well. Apa-expressing clones were identified by Westem- 
blot of cell extracts with monoclonal antibody 6A3 and kept in liquid nitrogen.
2.14 Preparation of protein extracts and culture filtrates
2.14.1 Transfected CV1 cells
The cells were grown for 48h before being scraped off for the preparation of a 
lysate. After centrifugation for 5 minutes at 1200rpm, the pellet was washed once in 
Dulbecco’s PBS. Both cell lysate and lyophilised supernatant were resuspended in 
RIPA buffer [PBS, 1% Igepal CA-630 (Sigma), 0.5% sodium deoxicholate, 0.1% 
SDS)] plus protein inhibitor cocktail [(AEBSF lOOpg/ml, 2pg/ml of leupeptin (ICN, 
Aurora, OH), sodium orthovanadate lOOmM and aprotinin 30pl/ml (Sigma, Dorset, 
UK)]. This mixture was allowed to stand for 30 minutes in ice, transferred to 
Eppendorf tubes and finally centrifuged for 10 minutes at lO.OOOxg; supernatants 
were recovered and kept at -70°C.
2.14.2 BCG-Glaxo
BCG-Glaxo strain was inoculated in Sauton's broth and grown for 2 weeks at 
37°C. Acid-fast staining confirmed the purity of the cultures. Cells were harvested by
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centrifugation for 40 minutes at lO.OOOxg, 4°C. The cell-pellet was snap-frozen in dry 
ice- absolute ethanol mix and kept for 24 hours at -70°C. Approximately 200ml of 
culture fluid was initially filtered through a GF/F membrane (Whatman, Maidstone, 
UK) and later concentrated 20X by ultrafiltration in a Stirred Cell model 8400 
(Amicon-Miliipore, Watford, UK) equipped with a 3000MW regenerated cellulose 
membrane (Millipore). Afterwards, the concentrated sample was dialysed overnight 
against water. This material (8ml) was lyophilised and resuspended in 1ml of sample 
buffer for SDS-PAGE. The cell pellet was thawed and processed according to the 
method described by Urquhart (1997); briefly, the pellet was resuspended in 10ml of 
sample washing buffer (SWB: KC1, 3mM; KH2P 0 4, 1.5mM; NaCl, 68mM; 
NaH2PC>4 , 9mM). After washing three times (lO.OOOxg, 50 minutes) in this solution, 
the pellet was mixed with 0.5g of 150-212 microns glass beads (Sigma) and 1ml of 
Lysis Buffer (0.11M Chaps; 0.11M Dithiotreitol; 58mM Tris; 10M Urea) plus a 
protease-inhibitor cocktail (Roche, Sussex, UK). Samples were processed 4 x 45 
seconds at speed 6.5 in a Hybaid Ribolyser (Hybaid). Tubes were centrifuged 
13.000xg for 10 minutes and supernatant recovered. Samples were subjected to a 
final centrifugation of 30.000xg for 30 minutes at 4°C to clear up the supernatant, 
which was kept at -70°C until further testing by Westem-blot.
2.15 Protein separation
10% SDS-PAGE (one-dimension polyacrylamide gel electrophoresis under 
denaturing 0.1% w/v SDS conditions) was performed using a Mighty Small II Mini- 
Gel System (Hoeffer Scientific Instruments, Little Chalfont, UK), in order to separate 
proteins based on their molecular size. Protein samples were denatured in sample 
buffer (for 10ml: 2.2ml Tris 0.5M pH 6.8, 2.25g SDS, 1.77ml glycerol, 0.4ml 2-P-
84
mercaptoethanol and 2mg bromophenol blue) and added to the gel alongside 
prestained Kaleidoscope® molecular weight markers (BioRad). A maximum of 20pl 
of sample was added per lane. The gel dimensions were 83 x 63 x 0.75mm and 
electrophoresis was performed at 28mA for approximately 2 hours with cooling. 
Resolving gel mixes were prepared by mixing Protogel solution (National 
Diagnostics), a 37.5:1 acrylamide to bis-acrylamide stabilised solution, to a final 
concentration of 10% in 1.5 M Tris pH 8.8. After addition of 200pl of 10% SDS 
solution, polymerization was achieved by adding ammonium persulfate and TEMED 
(BioRad). Stacking gel was overlayed onto the resolving gel. The Protogel mix 
concentration in the stacking gel was 4%, diluted in 0.5 M Tris pH 6.8. After 
electrophoresis, gels were either used for immunoblotting or fixed in 25% (v/v) 
isopropanol, 10% (v/v) acetic acid for 30 min, and stained in 0.006% (w/v) 
Coomassie Blue R-250 (Sigma) diluted in 10% (v/v) acetic acid, for 1 hour or 
overnight. The gels were destained with a mixture of 5% methanol and 7% glacial 
acetic acid.
2.16 Western blot analysis
For the transference, the gel was briefly immersed into transfer buffer (48mM 
tris, 39mM glycine, 0.037% SDS, 20% methanol) and added to the PVDF membrane 
previously soaked in the same buffer. Transfer was performed in a semi-dry blotting 
system (Biometra, Gottingen, DE) for one hour at 60mA. Afterwards, the PVDF 
membrane was incubated in blocking-buffer (TBS: lOmM Tris/HCl (pH 7.5), 150 
mM NaCl, 0.1% Tween 20® plus 10% of skim milk and 2mM EDTA) for 2h at room 
temperature. After washing once in TBS-0.1% Tween 20® for 15 min, the membrane 
was incubated with the first antibody for one hour. Mouse anti C-terminal 6xHis
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antibody (Invitrogen) at 1:2000 dilution in TBS 0.05% Tween 20® (TBS/T) 3% skim 
milk was used for the detection of 6xHis-tagged proteins. For the detection of Apa 
protein, a specific monoclonal antibody, mAb 6A3 (Espitia, 1995) was used at 1:250 
dilution. After washing 5X for 5 minutes, 1:1500 dilution of the second antibody, 
anti-mouse IgG alkaline phosphatase (DAKO, Ely, UK) was applied to the membrane 
for one hour at RT. The membrane was then washed 5X with TBS/T, 2X with TBS 
only and once with PBS. Bands were visualised after addition of substrate NBT-BCIP 
(Sigma-FAST) diluted in water. The reaction was stopped with tap water.
2.17 Protein staining with colloidal gold
Staining with stabilised colloidal gold solution (AuroDye forte®, Amersham) was 
carried out after protein transfer to PVDF membranes. At low pH, the negatively 
charged gold particles bind to proteins by hydrophobic and ionic interactions. This 
type of staining is as sensitive as silver staining, although more simple to perform. 
After blot transfer, the membrane was incubated with an excess of PBS supplemented 
with 0.3% of Tween 20® at 37°C for 30 minutes with gentle agitation. Afterwards, the 
membrane was washed intensively with the same solution, at room temperature. The 
washed blot was drained, washed briefly with distilled water and incubated with an 
excess of AuroDye forte® solution for 2-4 hours, with gentle agitation. At the end, the 
blot was washed with tap water. Overstaining did not occur.
2.18 Staining of blotted glycoproteins
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Purified recombinant Apa (RecApa) produced in the mammalian cell line CV1 
was tested for the presence of carbohydrate groups. Typically, lpg  of purified protein 
was loaded per well and a 10% SDS-PAGE was performed, followed by transfer of 
the proteins to a PVDF membrane by semi-dry blotting procedure. CandyCane® 
glycoprotein molecular weight standard (Molecular Probes, Eugene, USA) was added 
alongside the samples; this standard contains a mixture of glycosylated and non­
glycosylated proteins. The Pro-Q Emerald 300 blot staining kit (Molecular Probes, 
Eugene, USA) was used to identify the glycoproteins present in the blot according to 
the instructions provided by the manufacturer. Briefly, the blot was gently agitated 
immersed in Fix solution (50% methanol + 50% milli-Q water) for 45 minutes, 
followed by a 2X washing in 3% of glacial acetic acid (Wash solution) for 10 
minutes. The carbohydrates were then oxidised by incubation for 30 minutes in 
periodic acid diluted in wash solution. After a series of 3 washes, the blot was 
incubated with the fluorescent Pro-Q Emerald 300 staining solution for 2 hours. After 
washing twice in the dark, the blot was air-dried and exposed to a 300nm ultra-violet 
light to visualise the fluorescent bands. The blot was photographed and reproduced 
with the image inverted using an Image Station 440CF (Kodak Digital Science), with 
assistance of the Kodak ID 3.5 program (Kodak) and a f-stop of 4.5 for 2 seconds 
plus multiple 1-second exposures.
2.19 Colony-blots
Plasmid pQE60.Apa was transformed into E. coli M l5 cells to obtain high 
levels of recombinant Apa expression; clones expressing high levels of Apa protein 
were selected by colony blot lifts. Briefly, the transformation mix of E. coli M l5 and 
pQE60.Apa was plated in LB agar containing both ampicillin and kanamycin and
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incubated 16 hours at 30°C. A replica of this plate was made by touching the agar 
surface with a nitrocellulose filter disc. The filter with the colonies side-up was 
transferred to a new LB agar plate containing lmM of IPTG and incubated 4h at 37°C 
to induce expression of the recombinant product. The filters were placed sequentially 
in a serie of solutions: [SDS 10%, denaturing solution (1.5M NaCl, 0.5M NaOH), 
neutralization solution (1.5M NaCl, 0.5M Tris pH 7.4) and 2 x SSC (0.3M NaCl, 
34mM trisodium citrate)] in order to lyse the colonies and induce the binding of 
proteins to the membrane. The filters were later washed twice in TBS and blocked for 
one hour with 3% bovine serum albumin (BSA) (Sigma) in TBS buffer. After another 
series of washes in TBS Tween/Triton (2 x 10 minutes) and TBS (IX), the 
membranes were incubated for 1 hour in 1:2500 dilution of mouse anti C-terminal 
6xHis antibody in blocking buffer, to detect the tagged recombinant protein. After 
washing, incubation with second antibody was carried out using a 1:1500 dilution of 
rabbit anti-mouse IgG alkaline-phosphatase (DAKO) in blocking buffer for one hour 
RT. At the end of incubation, the discs were washed three times with TBS 
Tween/Triton and developed with NBT-BCIP (Sigma-FAST). Colonies showing the 
most intense signal were selected and retrieved from the original master plate.
2.20 Purification of 6xHis-tagged recombinant protein
2.20.1 Preparation o f  periplasmic extract
According to Horn and collaborators (1999), E. coli M l5 transformed with the 
pQE60.Apa construct expresses Apa protein into the periplasmic space due to the 
inclusion of the associated N-terminal secretion sequence. The recombinant bacteria 
were grown at 37°C in 1 litre of LB medium, supplemented with ampicillin and
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kanamycin, until culture reached an OD6 0 0  of 0.7. Then, 2mM of IPTG was added to 
the culture and a further 5 hours of incubation was carried out. The cells were 
harvested by centrifugation at 4000xg for 15 minutes at 4°C. To induce an osmotic 
shock on the cells, the pellet was resuspended in approximately 500ml of a cold 
solution of 30mM Tris, 20% sucrose, pH 8.0; ImM of EDTA was added dropwise 
and the suspension was incubated on ice for 10 minutes with gentle agitation. The 
cells were centrifuged at 8000xg for 20 minutes at 4°C and the supernatant was 
substituted by the same volume of 5mM of ice-cold MgS0 4 ; the preparation was 
gently agitated for 10 minutes at 4°C. After a new centrifugation at 8000xg, the 
supernatant containing the periplasmic proteins was collected, filtered through a 
0.2pm filter (Millipore), concentrated 50X by ultrafiltration and dialysed extensively 
at 4°C against lOmM Tris pH 8.0 with three changes. Dialysis proceeded overnight 
with buffer-to-sample ratio of 1:60. Sample was kept at -70°C until further 
processing.
2.20.2 Ni-NTA affinity chromatography
A nickel-nitrilotriacetic acid agarose (Ni-NTA) column containing 2ml of 
resin with high affinity for terminal 6-histidines-tagged proteins (Ni-NTA, QIAgen), 
was equilibrated with 5ml of lOmM Tris pH 8.0. The periplasmic extract containing 
Apa carrying a His tag was loaded into the column. The column was washed initially 
with 10 volumes of lOmM Tris pH 8.0 plus lOmM of imidazole (Sigma) and then 
again with 10 volumes of the same buffer plus 20mM imidazole. Fractions were 
collected trough the process to evaluate the performance of the procedure. Purified 
recombinant Apa (RecApa) was eluted four times with lOmM Tris pH 8.0 containing 
200mM of imidazole. All steps were carried out in the cold room at 4°C to diminish
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the action of proteases. Eluates were dialysed against water and lyophilised. Western- 
blotting using the specific mAh 6A3 as described previously, detected the 
recombinant Apa protein in the eluates.
For purification of RecApa produced in mammalian cells, the routine 
procedure described above was followed. However, two set of washes with 20mM of 
imidazole were performed instead of one since mammalian cells are richer in 
histidine-containing proteins than prokaryotic cells.
2.21 Endotoxin removal by Polymyxin B columns
A support of immobilised Polymyxin B in agarose (Detoxi-Gel Endotoxin 
Removing Gel, Pierce, Rockford, USA) was used to decrease the levels of endotoxin 
in the RecApa samples used for in vitro cell cultures. Polymyxin B is an antibiotic 
that contain a cationic cyclopeptide with a fatty acid chain and can bind and neutralise 
the lipid A portion of bacterial LPS (Morrison & Jacobs, 1976). The procedure used 
was recommended by the manufacturer’s instructions. Briefly, the lyophilised Apa 
samples were resuspended in 2 ml of ultra pure 0.1M ammonium bicarbonate, pH 7.8 
(Fluka, Buchs, Switzerland) diluted in endotoxin-free water (Biowhittaker). This is a 
volatile buffer, which allows the sample to be lyophilised later as a salt-free powder. 
The prepacked 1 ml columns were regenerated with 5 washes with sodium 
deoxicholate (Fluka), followed by 5 washes with pyrogen-free water. Afterwards, the 
column was regenerated with 5 volumes of 0.1 M ammonium bicarbonate buffer. The 
sample was applied; the column was capped and incubated at room temperature for 
30 minutes to increase the binding of LPS to the matrix. The sample was eluted with 
a gradient of 0.1-0.5 M of NaCl. With this procedure, there was a reduction of 
approximately 54X in the amounts of endotoxin contamination in the sample, i.e.
RecApa was usually obtained at 5-6 EU/mg of protein and these levels were 
considered acceptable for use in in vitro cell cultures.
2.22 Quantification of total protein
Recombinant Apa derived from mammalian cells, unrelated protein samples 
and cell extracts obtained in low amounts were quantified by the NanoOrange® 
protein quantitation kit (Molecular Probes), a sensitive fluorometric method able to 
detect concentrations of protein in solution of lOng/ml to lOpg/ml. The protocol was 
followed according to manufacturer’s instructions. Briefly, a standard curve from 
lOpg/ml to lOng/ml was prepared diluting bovine serum albumin in the working 
solution containing the NanoOrange® quantitation agent. Test sample was diluted 
1:250 in the same solution. All protein samples were heated at 90°C for 10 minutes, 
in the dark, for denaturation. Samples were cooled at room temperature for 20 
minutes. Readings were made in quartz cuvettes with a 3mm path-length in a Perkin- 
Elmer LS50B Luminescence Spectrometer (Perkin-Elmer, Foster City, USA) with an 
excitation emission at 485nm and capture at 570nm. A standard curve of fluorescence 
versus protein concentration was generated subtracting the blank from the samples.
2.23 Quantification of recombinant protein
Detection of purified recombinant Apa protein was done by Western-blotting 
as described previously, using the mAh 6A3. The amount of purified protein in the 
samples was estimated by measuring absorbance at 260nm and 280nm of the protein 
solution, using 1 0 mm path-length cuvettes and applying the following formula 
(Dawson, 1989):
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Protein conc. (mg/ml) = 1.55^280 -  0.76^260
2.24 Isolation of murine bone marrow-derived dendritic cells (BMDCs)
The protocol was adapted from Inaba and collaborators (1992). Briefly, mice 
were killed by cervical dislocation and both femurs were removed. In a sterile Petri 
dish (Nunc) containing approximately 10ml of IMDM complete medium, the bone 
marrow from both femurs was flushed with the help of a 2 ml syringe and a 25G 
needle. The cell suspension was centrifuged once at 1200rpm and after dilution in 
new media, the cells were distributed in new sterile Petri dishes (up to 5 per mouse). 
1:10 dilution of supernatant from a stable cell line expressing murine GM-CSF 
(granulocyte-macrophage colony growth factor) (a kind gift of Dr. Brigitta 
Stockinger, NIMR) was added to each plate. After two days of incubation at 37°C, 
5% CO2 , the media and the cells in suspension were discarded. Fifteen millilitres of 
fresh media plus GM-CSF were added and the cells left undisturbed for additional 4 
days. After this period, it was possible to see cells with dendritic morphology in 
suspension or loosely attached. These cells were collected, counted and used as APCs 
(antigen-presenting cells).
2.25 Isolation of murine spleen cells
Mice were killed by cervical dislocation and spleens were removed. The 
organ was homogenised in 10ml of AIM-V serum-free media supplemented with 
80pM of 2-p-mercaptoethanol or complete IMDM and a single-cell suspension was 
obtained after crushing it trough a 70pm cell strainer (Falcon-Becton Dickinson, Le
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Pont de Claix, FR). The erythrocytes were lysed osmotically with 1.5 ml (per spleen) 
of Red Blood Cell Lysis Buffer (Sigma). Spleen cells were washed twice, counted 
and resuspended at desired concentrations in complete media.
2.26 DNA vaccination
2.26.1 Strains o f  mice used
Vaccination with plasmid DNA was performed using 6 - 8  weeks old females. The 
Institute’s Biological Services, National Institute for Medical Research (NIMR) 
supplied all animals. Food and water were given at will. Strains used were the inbred 
C57BL/6 (H-2b) and Balb/c (H-2d).
2.26.2 Vaccination and challenge procedures
Experiment Mouse strain Vaccines used
ApaDNA: immune 
response and protection 
studies
C57BL/6 pCMV4.Apa (Apa), 
pSecT2C.Apa (Apa), pCMV4 
(vector), BCG and saline
Table 2.4: Vaccination scheme for ApaDNA groups.
For ApaDNA-vaccination studies, mice were injected with lOOpg of plasmid 
DNA intramuscularly. Control groups were either injected with saline four times or 
once with 1 x 106 BCG-Glaxo, intradermally, at the base of the tail (Table 2.4). The 
number of DNA injections was 4 with intervals of 3 weeks between inoculations.
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Mice were analysed and challenged with MTB at 3 and 6  weeks after the last dose, 
respectively. Bacterial load was determined 5 weeks later in the lungs and spleen.
For the priming-boosting experiments, 6 - 8  weeks old Balb/c or C57BL/6 
females were injected once with a single antigen or in combinations of three or four 
antigens at the same time. The amount of DNA injected intramuscularly was lOOpg 
for prime-boost I. For prime-boost II, approximately 50-75pg each of pCMV4.Apa, 
pCMV4.83, pCMV4.65 and pCMV.70 plasmids were injected simultaneously in the 
same animal, each plasmid in a different anatomical site (Table 2.5). The muscles 
from the front and rear limbs were used for injection.
Experiment Mouse strain Priming vaccines Boosting
Prime-Boost I C57BL/6 pCMV4.Apa, pCMV4, BCG BCG or 
pCMV4.Apa
Prime-Boost II Balb/c pCMV4.Apa, pCMV4.83 
(MPT83), pCMV4.65 
(HSP65), pCMV.70 
(HSP70), pBT7 (MPT70), 
pCMV4, BCG
BCG or 
pCMV4.Apa, 
pCMV4.83, 
pCMV.65 and 
pCMV4.70
Table 2.5: Vaccination scheme for prime-boost I and II.
In the same fashion, another group of animals in this experiment received 
simultaneously: pBT7, pCMV4.65 and pCMV.70. The boost was performed with 
approximately 1 x 106 CFU of BCG, injected intradermally at the base of the tail, one 
month after priming with DNA. Groups with initial BCG priming and plasmid DNA 
boost (one month after priming) were also set (Table 2.5). After approximately 6-12
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weeks, the animals were either killed for immune response analysis or challenged 
with 1 x 105 colony-forming units (CFU) of M. tuberculosis injected intravenously. 
Five weeks later, the mice were killed by a Schedule One method and the bacterial 
load in the lungs and spleens was evaluated. Briefly, the organs were weighted and 
homogenised in PBS. Serial 10-fold dilutions of the homogenates were plated on 
Middlebrook 7H11 Bacto Agar (Difco). Colonies were counted 3-4 weeks later and 
results expressed as CFU/g of tissue. The experiment was repeated twice.
Experiment Mouse strain Priming vaccines Boosting
Prime-boost III C57BL/6 and Balb/c pCMV4.Apa, 
pCMV4.65, pCMV.70, 
pCMV4, BCG.
BCG
Table 2.6: Vaccination scheme for prime-boost III.
In the prime-boost III studies, the animals received two or three initial doses 
of combinations of pCMV4.Apa, pCMV4.65 and pCMV.70 plasmids (Table 2.6). 
The intervals between DNA vaccinations were three weeks and BCG was injected 
one month after the last dose of DNA. Immune response analysis and infection 
occurred similarly as described for prime-boost II groups.
In prime-boost IV, a large group of C57BL/6 females (12 per cage) were 
primed twice or three times with vaccine combinations of pCMV4.65, pCMV4.70 
and pCMV4.Apa. Groups of animals primed twice with pCMV4.65 and pCMV4.70 
plasmids (no ApaDNA) and boosted or not with BCG were also included. Control 
groups included animals receiving three doses of saline or vector, and also two and 
three doses of vector followed by a boost with BCG. 50-75pg each of pCMV4.Apa,
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pCMV4.65 and pCMV.70 plasmids were administered simultaneously in the same 
mouse, each vaccine injected intramuscularly in a different limb (a total per priming 
dose of 150-200pg of DNA injected per animal). For vector injections, the total 
amount injected per dose was 200pg. The boost with 1 x 106 BCG bacteria was 
administered intradermally at the base of the tail, one month after the last DNA 
injection. Interval between DNA injections was three weeks. Animals were infected 
fifteen weeks after the last vaccination. Bacteriologic burden in the spleen and lungs 
was measured after six weeks of infection (Table 2.7).
Experiment Mouse strain Priming vaccines Boosting
Prime-boost IV C57BL/6 pCMV4.Apa, pCMV4.65, 
pCMV4.70, pCMV4, BCG
BCG
Table 2.7: Description of prime-boost IV groups.
In the prime-boost V experiment, groups of eight Balb/c females per cage 
received BCG intradermally, as the priming vaccine, and boosting vaccinations were 
made with a combination of mycobacterial antigens in DNA format. The amounts of 
DNA and BCG and sites of injection were similar to prime-boost III and IV 
experiments described above. The Test group was injected once with BCG and eight 
weeks later received a boosting combination of HSP65 and HSP70 plasmids. A 
second DNA boosting dose was given three weeks later. Animals were challenged 
intravenously with 105 CFU of M. tuberculosis H37Rv three weeks later. The control 
groups included naive animals, mice receiving a first dose of BCG and then two 
boosting doses of either saline or pCMV4 empty vector. And, in the last control 
group, the animals received saline as the priming vaccine and two doses of HSP65
and HSP70 plasmid cocktail as the boosting vaccine. The experiment is described in 
table 2 .8 .
Experiment Mouse strain Priming vaccines Boosting
Prime-boost V Balb/c BCG, pCMV4.65, 
pCMV4.70, pCMV4
pCMV4.65, 
pCMV4.70, pCMV4
Table 2.8: Scheme for prime-boost V protocol.
2.27 Enrichment for murine splenic CD4+ or CD 8 + T-cells
For the enrichment of CD4+ and CD8 + T-cell subpopulations, Mouse T Cell 
Subset Column Kits (R & D Systems, Oxon, UK) were used according to the 
manufacturer's instructions. Briefly, erythrocyte-depleted spleen cells were 
resuspended in 2ml of IX sterile column wash buffer (R & D Systems) and a 
monoclonal antibody cocktail ( 1 ml) designed to negatively deplete the cell population 
without interest, thereby enriching for the desired T cells, was added. The mixture 
was incubated at room temperature for 15 minutes. Following two washes by 
centrifugation at 1300 rpm, the antibody-treated cells were loaded into the column 
and let it stand there for 10 minutes at room temperature. Antibody-treated cells 
bound to glass beads present in the column through Fc and F(ab) interactions. 
Reasonably pure (up to 90%) CD4+ or CD8 + T cell populations were eluted with 15 
ml of column buffer. The cells were harvested by centrifugation (1200rpm, 5 
minutes), and after washing, they were counted and plated at the appropriate 
concentrations. In all cases, the viability of the isolated cells was above 90%, as 
determined by Trypan Blue (Sigma) exclusion. When isolating cells from M.
tuberculosis infected animals, all procedures were carried out in a sterile manner in 
microbiological class I cabinets in the Containment III unit of the NIMR.
2.28 Anti-Apa enzyme linked immunoabsorbant assay (ELISA)
Nunc Maxisorp ELISA plates (Nunc, Paisley, UK) were coated with 1 pg/well of 
RecApa diluted in lOOpl of carbonate buffer (34mM NaHC0 3 , 15mM Na2COs), pH 
9.6. Plates were covered and incubated for 1 hour at 37°C. Afterwards, the plates 
were left up to 72 hours at 4°C. In the day of the assay, the plates were washed four 
times with PBS/0.05% Tween 20® (PBS/T) and blocked for two hours at RT with 
lOOpl/well of PBS/T plus 5% of skim milk. The plates were washed again another 
four times. Serum obtained from vaccinated animals plus controls was serially diluted 
in blocking buffer and lOOpl/well dispensed in the plates. As a positive control, IgGl 
anti-Apa mAb 6 A3 was used. The plates were left for 2 hours at 37°C and after 
washing, incubation with the second antibody was carried out. Specific biotinylated 
anti-mouse IgGl, IgG2a or total IgG (Amersham) was diluted 1:1000 in blocking 
buffer and dispensed at 100pi per well. The plates were incubated for one hour at 
37°C; washed four times and incubated another hour with streptavidin-alkaline 
phosphatase (Amersham) diluted 1:2500. Plates were washed 3 times and lOOpl/well 
of p-Nitrophenol substrate (SigmaFast) was added for up to one hour. The reaction 
was stopped with lOOpl/well of 3N NaOH. Spectrophotometric readings were 
obtained at 405nm.
2.29 Cytokine measurements
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Duplicate cultures of 3 x 106 spleen cells, pooled from 2-4 mice were incubated in 
24-well plates in 2-ml of serum-free AIM-V media (GIBCO-BRL) supplemented 
with 80pM of 2-p-mercaptoethanol or complete IMDM for up to 72 hours at 37°C. A 
number of different antigens were tested in individual wells, as follows: 6 pg/ml of 
RecApa; 6 pg/ml of native Apa (purified from the culture filtrates of Mycobacterium 
tuberculosis H37Rv strain, a kind gift from Dr. John Belisle, Fort Collins, USA); 
lOpg/ml of concanavalin A (Sigma); lOpg/ml of PPD; 10 micrograms per milliliter of 
the peptide 42’, a sequence of mannosylated aminoacids 
[DPEP APP VPT (Mana)T AASPPST (Mana) AAAPP AP AT (Mana)P VAPPPP AAANT 
PNA] from the N-terminal part of the Apa protein or control peptide 42’ (same 
sequence, non-glycosylated), kind gifts from Dr. Fanny Guzman (Laboratory of 
Immunology, HSJD, Bogota, Colombia). The supernatants were collected after 24h, 
48h and 72h, filtered through 0.2pm filters and kept at -70°C. Cultures of 4 x 105 
isolated CD4+ cells, pooled from 2-4 mice, were incubated in triplicates in 96-well 
plates with 250pl of supplemented AIM-V media or complete IMDM. Immature (6 th 
day) BMDCs ( 8  x 104  cells per well) or gamma-irradiated (15000 rads) splenocytes 
were used as antigen presenting cells. Supernatants were collected after 24,48 and 72 
hours. Using a similar protocol, cultures of isolated CD8 + T-cells were incubated in 
triplicates with immature BMDCs, in 250pl of complete IMDM. Cells were 
stimulated with 6 pg/ml of RecApa. Supernatants were collected after 24, 48 and 72 
hours.
Cytokines released in the supernatants were assayed using commercial sandwich 
ELISA kits for the presence of interferon-gamma (IFN-y), interleukin 4 (IL-4), 
interleukin 10 (IL-10) and interleukin-2 (IL-2) ((Amersham or R&D Systems), and 
transforming growth factor beta-1 (TGF-pl) (BD-Pharmingen, Oxford, UK),
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according to the manufacturer’s protocol. In the case of TGF-pl, acid activation of 
the cytokine was performed before testing: 4pi of IN HC1 per lOOpl of supernatant 
and incubation for 60 minutes at 4°C followed by neutralisation with 4pi of IN 
NaOH.
2.30 ELISPOT assays
ELISPOT plates MAIP S45 (Millipore) were coated with lOOpl/well of lOpg/ml 
anti-IFN-y mAb R4-6A2 (BD-Pharmingen) diluted in calcium-magnesium-free 
sterile PBS pH 7.4 and incubated overnight at 4°C. Plates were washed twice with 
200pl/well of AIM-V medium (Gibco-BRL), supplemented with 2% of FCS and 
blocked afterwards with the same volume per well of AIM-V/10% FCS for 2 hours at 
37°C. Total spleen cells, CD4+ or CD8 + -enriched cell suspensions were obtained 
and incubated with or without antigen at approximately 1 0 7 cells in six-wells plates 
with 5ml of AIM-V/2% FCS at 37°C, 5% CO2 . Either 6 pg/ml of recombinant Apa or 
HSP65 or lOpg/ml of Purified Protein Derivative (PPD) from MTB (Veterinary 
Laboratories Agency Weybridge, Surrey, UK), was used to stimulate the cells. After 
48 hours of incubation, the cells were resuspended to a single-cell suspension, 
counted and added in lOOpl volumes at various 2-fold serial dilutions to the coated 
ELISPOT MAIP S45 plates. The maximum number of cells added per well was 1 x 
106. After adding to the plate, the cells remaining in the suspension were re-counted 
to increase accuracy. Plates were incubated during 16 hours at 37°C, 5% CO2 before 
being washed 2  times with 0 .2 pm-filtered distilled water; this wash induced osmotic 
lysis of the cells and reduced background. This was followed by three washes with 
0.2pm filtered PBS/T (PBS 0.05% Tween 20). During each wash, the plate was
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shaked vigorously for 30 seconds in a microplate shaker. Biotinylated anti-IFN-y 
mAb (clone XMG 1.2, BD-Pharmingen) was diluted to a concentration of 1 pg/ml in 
PBS/T plus 0.1% Bovine Serum Albumin (Fraction V, Sigma) and lOOpl/well were 
added to the plates. This was followed by an incubation of 2 hours at room 
temperature. After washing 5 times, the plates were tapped dry and lOOpl/well of 
streptavidin-alkaline phosphatase (BD-Pharmingen) diluted 1:1000 in PBS/T-BSA 
was added. The plates were placed for one hour at room temperature, washed 5 times 
and 50pl/well of NBT-BCIP substrate solution (SigmaFAST, Sigma) added per well. 
Colour was allowed to develop from 5 to 15 minutes in the dark. Washing the plate 
extensively with water stopped the reaction. The plates were dried, also in the dark, 
before spot counting was performed using a dissecting microscope (3OX 
magnification). Results were expressed as the mean number of cytokine-producing 
cells per 106  or 105 total cells, subtracted from the controls. Each sample was assayed 
in triplicate. Controls included wells without cells (background) and non-stimulated 
cells. A transfected cell line producing constitutive IFN-y (X63g, a courtesy of Dr. 
Brigitte Stockinger, NIMR) was used as the positive control to evaluate the efficiency 
of the assay, which usually ranged from 97% to 100% (all plated cells producing 
IFN-y were detected).
2.31 Stimulation of CD8+ T-cells
A protocol described by Chen and collaborators (1993) for promoting 
presentation of extracellular antigens into the MHC class I presentation pathway was 
used. Briefly, 200pg of RecApa or recombinant MPT83 (Xue, 2000) was mixed with 
50pg of Lipofectin (Gibco-BRL) in 450pl of AIM-V media and incubated for 10
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minutes at RT. This solution was then mixed with 1 x 106  BMDCs purified from 
C57BL/6 or H-2b MHC-II knockout (KO) mice and incubated for a further 15 
minutes at RT. These cells were washed, counted with Trypan-Blue exclusion and 
dispensed at 5 x 104  per well in 96-wells plate. Cultures of 5 x 105 CD8 + T-cells 
isolated from the spleens of MTB-infected mice, vaccinated mice or controls were 
added to the plates containing these liposome-stimulated DCs in a final volume of 
250jil. MTB-infected material was always handled in proper cabinets at the 
Containment III Unit (NIMR). Supernatants were collected after 24-72 hours and 
sterilised by filtration. Twenty U.I./ml of murine recombinant IL-2 (Boehringer- 
Mannheim, Sussex, UK) was added to the wells and the cultures maintained for 7-10 
days before being subjected to intracellular cytokine staining and FACS analysis.
2.32 The JAM assay
To measure cytolytic (CTL) activity, four weeks after the end of the ApaDNA 
vaccination, two or three animals were killed from test and control groups; 4 x 106  
splenocytes, depleted of erythrocytes, were plated in 24-wells plates together with 5 x 
105 lethally irradiated (20000 rads) EL-4 cells expressing the apa gene. Twenty 
units/ml of mouse recombinant IL-2 (Roche) were added to the cultures. The cells 
were incubated at 37°C, 5% CO2 for 6  days. CTL activity was measured by the JAM 
assay (Matzinger, 1991). Target EL-4 and EL-4.Apa cells, as well as Concanavalin A 
(104) activated blast cells (H-2k, CBA mouse spleen cells activated for 48 hours), 
were labelled with [ H] thymidine (Amersham) at a final concentration of 5 pCi/ml. 
The cells were left undisturbed for 6  hours. The effector cells were washed and plated 
in round-bottomed 96-wells plates together with labelled target cells at various 
effector-to-target (E/T) ratios and incubated for further 6  hours. The total volume was
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0.2ml. The cells were harvested onto glass fibre mats using a Titertek 96 Mach 2 cell 
harvester (Tomtec, Orange-CT, USA) and counts were read in a 1205 Betaplate™ 
liquid scintillator (Pharmacia-LKB, Gaithersburg-MD, USA). The percentage of 
specific lysis was expressed as:
% Specific killing = Retained DNA in the absence of killers (CPM) -  Retained 
DNA in the presence of killers (CPM)/ Retained DNA in the absence of killers 
(CPM).
2.33 Intracellular FACS staining
All procedures with the exception of FACS reading, were carried out in 
containment III facilities. Lungs were dissected from MTB-infected mouse at the 
day’s 38-42 post-infection. The tissues were cut with sterile scissors and forceps into 
fine pieces and smashed against a 70pm cell strainer (Falcon). Red-blood cells (RBC) 
were eliminated from the resulting cell suspension using RBC lysis buffer (Sigma). 
The lung cells were washed twice, counted and resuspended in AIM-V media. For 
stimulation of cytokine production, lpg/ml each of anti-mouse CD3e and anti-mouse 
CD28 monoclonal antibodies (BD-Pharmingen) were added. To block extracellular 
secretion, monensin (Golgi-Stop™, BD-Pharmingen) was also added to the cells, and 
the suspension incubated for 6  hours at 37°C. At the end of incubation, the cells were 
washed twice and a single-cell suspension was adjusted to 1 x 1 0 6 cells per tube. 
Incubating the cells for 15 minutes at RT with anti-mouse CD16/CD32 antibody 
(BD-Pharmingen) blocked Fc II/III cell receptors and avoided unspecific staining. For 
surface receptors, cells were stained for 30 minutes in the dark and in ice with 1:100 
dilution of the following antibodies (BD-Pharmingen): fluorescein-isothiocyanate
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(FITC)-conjugated anti-CD4+ clone H I29.19 and fluorescein-isothiocyanate (FITC)- 
conjugated anti-CD8 + clone 53-6.7. After washing with PBS 1% FCS, 0.02% NaNa 
(FACS buffer), the cells were fixed in ice for 2 hours with 4% of fresh 
paraformaldehyde diluted in Dulbecco’s PBS pH 7.5. After a brief washing with 
FACS buffer, the cells underwent another round of fixation using 
Cytofix/Cytoperm™ reagent (BD-Pharmingen), which also contains 
paraformaldehyde (20 minutes on ice). Cells were washed twice in permeabilisation 
buffer (0.1% saponin) and stained for 30 minutes on ice with the anti-IFN-y PE- 
conjugated clone XMG 1.2 (BD-Pharmingen). The cells were analysed using a 
fluorescence-activated cell analyser machine FACS Calibur™ and CellQuest™ 
software (Becton Dickinson).
2.34 Cell Sorting
Spleen cells from two to three DNA-vaccinated mice and controls were enriched 
for CD4+ T cells using Mouse T Cell Subset Column Kits (R & D Systems). These T 
cells were then diluted in sterile Dulbecco’s PBS (Invitrogen) plus 5% FCS and 
blocked for 15 minutes at RT with anti-mouse CD16/CD32 antibody (BD- 
Pharmingen) followed by staining for 30 minutes on ice and in the dark with FITC- 
conjugated anti-CD4+ clone RMA4.5 (BD-Pharmingen), at 1:100 dilution. The cells 
were washed with Dulbecco’s PBS, passed through a 40pm filter to remove 
particulates and resuspended at 2 x 107 cells/ml. Propidium iodide was added to gate 
out the dead cells. FITC-positive (i.e. CD4+ T cells) and negative cells were sorted 
using a MoFlo cytometer FACS sorter (Dako Cytomation, Glostrup, Denmark), at the 
Flow Cytometry Lab, NIMR. Sterility was preserved throughout the procedure. 
Levels of purity for the selected population reached 99.9%. After sorting, the cells
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were recovered in complete media, counted and plated in a 96-wells plate at 4 x 105
tVicells per well. Immature, 6  day BMDCs were used as APCs. RecApa or native Apa 
antigens were added in various concentrations. Supernatants were collected and 
filtered at 24h, 48 and 72 hours.
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CHAPTER THREE
Results
3.1 Expression of the M. tuberculosis apa gene in infected cells
Previous evidence demonstrated that, in guinea pigs, the Apa protein is recognised 
by the immune system of animals inoculated with live but not dead BCG and is an 
immunodominant antigen, even if not expressed in high amounts in culture (Romain, 
1993). More importantly, an impressive immune response against the Apa antigen was 
observed in human patients with active tuberculosis (Espitia, 1995; Samanich, 2000; 
Kumar, 2003). This evidence would suggest an increase of expression of this specific 
protein by M. tuberculosis during intracellular infection, which could make this antigen 
more visible for the immune system. To evaluate this hypothesis, transcription levels of 
Apa mRNA were estimated in infected cells. The murine macrophage-like cell line 
RAW264 and bone marrow derived macrophage and dendritic cells (BMC) cultured 
from Balb/c mice were infected at a multiplicity of infection of 10 M. tuberculosis 
bacteria per eukariotic cell. RNA from M. tuberculosis was isolated from the infected 
cells as described in Material and Methods.
The transcription levels of messenger RNA (mRNA) for Apa in MTB infected 
cells were quantified by Real-time™ PCR using apa specific primers. Mycobacterial 
sigma factor A gene (sigA) was used as the reference gene in this study since its 
expression levels are independent of a variety of changes in growth conditions and also
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in M. tuberculosis grown in macrophages (Manganelli, 1999; Raynaud, 2002). The levels 
of Apa-expression in infected cells were compared to levels of Apa-expression in M  
tuberculosis grown in axenic culture. Apa mRNA expression in infected cells did not 
seem to vary from the levels of expression obtained in extracellular conditions, either in 
infected murine RAW264 or BMC cultures (fig.3.1). Interestingly however, a clear 
increase of transcription in the apa gene was seen repeatedly when the cells were 
previously activated in vitro with recombinant IFN-y (fig.3.1). These results were 
obtained with two independent RNA samples. In general, four PCR runs were executed 
for each sample. Similar results were obtained by performing the same experiment with a 
different type of cell, the human THP-1 monocytic tumour line. A peak on the expression 
of the apa gene was seen only when these cells were previously activated with phorbol- 
myristate acetate (PMA) and human recombinant IFN-y and were then infected with M. 
tuberculosis (fig.3.2). Treatment with PMA only did not induce significant up-regulated 
levels of apa expression.
3.2 Expression of the apa gene in E. coli
The entire coding sequence of the M. tuberculosis apa gene, including the N- 
terminal signalling sequence, was cloned into the pQE60 expression vector in order to 
obtain a recombinant protein to be used in immunological assays. The expression vector 
described in fig.3.3 was used in these experiments. The apa gene was cloned downstream 
to a phage T5 promoter under control of two lac operators and also in frame with a 6  
histidines (6 xHis) tagged sequence at the C-terminus, which allowed the fusion protein to 
be purified from the affinity columns as described.
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Figure 3.1 Expression of apa by M. tuberculosis (MTB) infecting RAW264 
murine cell line and bone-marrow derived macrophages (BM) from BALB/c mice.
The amount of apa mRNA relative to that of the normalising gene, sigA, was determined 
by Real-time™ quantitative reverse-transcription (RT) PCR. For activation, lOOU/ml of 
mouse recombinant IFN-y was added to the cells for 16 hours. The gene-transcription 
ratio of MTB grown in axenic culture was taken as 1. The values shown are the means of 
results obtained in several experiments and the error bars indicate the standard errors.
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Figure 3.2 Expression of apa by M. tuberculosis (MTB) in human THP-1 cell line.
THP-1 cells were activated with PMA for one day before infection. For activation, the 
cells were exposed to lOOU/ml of human recombinant IFN-y for 16 hours. The amount of 
apa mRNA was calculated as in fig. 3.1 and measured by Real-time™ RT-PCR. The 
gene-transcription ratio of MTB grown in axenic culture was taken as 1. The values 
shown are the means and the error bars indicate the standard errors.
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Figure 3.3 The pQE60.Apa plasmid expression system. Apa was cloned into 
the Nco I and BamH I restriction sites. The secreted Apa protein was fused with a 
6xHis-tagged sequence at the C-terminal part. There are stop codons in all 3 reading 
frames. PT5, T5 phage promoter; lac O, lac operator; RBS, ribosome-binding site; 
MCS, multiple cloning site; 6xHis, 6-histidines tag sequence; Col El, origin of 
replication; bla, ampicillin resistance gene; neo, kanamycin-resistance gene; IPTG, 
isopropyl-thiogalactoside.
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To avoid toxicity by highly expressed recombinant proteins, E. coli M l5 strain 
was used as host. This strain contained the pREP4 plasmid in high copy number, which 
contains the lacl repressor gene, for tightly controlled expression in trans of the 
recombinant protein (fig.3.3). Maintenance of both plasmids was achieved by double 
(ampicillin-kanamycin) antibiotic selection.
Mini-cultures of E. coli containing pQE60.Apa were prepared to determine the 
best amount of IPTG and period of induction. Analysis of whole-cell extracts from these 
cultures by SDS-PAGE revealed an increased level of expression related to the time of 
culture. Westem-blot analysis of the bacterial-cell extracts with the Apa-specific 
monoclonal antibody 6A3, revealed a major band of approximately 47-kDa, a minor 
band of 45-kDa, followed by a couple of lower molecular weight bands, which could 
probably reflect some degradation occurring in the cell extract (not shown). Comparable 
findings have been reported using similar expression vectors (Laqueyrerie, 1995; Horn, 
1999).
3.2.1 Purification o f RecApa with affinity chromatography
Since the fusion protein was cloned with its N-terminal signal sequence, it was 
expected to find most of the RecApa protein in the periplasmic space of the recombinant 
E. coli M l5 (Horn, 1999). This was confirmed by comparing bacterial cell and 
periplasmic extracts by SDS-PAGE; non-denaturing conditions for the preparation of the 
extract were also found to provide the best results (not shown). The periplasmic extract 
was prepared by osmotic shock of the bacterial cultures. RecApa was purified using Ni- 
NTA affinity chromatography as described. Samples were collected trough all steps of
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the chromatographic process and analysed by SDS-PAGE. Sensitive colloidal gold 
staining showed that almost all RecApa protein was carried out of the column with the 
first elution. A single band of approximately 47-kDa can be clearly demonstrated 
(fig.3.4). The 45-kDa band was not found in this fraction and other groups had reported 
similar findings (Horn, 1999). This result is probably related to the fact that the 45-kDa 
band represents a C-terminal truncated form of Apa (Romain, 1999; Horn, 1999) and 
therefore does not contain the affinity tag. A small contaminant band of approximately 
31-kDa was also co-purified with RecApa but did not react with the 6A3 monoclonal 
antibody (fig.3.5). The band was present in very low quantities in the RecApa samples, 
being only detected with colloidal gold staining, but not Commassie Blue or silver nitrate 
staining. No further purification has been performed to specifically remove this band.
Purified recombinant Apa samples obtained by the methods described above were 
found to carry high levels of LPS contamination. Commercial polymyxin B mini­
columns were used to decrease LPS levels in purified RecApa samples. The procedure 
was very efficient and the levels of LPS dropped from 324 EU to 5-6 EU per milligram 
of protein sample, being considered acceptable for use in all the in vitro cellular assays.
3.3 DNA vaccination with the M. tuberculosis apa gene
Due to the reported immunodominant characteristics and the up-regulation of 
expression during infection, the immunogenicity of the Apa antigen in the naked DNA 
format was evaluated in the murine model.
3.3.1 Construction o f the Apa-plasmid DNA vaccines
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Figure 3.4 Aurodye™ blot staining of RecApa Ni-NTA column eluates. The
same volume of sample was collected from all eluates. After protein transfer, the 
PVDF membrane was stained as described in Material and Methods. RecApa was 
eluted four times with 200mM of imidazole. 1, periplasmic extract; 2, periplasmic 
extract after the flowthrough; 3, first elution with 200mM imidazole; 4, second 
elution; 5, third elution; 6, fourth elution. Arrow indicates the recombinant Apa 
product.
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Figure 3.5 Western-blot analysis of RecApa Ni-NTA column eluates. A 10%
polyacrylamide running gel was loaded with equal volumes obtained from the Ni- 
NTA column eluates and transferred for Western-blot analysis as described. A clear 
47-kDa RecApa product can be seen. Smaller bands are probably resultant from 
sample degradation. A, first elution with 200mM imidazole; B, second elution; C, 
third elution; D, fourth elution; E, lysate of E. coli M l5 strain, transfected with the 
pQE60 vector control.
114
All vectors used contained the promoter of the cytomegalovirus (CMV) 
immediate early gene, in order to obtain high levels of expression. The M. tuberculosis 
H37Rv apa gene coding sequence (including its N-terminal signal sequence), was cloned 
in frame, downstream of this promoter in the pCMV4 vector (fig.3.6A). An important 
characteristic of this vector is the presence of the intron A, the largest non-coding 
sequence from the CMV immediate-early 1 gene, reportedly capable of increasing the 
expression of cloned genes in this plasmid (Chapman, 1991; Tascon, 1997). A second 
plasmid expressing Apa, pSecTag2C.Apa, was also constructed (fig.3.6B). This plasmid 
allowed the extracellular secretion of the cloned product since it contained the murine Ig 
K-chain V-J2-C signalling peptide. Between other features, a 6xHis-tag was also fused at 
the C-terminal part of Apa, allowing further purification of the protein (fig.3.6B). After 
cloning, mapping of the insert with restriction enzymes confirmed the identity of the 
gene and the correct orientation of the insert.
3.3.2 In vitro transfection o f cell lines with mammalian vectors
The ability of these plasmid constructs to express Apa was tested in vitro. Both 
plasmids were transfected into CV1 cells; green-fluorescent protein (GFP)-expressing 
vectors were used as transfection controls (not shown). In vitro expression was detected 
in cell lysates and supernatants by Western-blot, using the Apa-specific monoclonal 
antibody 6A3 (Espitia, 1995). Recombinant Apa was included as the positive control. 
The results demonstrated efficient in vitro expression of Apa protein by both plasmids 
(fig.3.7). No reactivity was observed in the cell extracts or supernatants of CV1 cells 
(lane A) transfected with pCMV4 vector (lane B).
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Figure 3.6 Schematic representations of ApaDNA vaccine vectors. The coding 
sequence of the apa gene, including its N-terminal secretion signal, was cloned 
directionally between the BamH I-Not I restriction sites of pCMV4 (A) and 
pSecTag2C (B). Plasmids were maintained in E. coli One Shot TOP 10® cells as 
described previously.
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Figure 3.7 Western-blot analysis of cell lysates and supernatant filtrates of 
CV1 cells transfected with Apa expression plasmids. A 10% polyacrylamide gel 
was loaded with 5-10pg of total protein from the lysates of CV1 cells transfected with 
vectors expressing mycobacterial Apa, and processed by Western-blot as described. 
Lysates of cells transfected with pSecTag2C vector alone did not react with the 6A3 
monoclonal antibody (not shown). A, CVl-pCMV4 lysate; B, CVl-pCMV4 
supernatant; C, CVl-pCMV4.Apa lysate; D, CVl-pCMV4.Apa supernatant; E, 
pSecTag2C.Apa lysate; F, pSecTag2C.Apa supernatant; G, RecApa.
117
The pattern of expression, i.e., a complex of two bands, was similar to that 
observed in culture filtrates of MTB or BCG (see fig.3.17). Bands of 58- and 59-kDa 
were also detected in the filtered cell supernatants from CV1 cells transfected with 
pCMV4.Apa (lane D), suggesting that the secretion machinery of CV1 cells was able to 
recognise the mycobacterial N-terminal leader sequence cloned as part of the apa gene.
An increase in band size for the recombinant Apa protein was noticed after 
transfecting the cell line with both plasmids. In the case of pSecTag2C.Apa lysates (lane 
E) and supernatants (lane F), the increase in protein size could be partially, but not fully 
attributed to the fact the apa gene is fused to additional sequences present in this vector. 
In both cases, some degree of glycosylation in the Apa protein induced by the 
mammalian cell could be involved. The anti-Apa monoclonal antibody 6A3 was also 
able to identify several high molecular weight bands in the lysate of CV1 cells 
transfected with pSecTag2C.Apa (lane E); and these products could possibly be truncated 
(devoid of N-signal leader for secretion), post-translationally modified forms of 
recombinant Apa protein with different degrees of glycosylation (Horn, 1999). 
Glycosylation of Apa has been reported as critical for immune responses generated 
against this protein in vivo (Romain, 1999; Horn, 1999). Since glycosylation of Apa 
could also play a role in in vivo immune responses associated with ApaDNA vaccination, 
recombinant Apa protein was purified by Ni-NTA affinity chromatography from the 
supernatant of CV1 cells transfected in vitro with pSecTag2C.Apa. This purified protein 
was tested for the presence of sugar moieties. A specific fluorescent dye reacting with 
periodate-oxidised carbohydrate groups in the purified protein suggested that the 
recombinant Apa produced in mammalian cells was indeed glycosylated (fig.3.8), 
however the specific nature of the sugar moieties was not further investigated.
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Figure 3.8 Fluorescent glycoprotein staining of Apa. Recombinant Apa purified 
from CV1 cells transiently transfected with pSecTag2C.apa showed increased 
molecular weight. Samples were purified by affinity chromatography and loaded in a 
10% SDS-PAGE. After blotting, sugar moieties were oxidised by periodic acid and 
reacted with the Pro-Q Emerald 300® fluorescent stain. The blot was exposed to 
300nm light and photographed. Half-blot was probed with anti-Apa 6A3 monoclonal 
antibody (a-Apa) for comparison. Lanes 2 and 5, CVl-cell extract; lanes 3 and 4, 
purified CVl-Apa; lanes 1 and 6, CandyCane® glycosylated molecular weight.
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In order to obtain stable transfectants expressing Apa for later use as targets in 
CTL assays, the murine EL-4 tumour cell line was transfected in bulk with circular or 
linear pCMV4.Apa vectors. As a control, EL-4 cells were also transfected with 
pCMV4.GFP. After an initial period of two weeks for selection with G418 antibiotic, the 
surviving cells were cloned by limiting dilution. Several clones were obtained and re­
cloned at less than one cell per well. No significant differences in the rates of transfection 
were observed between circular or linear vectors. Apa-expressing clones were selected 
by Western-blot, using the Apa-specific 6A3 monoclonal antibody, as described. A clone 
(AJF.26) stably expressing high levels of Apa protein, represented by a complex of two 
bands of approximate molecular weight of 59- and 60-kDa (fig.3.9), was expanded, 
aliquoted and kept in N2 for future use.
3.3.3 Antibody responses from ApaDNA-vaccinated mice
In order to characterise antigen-specific antibody responses, groups of C57BL/6 
were either vaccinated with 4 doses of plasmids expressing the mycobacterial apa gene, 
empty vector, BCG or saline, as described in Material and Methods.
As expected, no significant differences were observed in humoral or cellular 
immune responses produced by animals vaccinated with pCMV4.Apa compared to the 
secretion-vector pSecTag2C.Apa (not shown). They are collectively called here as 
ApaDNA vaccine. In all chosen dilutions, the sera obtained from ApaDNA-vaccinated 
animals showed elevated specific anti-Apa IgG levels (fig.3.1 OA), and showing 
consistency with the results of in vitro gene expression. In contrast, control groups or 
BCG vaccinated mice sera were essentially negative for anti-Apa IgG-antibodies.
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Figure 3.9 Western-blot of Apa-expressing EL-4 clone. Among EL-4 clones under 
drug selection, Apa-positive clones stably transfected with pCMV4.Apa, were 
identified according to the reactivity with anti-Apa 6A3 monoclonal antibody (a- 
Apa). Equal amounts of cell extract proteins (lOpg) from EL-4 stable transfectants 
were loaded in 10% polyacrylamide SDS-PAGE and blotted. The clone AJF.26 
reacted more expressively with this antibody and was selected for future use. The 
Apa-complex of two bands of approximately 59 and 60-kDa can be seen in lane 3. 
Lane 1, RecApa produced in E. coli, 2pg; lane 2, EL-4 cell extract; lane 3, EL-4 clone 
AJF.26.
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Figure 3.10 Serological responses to RecApa by ApaDNA vaccinated mice.
C57BL/6 mice were immunised intramuscularly four times, three weeks apart, with 
saline, vector, ApaDNA or once intradermally with BCG. Serum samples were 
collected three weeks after the last injection and analysed by ELISA for the presence 
of anti-Apa total IgG (A), IgGl (B) and IgG2a (C) antibodies. Monoclonal antibody 
6A3 (mAb 6A3, IgGl isotype, Espitia, 1995), specific for the Apa protein was used 
as the positive control. Results show the mean data of four mice.
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Investigation on the IgG isotypes involved during ApaDNA vaccination revealed 
that both anti-Apa IgGl and IgG2a isotypes were present (fig.3.1 OB & C). These results 
then suggested the presence of a specific Thl/Th2 mixed type of immune response in 
Apa-DNA vaccinated mice and are also consistent with findings reported by other groups 
(Morris, 2000; Garapin, 2001).
3.3.4 Production o f cytokines by spleen cells from Apa-DNA vaccinated mice
To study how cellular immune responses are affected by the ApaDNA construct, 
spleen cells from vaccinated C57BL/6 mice and controls were stimulated with 6pg/ml of 
purified RecApa, native Apa (purified from culture filtrates of M. tuberculosis), lOpg/ml 
of PPD, control antigens or medium alone. Cytokines were detected in filtered 
supernatants of the cultures by ELISA collected in a period of 72 hours. Measurement of 
supernatants collected at 24 hours demonstrated that splenocytes from ApaDNA- 
vaccinated mice had the ability to produce significant amounts of IL-2 in vitro, even if 
stimulated with non-glycosylated RecApa (fig.3.11 A). In comparison, the levels of IL-2 
produced by spleen cells from animals injected with saline, vector or BCG were 
significantly lower. In addition, when splenocytes were highly enriched for CD4+ T 
cells, the production of IL-2 in vitro from ApaDNA mice (but not controls) could also be 
demonstrated (fig.3.1 IB).
Production of IFN-y is a critical requirement for protective immunity against M  
tuberculosis (Cooper, 1993; Flynn, 1993). To assess the role of the ApaDNA vaccine at 
inducing IFN-y production, spleen cells from vaccinated mice and controls were cultured 
in vitro with either RecApa, native Apa, PPD, Concanavalin A (Con A) or a synthetic
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Figure 3.11 Production of IL-2 by ApaDNA vaccinated mice. C57BL/6 mice were 
immunised intramuscularly four times, three weeks apart, with saline, vector, ApaDNA 
or once intradermally with BCG. Spleen cells were cultured with or without (not shown) 
6pg/ml of purified RecApa. 24h-supematants were assayed for the presence of IL-2. 
Total spleen cells (A) or CD4+ T cells (B) were cultured as described. Results are 
expressed as the mean plus the standard error (SE) number from triplet wells. The 
experiment was repeated twice.
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peptide comprising the first 42 amino acids from the N-terminal part of the mature Apa 
protein. Cells obtained from mice vaccinated with ApaDNA (but not controls) secreted 
high levels of IFN-y in vitro, when stimulated with either recombinant or native Apa 
protein; glycosylation did not seem to play a role in increasing cytokine secretion 
(fig.3.12B). BCG- but not ApaDNA-vaccinated mice produced significant amounts of 
IFN-y when exposed in vitro to PPD (fig.3.12C). Cells from ApaDNA vaccinated mice, 
however, did respond significantly to PPD in vitro (l.OOlng/ml ± 0.14), if compared to 
saline and vector groups (0.201 ± 0.01 and 0.293 ± 0.06 ng/ml, respectively), confirming 
the presence of Apa protein in the antigenic mixture present in PPD preparations. 
Interestingly, the Apa-peptide 42’(mannosylated) did not induce responses from spleen 
cells from vaccinated mice, suggesting that at least one specific T cell epitope should be 
localised further downstream in the Apa sequence (preliminary data).
CD4+ T cells are among the most important in the protective response against M. 
tuberculosis (Flynn & Chan, 2001). To investigate the CD4+ T cell responses from 
vaccinated animals, spleen cell suspensions were enriched for CD4+ T cells by negative 
depletion of other spleen subpopulations in affinity columns and stimulated in vitro with 
RecApa plus either BMDCs or irradiated macrophages as antigen-presenting cells. As 
expected, T cells derived from ApaDNA- but not vector-vaccinated mice were able to 
specifically produce increased levels of IFN-y in vitro (not shown). The purity of these 
CD4+ preparations could be increased further up to 99.9% when FACS-sorting was 
performed. Spleen cells from either ApaDNA- or vector-vaccinated mice, previously 
stained with anti-CD4+ FITC-monoclonal antibody, were sorted under sterile conditions. 
The recovered cells were cultured in vitro for up to 72 hours, in the presence of RecApa 
or medium and APCs.
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Figure 3.12 Specific IFN-y levels produced by spleen cells from ApaDNA 
vaccinated mice. IFN-y levels were determined by ELISA in 72-hours stimulated 
cultures. Cells were collected three weeks after last dose and stimulated either with 
RecApa or native Apa (A), Concanavalin A (B) or PPD (C). Data representing a typical 
experiment repeated three times are expressed as means plus standard errors for three 
mice in each group.
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Again, only CD4+ but not CD4- cell population from ApaDNA-vaccinated mice 
were able to show increased levels of IFN-y in the supernatant (fig.3.13). Bone marrow- 
derived dendritic cells or macrophages, in the presence of RecApa in culture, were not 
capable of producing IFN-y (fig.3.13 and preliminary data). Cytokines such as IL-4, IL- 
10 and TGF-pl have either an inhibitory effect on Thl cell responses or in cellular 
responses in general and could possibly suppress protective anti-mycobacterial responses 
(Turner, 2002; Toossi, 1995). The same supernatants collected to measure IFN-y levels 
were also used to analyse the levels of these cytokines. Neither total spleen nor CD4+ T 
cells from DNA vaccinated mice (or controls) were able to show measurable levels of 
any of these cytokines in response to in vitro RecApa stimulation (not shown). These 
measurements were repeated three times in two different vaccination experiments.
3.4 CD8+ T cell responses to Apa
Control of tuberculosis infection in mice involves the participation of CD8+ T 
cells. Besides cytotoxic functions, secretion of cytokines derived from CD8+ T cells, 
particularly IFN-y, is regarded as highly beneficial, if not critical to the protective 
response against MTB (Tascon, 1998). To investigate the CD8+ T cell response in 
ApaDNA vaccinated mice, spleen cell cultures were enriched for CD8+ T cells by 
negative selection during column purification. Isolated CD8+ T cells from vaccinated 
mice and controls were cultured in vitro with RecApa antigen and immature BMDCs as 
antigen-presenting cells. In order for the MHC-restriction to be preserved, BMDCs were 
isolated from MHC-II knockout (MHC_/') mice and cultivated in vitro, as described in 
Material and Methods.
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Figure 3.13 CD4+ T cells from ApaDNA vaccinated mice produce IFN-y in 
response to Apa. Spleen cell preparations from ApaDNA vaccinated mice or control 
vector were enriched for CD4+ T cells by affinity column purification; the isolated 
population was submitted to another round of purification by FACS-sorting, as 
described. The CD4+ T cells were co-cultured with bone-marrow derived dendritic 
cells as APCs, plus RecApa or native Apa for 72 hours. IFN-y was measured by 
ELISA in the supernatant. Data represents the mean + standard error for three mice in 
each group. The experiment was repeated twice.
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Supernatants were collected at intervals to measure IL-2 and IFN-y cytokines by 
ELISA. The results demonstrated that when CD8+ T cells from ApaDNA-vaccinated 
mice were antigenically re-stimulated in vitro, they secreted very low amounts of either 
IL-2 or IFN-y (fig.3.14A & B).
CD8+ T cells do not respond well to antigens provided in the extracellular format. 
As an extra control for the experiment described above, immature bone marrow dendritic 
cells were induced to process a complex of cationic liposomes and RecApa. These 
complexes have been demonstrated to increase loading into the class I processing 
pathway (Chen, 1993). CD8+ T cells were isolated by column purification from the 
spleen of C57BL/6 mice which have been infected intravenously with M. tuberculosis 
H37Rv for 30 days. The isolated lymphocytes were transferred to U-bottom sterile plates 
containing dendritic cells exposed to either RecApa-liposomal complexes, liposomes 
alone or recombinant MPT83-liposomal complexes, as described previously. MPT83 was 
able to stimulate cytotoxic T cell responses in mice and was detected during 
mycobacterial infection (R.E. Tascon, unpublished results). The results demonstrated that 
IFN-y levels from CD8+ T cells were increased when activation with MPT83 occurred 
(fig.3.15A). After intracellular FACS-staining of CD8+ IFN-y+ T cells, a significant 
percentage of CD8+ T-cells from M. tuberculosis infected mice were stained positively 
for IFN-y in response to MPT83 protein (fig.3.15B). However, only a small fraction of 
CD8+ T cells from the infected animals showed a similar phenotype in response to 
liposome-RecApa or liposome-control.
The ability of CTL to lyse infected targets is thought to facilitate control of the 
infection by releasing the bacilli so they can be taken up at low multiplicity by freshly 
activated macrophages and destroyed (Serbina, 2000). To address whether specific Apa-
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Figure 3.14 Production of IL-2 and IFN-y in Apa-stimulated CD8+ T cells from 
ApaDNA vaccinated mice. C57BL/6 mice were immunised intramuscularly four times, 
three weeks apart, w ith  saline, vector, ApaDNA or once intradermally w ith  BCG. CD8+ 
T cells were isolated as described in Material and Methods and cultured w ith  6pg/m l o f 
purified RecApa. 24h-supematants were assayed for the presence o f  IL-2  (A ) and 72h- 
supematants assayed for IFN-y (B). Results are expressed as the mean plus the standard 
error (SE) from triplet wells. The experiment was repeated three times.
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Figure 3.15 Dendritic cell processing of exogenous antigen for CD8+ T cells.
Immature BMDCs were loaded with mixtures of liposomes and RecApa or MPT83 
recombinant proteins. These APCs were immediately washed and then co-cultured 
with isolated CD8+ T cells from the spleen of C57BL/6 mice infected with M. 
tuberculosis. (A) IFN-y as measured by ELISA in 72 hours supernatants. Data 
represents the mean + standard error from four mice in each group. (B) 
Representative flow cytometry dot plots depicts the percentage of cells labeled with 
anti-CD8 and intracellular anti-IFN-y from the co-cultures of liposome-induced 
dendritic cells and CD8+ cells maintained for 10 days. The experiment was done 
twice.
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CTL responses were occurring in ApaDNA vaccinated mice, a murine tumour cell clone 
with stable Apa expression was generated in vitro by transfecting EL-4 cells (H-2b) with 
the pCMV4.Apa plasmid. Spleen cells from mice either vaccinated four times with 
ApaDNA or empty vector were isolated as described and incubated with lethally 
irradiated EL-4.Apa cells for six days. EL-4, EL-4.Apa or positive control Con A- 
activated blasts, derived from spleen cells of CBA mice (H-2k) were used as targets in a 
3H JAM cytotoxicity assay (Matzinger, 1991). As demonstrated in fig. 3.16A & B, 
alloreactive spleen cells from C57BL/6 mice (H-2b) vaccinated either with vector or 
ApaDNA, exhibited high cytotoxicity against Con A blast targets from CBA mice (H-2k) 
in all effector-to-target (E/T) ratios, as expected; on the other hand, the cytotoxicity 
levels against EL-4.Apa targets was surprisingly similar between both mice vaccinated 
with ApaDNA or empty vector (fig.3.16C), suggesting the lack of Apa-specific 
subpopulations of cytotoxic cells in ApaDNA vaccinated mice.
3.5 Prime-boost vaccination with ApaDNA vaccine and BCG (Prime-boost I)
3.5.1 Expression o f Apa antigen by BCG-Glaxo
Heterologous prime-boost is a vaccination strategy able to generate unprecedented 
levels of cellular immunity and afforded significant levels of protection to several 
diseases, including tuberculosis (McShane, 2001; Feng, 2001, Skinner, 2003a). The 
heterologous prime-boost protocol involves administering two different vaccines, non- 
concomitantly, each encoding the same antigen (Li, 1993). In the strategy used here, the 
ApaDNA vaccine was combined with the BCG Glaxo strain (Glaxo-SmithKline, UK) in
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Figure 3.16 Cytotoxic responses induced by ApaDNA and vector-vaccinated mice.
C57BL/6 mice were injected four times, with lOOpg of either ApaDNA or pCMV4 
vector; spleen cells from three mice per group were cultured with irradiated EL-4.Apa 
cells and IL-2. CTL activities from vector (A) and ApaDNA (B) mice were tested against 
3H-thymidine-labelled EL-4, EL-4.Apa and Con A-blasts from CBA mice (H-2k), using 
the JAM assay (Matzinger, 1991). Calculations for specific killing are described in 
chapter two. (C) CTL curves for vector- and ApaDNA-effectors against EL-4.Apa- 
targets compared closely.
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a prime-boost regimen using the mouse model of intravenous M. tuberculosis infection. 
BCG strains sometimes exhibit differential expression for certain antigens (Oettinger, 
1999). In order to comply with the prime-boost principle, it was important to address 
whether BCG-Glaxo expressed significant levels of the Apa protein. BCG-Glaxo 
growing as a surface pellicule in a non-protein based medium (Sauton medium) were 
harvested during logarithmic phase, for the preparation of protein extracts from BCG-cell 
lysate (lane 1) and culture filtrate (lane 2, fig.3.17). M. tuberculosis lysate (lane 3) and 
purified recombinant Apa (lane 4) were used as positive controls. The results 
demonstrated that when detection was performed using the anti-Apa specific monoclonal 
antibody 6A3, it was possible to visualise the characteristic doublet band from the Apa 
complex in all four fractions described above. The approximate molecular weight for the 
Apa bands were 47- and 48-kDa; stronger bands were clearly seen in the culture filtrate 
of BCG-Glaxo (lane 2). No reactivity was detected in the negative control, E. coli lysate 
(lane 5). BCG-Glaxo viable bacteria were utilised in all prime-boost experiments.
3.5.2 Immune responses in animals receiving the prime-boost I  vaccination protocol
Besides being capable of inducing excellent levels of cell-mediated immune 
responses, prime-boost strategies also raise significantly the humoral responses, 
particularly the IgG2a isotype, normally associated with the production of IFN-y 
(Ramshaw & Ramsay, 2000; Amara, 2001). The prime-boost I protocol (fig.3.18) was 
designed to analyse the potential of ApaDNA priming plus BCG boosting to improve 
protective responses. C57BL/6 mice were primed once with ApaDNA, intramuscularly 
and boosted one month later with BCG-Glaxo, as described.
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Figure 3.17 Expression of Apa in BCG-Glaxo strain. 8-10pg of total protein 
extracts were loaded in a 10% polyacrilamide denaturing gel and electroblotted into 
PVDF membranes for Westem-blot analysis, as described. The blot was probed with 
anti-Apa mAb 6A3 diluted 1:250. Lane 1, BCG-Glaxo cell lysate; lane 2, BCG-Glaxo 
culture filtrate; lane 3, M. tuberculosis cell lysate; lane 4, RecApa; lane 5, E. coli cell 
lysate (control).
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Figure 3.18 Schematic representation of the vaccination protocol prime-boost
I. 6-8 weeks old C57BL/6 females were injected intramuscularly with plasmid DNA 
or intradermally with BCG, as either the priming or boosting depending on the group. 
Control groups included saline, vector and vector plus BCG. CFUs, colony forming 
units.
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Groups of animals where BCG was given once as the priming vaccine and ApaDNA 
as a booster were also included. Approximately six weeks after the boosting injection, 
serum was obtained and anti-Apa antibody titres were determined. Both groups of 
animals receiving either ApaDNA as priming or boosting vaccine, showed raised specific 
IgG antibody levels (fig.3.19A). Mice receiving vector only or vector plus BCG did not 
show significant reactivity. Interestingly, when IgG isotypes were analysed separately, 
only animals receiving BCG as the priming vaccine showed measurable IgG2a 
antibodies (fig.3.19B). It was not possible to detect anti-Apa IgG2a antibodies in 
ApaDNA primed-BCG boosted mice at the time of screening. On the other hand, IgGl 
titres were of very low magnitude for all animals analysed (fig.3.19C).
The production of IL-2, IFN-y and IL-4 cytokines by spleen cells from prime-boosted 
vaccinated mice and controls, in response to RecApa stimulation in vitro, were also 
analysed. Animals were killed by Schedule one protocol in the sixth week after boosting 
and spleen cells isolated and stimulated in vitro with recombinant Apa protein. The 
amount of IL-2 secreted by prime-boost groups was considered low but still notably 
increased in comparison with controls either receiving vector alone or vector-BCG 
combination (fig.3.20A). There was no significant difference in the amount of IL-2 
produced between the animals primed either with ApaDNA or BCG. In the case of IFN- 
y, groups of mice receiving BCG as the priming agent exhibited a significantly higher 
production of IFN-y (P < 0.05) when compared with animals receiving ApaDNA first 
(fig.3.20B). It is interesting to note that the trend was repeated when cells from the same 
group were analysed for the production of IL-4 cytokine (fig.3.20C); although the overall 
levels of IL-4 produced were very low, significantly higher levels of this Th2 cytokine 
were produced in the group of mice primed with BCG and boosted with DNA.
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Figure 3.19 Serological responses to RecApa in prime-boosted vaccinated mice.
C57BL/6 mice were immunised once with lOOpg of ApaDNA and boosted one month 
later with BCG-Glaxo or vice-versa, as described. Controls received empty pCMV4 
vector only or pCMV4 empty vector added to BCG. Titres of total anti-Apa IgG (A), 
IgG2a (B) and IgGl (C) antibodies, were determined six weeks after boosting. The 
monoclonal antibody 6A3 (IgGl isotype) was used as the positive control. Each point 
represents the mean data for four mice.
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Figure 3.20 Cytokine production by spleen cells from prime-boosted I 
vaccinated mice. Spleen cells were cultured and stimulated for 48-72 hours with 
RecApa or medium. The levels of IL-2 (A), IFN-y (B) and IL-4 (C) secreted in the 
supernatant were analysed by ELISA, as described. Asterisks indicate that the amount 
of cytokine secreted is statistically significant compared to the vector or vector plus 
BCG group, as determined by Student t test (P < 0.05). The significance of the 
difference between BCG + ApaDNA group and ApaDNA + BCG group was P < 0.05 
([]). Error bars indicate standard error of the means. The experiment was repeated 
twice
In both cases, controls stimulated with RecApa in vitro did not show detectable levels 
of either IL-4 or IFN-y.
3.5.3 Protective responses in animals receiving the prime-boost I  vaccination protocol
The type of immune response induced by the prime-boost strategy is particularly 
dependent on the nature of the boosting agent (Ramsay, 1999). In these terms, it has been 
demonstrated that BCG is a more effective boosting agent than viral carriers in prime- 
boost protocols against murine tuberculosis (Feng, 2001). Since the specific immune 
responses were up-regulated by the prime-boost I vaccination protocol, vaccinated mice 
were then challenged with M. tuberculosis H37Rv. In the experiments described here, 
BCG was tested both as priming or boosting agent, combined with one injection of 
lOOpg of ApaDNA plasmid. C57BL/6 mice were infected ten weeks after the boosting 
dose and killed five to six weeks later to analyse the bacteriologic burden in the spleen 
and lungs. The use of combinations of ApaDNA and BCG, independent of the order, did 
not confer better protection than BCG itself, both in the lungs and spleen (fig.3.21). All 
BCG-vaccinated groups showed significant protection in both lungs and spleen (P < 
0.05).
3.6 Prime-boost with DNA combination vaccine and BCG (Prime-boost II)
An usual strategy to increase the potency of DNA vaccines against tuberculosis is 
demonstrated by the use of multisubunit vaccination with different DNA vectors 
(Huygen, 2003).
A
i c f -
* *  •8 irf
1
B
<ui
Spleen
i c f -
1 cf -
— I  1   1--- — —-----1
V ector V ector + BCG ApaDNA + BCG BCG + ApaDNA
Lungs
8
%'-P3
kV)
J  1(f-
1 cf -
—I-------------------- 1
Vector V ector + BCG ApaDNA + BCG BCG + ApaDNA
Figure 3.21 Protection provided by prime-boost I immunisation. C57BL/6 mice 
were vaccinated intramuscularly with ApaDNA, empty vector, or BCG and boosted 
one month later with BCG or ApaDNA. The mice were challenged intravenously with 
approximately 105 CFU of M. tuberculosis H37Rv. Protection was assessed thirty- 
eight days later in the spleen (A) and lungs (B). Asterisks indicate protection 
statistically significant compared to vector group (P < 0.05), as determined by the 
Student t test. Error bars indicate standard errors of the means.
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Improved IFN-y responses, reduced bacterial burden and prolonged survival time 
were reported when these multisubunit regimens were tested in mice (Kamath, 1999; 
Delogu, 2002). The prime-boost II immunisation experiment was designed to examine 
the immune responses and to investigate whether the simultaneous injection of ApaDNA 
vaccine, in combination with other DNA gene constructs expressing different 
immunodominant mycobacterial genes could induce resistance against tuberculosis 
(fig.3.22). Groups of mice were vaccinated once with DNA combinations comprising the 
HSP65, HSP70, Apa, MPT83 and MPT70 encoding plasmids. These MTB antigens were 
selected for evaluation together with ApaDNA, due to their previously documented 
immunogenicity in the context of DNA vaccination against tuberculosis (Tascon, 1996; 
Tascon, 1997; Lowrie, 1999; Chambers, 2000). Each plasmid was injected separately in a 
different limb. BCG, as a booster, was injected intradermally one month later. Groups 
receiving BCG as the priming vaccine, instead of DNA, were also evaluated.
3.6.1 Immune responses in animals receiving the prime-boost II vaccination protocol
In order to assess whether the prime-boost with DNA Combos I 
(Apa/HSP65/HSP70/MTP83) and II (HSP65/HSP70/MTP70) plus BCG stimulated 
appropriate cell-mediated immunity, spleen cell cytokine responses from vaccinated 
animals were evaluated as described. Since IFN-y is a critical component of the anti- 
mycobacterial protective response, a special focus was taken on analysing the specific 
IFN-y responses from these vaccinated mice. PPD stimulation of spleen cells induced an 
increase in the frequency of IFN-y+ cells from all groups of animals vaccinated with 
BCG (fig.3.23).
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Figure 3.22 Schematic representation of the vaccination protocol for prime- 
boost II. 6-8 weeks old Balb/c mice were vaccinated with fifty micrograms of each 
specific DNA vaccine as described in Material and Methods. Vector control groups 
received 200pg of empty plasmid. CFUs, colony forming units.
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Figure 3.23 IFN-y-secreting spleen cells from prime-boost II vaccinated mice.
Spleen cells (4 mice/group) were cultured with PPD. Viable and counted cells were 
serially diluted in ELISPOT plates and processed as described. Results are expressed as 
the mean number of spot-forming cells per million, minus spots from non-stimulated and 
background control wells. Errors bars indicate standard errors. SFC, spot-forming cells; 
Combo I, Apa, HSP65, HSP70 and MPT83; Combo II, HSP65, HSP70 and MPT70. 
Assays were performed in triplicate and duplicate. *, P < 0.05 versus vector + BCG or 
Combo I and II groups.
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Groups of mice primed with Combo I and Combo II vaccine combinations plus 
BCG, all had significant increases (P < 0.05, Student’s t test) in IFN-y+ cell frequencies 
when compared with vector + BCG control. Robust, but not statistically significant IFN-y 
responses were generated in mice primed with BCG and boosted with Combo I plasmids 
when compared to DNA priming (fig.3.23). Stimulation of the spleen cells with 
recombinant HSP65, generated increased IFN-y+ cell frequencies in all groups injected 
with the HSP65 DNA vaccine, but particularly in groups primed with Combo I and 
boosted with BCG (P < 0.05) in comparison with mice injected with vector plus BCG 
(preliminary results). Although with its inhibitory role still to be better clarified during 
the immune response in the tuberculous host, induction of IL-4 and IL-10 by anti- 
mycobacterial vaccines is not a desired feature for a future vaccine against human 
tuberculosis. IL-4 and IL-10 levels produced in vitro by spleen cells were also evaluated 
by ELISA. Again, in response to PPD, groups that received BCG produced levels of IL-4 
and IL-10 always increased in comparison to groups that did not receive BCG as part of 
their vaccination protocol (fig 3.24A & B). In addition, the groups of mice producing 
high levels of Thl -IFN-y were also producing increased levels IL-4 and IL-10 cytokines. 
Animals receiving saline or DNA Combos without boost did not produce important 
amounts of IL-4 and IL-10.
3.6.2 Protective responses in animals receiving the prime-boost II vaccination protocol
In order to evaluate the ability of the prime-boost II protocol to confer levels of 
protection superior to BCG, vaccinated animals were infected intravenously with M. 
tuberculosis H37Rv after twelve weeks of post-vaccination resting.
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Figure 3.24 Specific IL-4 and IL-10 cytokine responses produced by spleen cells 
from prime-boosted II vaccinated mice. Spleen cells from vaccinated mice were 
collected as described and cultured in vitro with lOpg/ml of PPD. IL-4 (A) and IL-10 (B) 
were measured in the supernatants by ELISA. Results show the mean plus SE of cells 
pooled from four mice. All groups receiving BCG produced significantly more (*, P < 
0.05) cytokine than saline or Combo I and II groups. The experiment was repeated twice.
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Spleen and lungs were removed to evaluate the bacteriologic burden present in 
these organs 5-6 weeks after challenge. As expected, the results show that the animals 
receiving BCG were protected in comparison to saline control (fig.3.25A & B). In 
addition, mice receiving one injection of any combination of plasmids (without BCG) did 
not significantly decrease the CFU counts in both organs. More importantly, there was no 
significant additional protective effect with one priming dose of Combo I or II DNA 
cocktails, on the protection induced by BCG. The mice primed with BCG and boosted 
with Combo I also did not demonstrate better protection than BCG alone (fig.3.25A & 
B).
3.7 Priming with two or three doses of DNA combination vaccines and boosting
with BCG (prime-boost III)
Whereas a single vaccination with DNA can induce a detectable humoral and 
CTL response in several model systems, cellular and humoral responses are boosted by 
successive additional immunisations (Gurunathan, 2000). Repeated injections of DNA 
vaccines, whether using a single antigen (Tascon, 1996) or a cocktail of different 
plasmids (Delogu, 2002), have demonstrated the ability to protect animals as well as 
BCG. In this context, C57BL/6 and Balb/c mice strains were primed repeatedly with 
DNA combinations composed of ApaDNA, HSP65 and HSP70 plasmids (Combo III), 
and were boosted or not with BCG (fig.3.26). Groups of Balb/c mice received either two 
or three priming doses of DNA Combo III cocktail vaccine, on intervals of three weeks, 
and were boosted or not with BCG, intradermally, one month after the last DNA 
vaccination.
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Figure 3.25 Protection provided by prime-boost II immunisation. Balb/c mice were 
primed once with the described combination of plasmids or BCG, followed by a boosting 
dose one month later. Challenge was performed intravenously with M. tuberculosis 
H37Rv sixteen weeks later. Bacteriologic burden in the lungs (A) and spleen (B) was 
expressed as the mean number of live bacteria ± SE. All animals injected with BCG were 
protected in both organs (*, P < 0.05), in comparison with mice not receiving BCG. The 
experiment was repeated twice. Combo I, Apa/HSP65/HSP70/MPT83; Combo II, 
HSP65/HSP70/MPT70.
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Figure 3.26 Schematic representation of the vaccination protocol prime-boost 
III. 6-8 weeks-old Balb/c or C57BL/6 mice were injected intramuscularly with fifty 
micrograms of each specific DNA vaccine. The plasmids were injected separately in 
the posterior and anterior limbs. Vector groups received 150pg of empty plasmid. 
CFUs, colony-forming units.
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C57BL/6 mice received two doses of DNA Combo III plus/minus BCG boost. 
Cytokine responses were studied both before and after intravenous infection with M. 
tuberculosis H37Rv.
3.7.1 Immune responses o f animals receiving the prime-boost III vaccination protocol
In order to investigate specific immune responses after the prime-boost III 
protocol, CD4+ and CD8+ T cells were isolated from the spleen of vaccinated animals 
and were co-cultured in vitro with antigen-presenting cells and either PPD, RecApa or 
medium. Frequencies of IFN-y+ cells were evaluated by ELI SPOT assay and levels of 
IFN-y produced in vitro were analysed by ELISA as described previously. Fifteen weeks 
after boosting, stimulation of CD4+ T cells from Balb/c mice vaccinated twice with the 
plasmid cocktail and boosted with BCG, did not differ significantly from controls 
vaccinated with vector + BCG or DNA only (fig3.27A). The same trend was observed 
when the cells were stimulated with RecApa (fig3.27B). Analysis of ELISA results 
showed a different picture: CD4+ T cells from DNA-primed BCG-boosted mice were 
capable of producing higher amounts of specific IFN-y in vitro than its counterparts, 
when stimulated with PPD (fig.3.28). On the other hand, the analysis of CD8+ T cell 
frequencies from prime-boosted mice by ELISPOT showed a significant increase in the 
numbers of IFN-y+ CD8+ T cells in response to PPD antigen, in Balb/c mice primed with 
DNA twice and boosted with BCG (fig.3.29). Controls and vector plus BCG groups did 
not show elevated numbers of CD8+ T cells producing IFN-y. The increase in IFN-y+ 
cell frequencies found was also correlated with an increase in the levels of IFN-y 
cytokine, as determined by ELISA (data not shown).
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Figure 3.27 IFN-y+ CD4+ T cells induced by prime-boost III protocol. Balb/c mice 
were primed by two doses of Combo III (Apa, HSP65 and HSP70) plasmids and boosted 
or not by BCG. CD4+ T cells were purified from the spleen and cultured in vitro with 
PPD (A) or RecApa (B) and the number of IFN-y+ CD4+ T cells determined by the 
ELISPOT assay. Three mice per group were used and the number of spot-forming cells 
(SFC), are expressed as the mean plus SE of triplicates. *, P < 0.05 versus saline group.
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Figure 3.28 IFN-y production by PPD-stimulated CD4+ T cells. Groups of Balb/c 
mice were immunised twice with the Combo III cocktail (Apa, HSP65, HSP70 plasmids) 
and were boosted with BCG. Controls received saline, DNA plasmids only or were 
primed with empty vector and boosted with BCG. CD4+ T cells were purified from the 
spleens of vaccinated mice and cultured in vitro with lOpg/ml of PPD and BMDCs as 
antigen presenting cells. Supernatants were collected after two days and measured by 
ELISA as described. Data shown are the mean determinations plus SE of three mice per 
group. *, P < 0.05 versus other groups.
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Figure 3.29 Specific IFN-y+ ELISPOT responses of CD8+ T cells from prime- 
boost III vaccinated mice. Groups of Balb/c were vaccinated twice with Combo III 
cocktail and boosted with BCG. Controls received saline, DNA plasmids only or vector 
plus BCG. CD8+ T cells were purified from the spleen of three mice per group and co­
cultured with BMDCs and 10pg/ml of PPD. The frequency of CD8+ T cells producing 
IFN-y was determined by ELISPOT as described. The numbers of SFC are expressed as 
the mean plus SE of triplicates. *, P < 0.05 versus saline or 2X Combo III. **, P < 0.05 
versus vector + BCG group.
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Priming of Balb/c mice with three doses of Combo III (Apa/HSP65/HSP70) 
plasmid cocktail supplemented by boosting one month later with BCG, induced an 
apparently higher but not statistically significant number of CD4+ IFN-y+ T cells, when 
compared with the BCG-vaccination group, in the cultures grown in the presence of PPD 
(fig.3.30A). A small increase in Apa-specific CD4+ IFN-y+ T cells from prime-boosted 
Balb/c mice was also demonstrated (fig.3.30B). Consistent with previous results, the 
levels of IFN-y secretion in the supernatant were determined (fig.3.31), and CD4+ T cells 
from DNA-primed BCG-boosted groups, showed higher IFN-y levels than cells from 
mice vaccinated with BCG alone in response to PPD antigen (P < 0.05).
The augmented number of CD8+ T cells producing IFN-y in response to PPD was 
maintained in Balb/c mice receiving three doses of DNA Combo III priming plus BCG 
boosting. The IFN-y+ CD8+ T cells from these mice showed higher frequencies and 
secreted more IFN-y in response to PPD, in the culture supernatants, when compared to 
control groups (fig.3.32A & B). On the other hand, CD8+ T cells isolated from prime- 
boost vaccinated mice did not respond to stimulation with 6pg/ml of recombinant Apa in 
vitro (not shown).
The analysis in C57BL/6 mice demonstrated that the frequency of CD4+ T cells 
producing IFN-y in response to PPD, from mice vaccinated with empty vector plus BCG 
or Combo III plasmid cocktail plus BCG, was increased in comparison to saline and 
DNA Combo III cocktail controls (fig.3.33A). In addition, a significant (P < 0.05, 
Student’s t test) increase in Apa-responsive CD4+ T lymphocytes producing IFN-y was 
also demonstrated in mice receiving Combo III plus BCG prime-boost, when compared 
to vector plus BCG group (fig.3.33B).
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Figure 3.30 Specific IFN-y+ ELISPOT responses of CD4+ T cells from prime- 
boost III vaccinated Balb/c mice. Mice were injected three times with Combo III DNA 
vaccine and boosted with BCG, as described. Controls received saline, DNA vaccines or 
vector plus BCG. CD4+ T cells were co-cultured with BMDCs and lOpg/ml of PPD (A) 
or 6pg/ml of RecApa (B). The frequency of CD4+ T cells producing IFN-y was 
determined by ELISPOT. The mean number of SFC is expressed plus standard error of 
three mice per group. *, P < 0.05 versus 3X Combo III or saline group.
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Figure 3.31 Specific IFN-y production by CD4+ T cells from prime-boost III 
vaccinated Balb/c mice. Groups o f mice received three immunisations w ith Combo II I  
cocktail (Apa, HSP65, HSP70 plasmids) and were boosted later w ith  BCG. Controls 
received saline, D N A  vaccines only or vector plus BCG boost. CD4+ T cells were 
purified from spleen cell suspensions and cultured in vitro  w ith  10pg/ml o f  PPD and 
BM DCs as antigen presenting cells. Supernatants were collected after 48 hours and 
assayed for IFN-y by ELISA. Data shown represents the means plus SE o f  three mice per 
group. *, P < 0.05 versus 3X Combo I I I  or saline. * * ,  P  < 0.05 versus vector + BCG 
group, as determined by Student t test.
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Figure 3.32 Specific IFN-y production by CD8+ T cells from prime-boost III 
vaccinated Balb/c mice. Groups o f mice were primed three times w ith Apa, HSP65 and 
HSP70 plasmids (Combo I I I)  and were boosted w ith  BCG. Controls received saline, 
D N A  only or vector plus BCG. (A ) CD8+ T cells were purified from the spleens o f  
vaccinated mice and co-cultured w ith  BMDCs and lOpg/ml o f PPD. The frequency o f 
CD8+ T cells producing IFN-y was determined by the ELISPOT assay as described. The 
number o f SFC are expressed as mean plus SE o f triplicates. (B) Supernatants from  the 
cell cultures were assayed for IFN-y by ELISA. Bars represent mean values plus standard 
errors from duplicate wells. *, P  < 0.05 versus other groups.
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Figure 3.33 IFN-y+ CD4+ T cells induced by prime-boost III protocol in C57BL/6 
mice. Animals received two doses o f Combo I I I  (Apa, HSP65, HSP70) plasmids and 
were boosted or not by BCG. CD4+ T cells were purified from the spleens and cultured 
in vitro w ith  PPD (A ) or RecApa (B) and the resulting number o f  IFN-y+ CD4+ T cells 
in the cultures was determined by ELISPOT assay as described. Three mice per group 
were used. The number o f SFC is expressed as the mean plus standard error o f triplicates. 
*, P < 0.05 versus 2X Combo II I  or saline. ** , P  < 0.05 versus 2X  Vector + BCG group.
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3.7.2 Intracellular cytokine staining o f lung T cells from mice receiving the prime-boost 
III vaccination protocol and challenged with M. tuberculosis
Mycobacterial antigen-specific CD4+ and CD8+ T cell populations producing 
IFN-y are necessary for an effective immune response against an infection by the tubercle 
bacilli (Flynn & Chan, 2001; Tascon, 1998). Analysis of these subpopulations in the 
lungs of infected and vaccinated mice is important to observe a possible correlation with 
an increase in IFN-y+ CD4+/CD8+ population frequencies and significant decreases in 
bacterial burden from vaccinated animals. After 5 weeks of infection, lung cells were 
isolated from groups of Balb/c mice receiving two priming doses of DNA Combo III 
cocktail and controls, for performing intracellular cytokine staining as described 
previously. At the time of the screening, there was no difference in the numbers of IFN- 
y+ CD4+ or CD8+ T cells, between any of the groups tested (fig.3.34). Total percentages 
of IFN-y+ CD4+, and particularly CD8+ T cells, were elevated in the lungs of all groups 
examined. A similar picture was also observed in the lungs of infected C57BL/6 
challenged under the same conditions (not shown).
3.7.3 Protective responses in animals receiving the prime-boost III vaccination 
protocol
In this experiment, prime-boost-inducing protective responses were evaluated in 
groups of Balb/c mice only. Animals were infected fifteen weeks after boosting with M. 
tuberculosis, as described previously. The results demonstrated that all animals receiving 
BCG as part of their regimen were protected in comparison with controls.
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Figure 3.34 Intracellular IFN-y staining of lung cells from infected prime-boosted 
III vaccinated mice. Intravenously-infected Balb/c mice from prime-boost III protocol 
had their lungs harvested 38 days post-infection. The cells were pooled and stimulated 
for 6 h with anti-CD3 and anti-CD28 antibodies plus monensin, as described in Material 
and Methods. The cells were stained with anti-CD4, anti-CD8 and anti-IFN-y and were 
analysed by two-colour flow cytometry as described. Cells were further gated on CD4 
(A) and CD8 (B), and the percentages of IFN-y-producing cells within each gate were 
plotted for each one of the groups.
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In addition, Balb/c mice receiving two doses of Apa/HSP65/HSP70 DNA 
combinations (Combo III) boosted with BCG did not show significant reduction in CFU 
numbers in both lungs and spleen, when compared to mice primed with empty vector 
boosted with BCG (fig.3.35A & B). Importantly, Balb/c mice vaccinated with three 
doses of Combo III mycobacterial vectors displayed a significantly increased protection 
in both spleen and lungs (P < 0.05) than animals injected with saline (fig.3.36A & B). 
Further, for mice primed three times with the plasmid cocktail and boosted with BCG, 
the protection induced in the lungs was significantly better than that observed in mice 
vaccinated with vector plus BCG (P < 0.05) (fig.3.36B), demonstrating an additive effect 
for the protective immunity offered by the two vaccination strategies.
3.8 Confirmation of the DNA-prime BCG-boost vaccination efficacy against
tuberculosis (prime-boost IV)
The challenge experiments described above were repeated with a larger number of 
animals. Groups of twelve mice per cage, were primed two or three times with the DNA 
Combo III cocktail (Apa/HSP65 and HSP70 plasmids) and were boosted or not with 
BCG, as described previously for prime-boost III experiment. C57BL/6 is usually the 
standard strain adopted for tests of new vaccines against tuberculosis (Orme, 2001) and 
was selected for this experiment. Groups of mice receiving three doses of vector alone 
were also included as controls. The mice were challenged intravenously with M. 
tuberculosis H37Rv, fifteen weeks after the BCG-boost administration. The results 
demonstrated that the animals receiving two doses of DNA combination containing Apa, 
HSP65 and HSP70 plasmids, controlled bacillary replication at levels achieved by BCG
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Figure 3.35 Challenge experiments in Balb/c mice from prime-boost III groups.
Mice were injected twice with Combo III (Apa, HSP65 and HSP70 plasmids) or empty 
vector, and boosted or not with BCG. The animals were then infected intravenously with 
MTB fifteen weeks later as described. Spleen (A) and lungs (B) from 3-5 mice per group, 
were harvested after 38 days and the mean number of viable bacteria per gram (gr.) of 
tissue was calculated. Error bars represent standard errors. *, P < 0.05 versus 2X Combo 
III or saline groups.
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Figure 3.36 Protection provided by prime-boost III immunisation in Balb/c mice.
Animals received three intramuscular doses of the Combo III (Apa, HSP65 and HSP70 
plasmids) or empty vector, and were boosted or not with BCG. The mice were 
challenged intravenously with 105 CFU of M. tuberculosis. Protection was assessed 
forty-two days later by enumerating the mean number of live bacteria in the spleen (A) 
and lungs (B). *, P < 0.05 versus saline group; **, P < 0.05 versus 3X vector + BCG 
group, as determined by the Student t test. Error bars indicate standard errors of the 
means.
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vaccination, in both the lungs and spleen (fig.3.37A & B). Importantly, mice receiving 
this plasmid DNA combination, boosted one month later by BCG showed a significantly 
better control of the infection when compared with the animals that received vector plus 
BCG (P < 0.001), in both lungs and spleen (fig.3.37A & B). In addition, groups of 
twelve C57BL/6 mice were set with the intention to evaluate the degree of contribution 
of the Apa antigen for the protective efficacy of the plasmid cocktail. The animals 
received two priming doses of HSP65, HSP70 and empty vector (as a substitute for the 
Apa plasmid) and were boosted or not, one month later with BCG. When compared, the 
protection induced by these combinations appeared to be intermediary. Groups receiving 
the DNA combination excluding the Apa plasmid, had significant decrease in bacterial 
loads versus saline control (P < 0.001); however, the protection achieved was not better 
than that exhibited by animals receiving the complete Apa/HSP65/HSP70 (Combo III) 
cocktail. In addition, mice that were vaccinated with the full plasmid Combo III cocktail 
and boosted with BCG, performed better in both lungs and spleen than mice injected 
with the combination lacking the Apa plasmid boosted with BCG (P < 0.001, fig.3.37A 
& B). Nonetheless, the group of mice lacking ApaDNA boosted with BCG was still able 
to afford significantly better protection than the control group vector + BCG (P < 0.001), 
in both organs. These results demonstrated the beneficial and critical effect of the Apa 
antigen in the protective response induced by this plasmid mixture.
For groups of C57BL/6 mice receiving three vaccination doses of Combo III 
plasmids, protection against M. tuberculosis challenge was highly significant in both 
lungs and spleen (P < 0.001, Student’s t test) when compared to vector control group, 
and also reached similar levels as the animals vaccinated with three doses of empty 
vector plus BCG (fig.3.38A & B).
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Figure 3.37 Protection experiment for prime-boost IV (first group). C57BL/6 mice 
were primed with two doses of Combo III (Apa/HSP65/HSP70 plasmids) and boosted or 
not with BCG as described. Groups not receiving ApaDNA were primed twice with 
HSP65, HSP70 DNA and empty vector (65/70/VEC). Controls received saline. 
Intravenous challenge with MTB was performed fifteen weeks after boosting. Six weeks 
later, CFU counts in spleen (A) and lungs (B) were compared. Data are expressed as the 
CFUs mean ± SE of twelve animals per group. *, P < 0.05 versus saline group (Student t 
test); **, P < 0.001 versus 2X vector + BCG group (ANOVA); t ,  P < 0.001 (ANOVA).
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Figure 3.38 Protection experiment for prime-boost IV (second group). C57BL/6 
mice was primed with three doses of Combo III (Apa/HSP65/HSP70 plasmids) and 
boosted or not with BCG. Controls received three injections of empty vector (VEC) and 
were boosted or not with BCG. Mice were infected intravenously with MTB fifteen 
weeks after boosting. Six weeks later, CFU counts in spleen (A) and lungs (B) were 
compared. Data is expressed as the mean ± SE of CFUs from twelve animals per group. 
*, P < 0.001 versus 3X VEC group, as determined by Student t test; **, P < 0.001 versus 
3X VEC + BCG group, as determined by Student t test.
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As in the results shown in figure 3.37, mice receiving three doses of Combo III 
plasmids plus BCG boosting were also able to significantly improve (P < 0.001, 
Student’s t test) protection obtained by vaccination with vector plus BCG, in both lungs 
and spleen (fig.3.38A & B). When animals from groups receiving three doses of saline or 
vector were compared, analysis of CFU counts in the lungs revealed that the group of 
mice receiving injections of empty vector behave similarly as the saline control mice; 
however in the spleen there was statistical significance (P < 0.05) showing a possible 
beneficial effect resultant from the immunogenic CpG islands present in the pCMV4 
plasmid backbone (not shown).
3.9 Protective responses of animals receiving the ApaDNA vaccine
To evaluate the protective effect exhibited by the ApaDNA vaccine alone, groups 
of C57BL/6 mice were immunised four times, intramuscularly, three weeks apart, with 
lOOpg of ApaDNA plasmid. As negative controls, mice were injected with empty vector. 
As the positive control, groups of mice were immunised once, intradermally, with BCG. 
Six weeks later, the animals were challenged intravenously with M. tuberculosis H37Rv, 
as described previously in Material and Methods. Bacteriological burden was measured 
in the lungs and spleen, five weeks after challenge. The results of these experiments 
demonstrated that, in contrast to the protective effect induced in mice by the ApaDNA 
vaccination when associated with the HSP65 and HSP70 vaccines, the level of protection 
induced by the ApaDNA vaccine injected alone was not significantly better when 
compared to the protection conferred by the empty vector control, at the time of 
screening (fig.3.39).
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Figure 3.39 Protection provided by ApaDNA immunisation. Groups of C57BL/6 
mice were immunised either with ApaDNA, empty vector or BCG. Six weeks later, the 
mice were challenged intravenously with 105 CFU of M tuberculosis H37Rv. Protection 
was assessed by determining the number of live bacteria (mean ± SE) in the spleens (A) 
and lungs (B). Compared to the other groups, protection in the BCG group was 
significant (*, P < 0.05) for both organs (Student t test). The experiment was repeated 
twice.
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3.10 Boosting BCG with DNA vaccines (prime-boost V)
More than one billion humans have already been vaccinated with BCG. It was 
then relevant to know the efficacy of giving a DNA vaccine to mice that have previously 
received BCG vaccination. To address this important issue, groups of mice were primed 
with BCG-Glaxo and then were rested for eight weeks. After this period, the animals 
were either injected with two doses of saline, empty vector or a combination of HSP65 
and HSP70 plasmids. Control groups receiving two doses of DNA only and naive groups 
were also set in parallel. The animals were then infected intravenously with M. 
tuberculosis H37Rv four weeks after the last injection. As shown in fig.3.40, animals 
receiving BCG or two doses of plasmid DNA combinations only were all significantly 
protected when measured against infected naive mice (P < 0.001), in both lungs and 
spleen. However, the groups of mice primed with BCG and then boosted with two doses 
of HSP65/HSP70 DNA cocktail, did not show significant improvement in protection 
when compared to mice vaccinated with BCG plus saline or empty vector.
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Figure 3.40 Protection provided by boosting BCG vaccination with DNA vaccines.
Balb/c mice received either BCG or saline and were boosted eight weeks later by two 
doses of mycobacterial HSP65 and HSP70 plasmids or empty vector or saline. Plasmids 
were injected separately in the posterior limbs. Animals were challenged intravenously 
with MTB, one month after the last dose. CFUs were determined in the spleen (A) and 
lungs (B) after six weeks. Data is expressed as the mean ± SE. *, P < 0.001 versus naive 
control group.
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CHAPTER FOUR
Discussion
4.1 Up-regulation of M, tuberculosis apa gene during infection
An increase in apa messenger RNA expression from M. tuberculosis grown in 
monocytic cell lines, was detected by Real-Time™ reverse transcription PCR (figs. 3.1 
and 3.2). Moreover, this increase was demonstrated in both human- and mouse-derived 
cells, previously activated with IFN-y, a situation mimicking the ongoing scenario of an 
in vivo immune response against the bacterium, generated by the host. Like other 
intracellular bacteria, MTB is expected to alter its program of gene expression in 
response to intracellular environmental changes. As the immunodominance presented by 
certain antigens during the anti-mycobacterial response is frequently associated with a 
proportional increase in their level of transcription, these results are consistent with such 
observations. Genes such as fbpB  and hspX, coding respectively for the mycolyl 
transferase antigen 85B and the a-crystallin 16-kDa protein showed increased level of 
transcription after infection of human monocytes (Wilkinson, 2001; Dubnau, 2002). In 
addition, studies with other pathogens have shown that genes, which are up-regulated 
during infection, are often essential for pathogenicity (Chiang, 1999). It would be 
interesting therefore, to observe the behaviour of a MTB mutant lacking the apa gene 
during infection in mice, to assess the role of Apa in mycobacterial virulence.
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A recent article (Schnappinger, 2003) reported that the transcripts of the apa gene, 
as analysed by microarray hybridisation, were repressed during M. tuberculosis infection 
of bone-marrow macrophages. A possible explanation for this discrepancy could be the 
augmented sensitivity (and specificity) presented by techniques such as quantitative 
reverse-transcription Real-Time™ PCR (qrtPCR) in comparison with the less sensitive 
microarray hybridisation. Its is interesting to note, that similarly to apa, the transcripts 
from the genes fopB (Wilkinson, 2001) and Rv0899 (OmpATb) (Raynaud, 2002), 
previously reported as significantly increased in infected monocytes by qrtPCR, were 
also considered to have similar expression levels in liquid cultures and in the phagosome 
of macrophages, when analysed by microarray hybridisation (Schnappinger, 2003).
4.2 Expression of the M. tuberculosis apa gene in E. coli and mammalian hosts
The Apa protein from M. tuberculosis was expressed in E. coli and the recombinant 
product was subsequently purified by affinity chromatography. Only the 47-kDa band 
was observed and the resulting protein was devoid of glycosylation (Horn, 1999). 
Although the recombinant clone chosen was selected on basis of higher levels of protein 
expression, the final yield of recombinant Apa protein (RecApa) in the system described 
here, was very limited. Approximately eleven litres of bacterial culture were necessary to 
obtain a maximum of two milligrams of recombinant protein as the end product ready for 
use in in vitro assays. A tempting explanation could be related to the presence of the N- 
terminal secretion signal, and consequently, the secretion and purification of the protein 
from the periplasmic space of E. coli, which is rich in proteases; these enzymes would 
then be responsible for the poor yield observed. The native Apa protein has been reported
172
to be rather unstable and very prone to degradation by proteases (Nagai, 1991). 
Exogenous addition of protease inhibitors during the purification procedures was avoided 
to prevent toxicity during cellular assays. One way to overcome this problem in the 
future would be to remove the N-terminal secretion signal and compare whether 
purification in denaturing conditions would be more rewarding in terms of protein 
recovery. The use of E. coli host strains that are deficient in periplasmic proteases 
(Kandilogiannaki, 2001) may also offer an additional alternative to improve the final 
yield of recombinant Apa obtained.
A second issue related to the purification of recombinant Apa from the E. coli host 
was the finding of lypopolysaccharide (LPS) contamination in eluted samples. Up to 380 
endotoxin units (EU) per milligram of recombinant protein were initially present in 
RecApa samples after Ni-NTA column purification. LPS through its bioactive centre 
lipid A can promote activation of dendritic cells through Toll-like receptors and other 
molecules (Triantafilou & Triantafilou, 2002), which in turn could induce the production 
of a variety of cytokines in mixed lymphocyte cultures (Qi, 2003). The presence of such 
contaminants in Apa samples would undoubtedly affect the results and make 
interpretation of RecApa-stimulation of immune cells very difficult. Preliminary testing 
using recombinant Apa without further LPS removal, induced unspecific production of 
IL-10 by spleen cells from ApaDNA-vaccinated mice; importantly, this production was 
not observed with the use of LPS-free RecApa (not shown).
Regarding the expression of DNA vaccine vectors encoding Apa in CV1 mammalian 
cells, it was observed an increase in the molecular size of the recombinant Apa protein 
that could not be solely attributed to additional plasmid sequences fused with the apa 
gene (fig.3.7). The product expressed from the pSecTag2C.Apa vector (secreted form)
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reached 72-kDa in CV1 cells while the molecular weight of the Apa protein in MTB was 
47-kDa. This recombinant secreted protein would cany as part of the vector-fusion 
sequences, a myc epitope and a 6XHis tag sequence, totalling around 27 additional amino 
acids, an estimated increase of 3-kDa on the predicted molecular weight of the final 
recombinant product. The amino acid content did not include additional prolines which 
could possibly influence the migration properties of the protein in SDS-PAGE 
(Furthmayer, 1971). These observations suggested that the recombinant Apa was very 
likely being post-translationally modified in the mammalian system to include an 
unknown content of sugar moieties. Similarly, the Apa protein secreted from CV1 cells 
transfected with the pCMV4.Apa, which did not include any fused vector sequences, still 
exhibited a relative increase in size from 47- to 59-kDa (fig.3.7). A number of bands of 
various molecular weights were also observed in the lysate of CV1 cells transfected with 
pSecTag2C.Apa vector (fig.3.7, lane E). These could possibly be a result of truncated 
forms of the protein, but also to glycosylated isoforms of the recombinant Apa. 
Importantly, staining of the purified Apa produced in the transfected mammalian cell 
confirmed the glycosylation of the protein (fig.3.8).
Several immunodominant antigens of M. tuberculosis and M. bovis have been 
reported to be glycosylated (Dobos, 1996). To date, the unambiguous demonstration of 
glycosylation in mycobacteria has been shown only for Apa and, recently for the M. 
bovis antigen MPB83 (Michell, 2003). Although similar to MPB83 in its carbohydrate 
composition (mannose), there are differences in the sugar linkages of Apa; while Apa 
contains (1—» 2)-linked mannobiose and (l->  2), (1—> 2)-linked mannotriose, the 
terminal mannose in MPB83 is (l->  3)-linked (Michell, 2003). The type of linkage seen 
in Apa is also observed in the di- and trimannosyl units of the mannose cap of LAM
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(Venisse, 1995) and as one of the linkages for the mannose present in the 
phosphatidylinositol mannoside (PIM) family of mycobacterial phospholipids such as 
PIM5 and PIM6 (Chatteijee, 1992).
Removal of covalently bound mannose from M. tuberculosis Apa antigen reduced 
by 10-fold its ability to elicit a delayed-type hypersensitivity reaction in guinea pigs 
immunised with BCG (Romain, 1999). The increase on the immunogenicity of 
mycobacterial Apa because of its glycoproteic nature could be explained through 
facilitated antigen presentation by better accessibility to surface receptors. Mannose 
Receptor (MR), is a C-type lectin which binds mannose through its eight Ca2+-dependent 
carbohydrate recognition domains and is present on the surface of dendritic cells and 
macrophages (Gordon, 2002); in addition, it is one of the favourite entry ports of MTB in 
macrophages (Ernst, 1998). MR confers an enhanced ability of the order of 200- to 
10.000-fold (Tan, 1997) to concentrate mannosylated antigens for presentation to T cells 
by MHC class II molecules and CD lb (Prigozy, 1997). DC-SIGN, another C type lectin 
specific for dendritic cells and a preferred entry port for MTB in human dendritic cells 
(Tailleux, 2003), binds mannosylated structures such as ManLAM (polymannosylated- 
capped lipoarabinomannan). These structures could potentially bind the Apa antigen and 
increase its presentation to CD4+ T cells (Engering, 2002).
It would be important to gain more information on possible host binding 
molecules and the nature of sugar moieties of the Apa protein produced in vivo after 
DNA vaccination, studying to what extent this could affect the immune responses. 
Variations in the glycosylation pattern of recombinant Apa produced in Mycobacterium 
smegmatis were implied as responsible for its loss of immunogenicity in DTH responses 
and lymphocyte proliferation assays (Horn, 1999). Preliminary results of enzymatic
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digestion of Apa purified from transfected mammalian cells with a-mannosidase were 
inconclusive and need repetition, perhaps with additional data provided by Con A 
binding and mass spectrometry analysis.
4.3 DNA vaccination with the apa gene
C57BL/6 mice that received four vaccinations with DNA encoding the 
mycobacterial Apa protein exhibited specific immune response where significant levels 
of IFN-y were produced in response to Apa by stimulated spleen cells. In these 
experiments, absence of specific production of IL-4 or IL-10 cytokines was also 
demonstrated, strongly suggesting the existence of a predominant Thl response. The 
initial analysis of the humoral response in these animals showed the presence of both 
IgGl and IgG2a antibodies, specific for Apa, which is also consistent with an ongoing 
Thl-Th2 mixed immune response. CD4+ T cells but not CD8+T cells from ApaDNA 
vaccinated mice secreted IFN-y in response to Apa, and in addition, these animals 
presented a specific absence of cytotoxic activity for the Apa antigen.
Upon activation, mature B-lymphocytes may undergo class-switching 
recombination to produce a single, specific Ig isotype, which could be IgA, IgE, or one 
of the IgG subclasses (Roitt, 2001). Between other signals, cytokines such as IL-4, IFN-y 
and TGF-p appear to play critical roles in this process. For instance, TGF-p may 
selectively stimulate switching for the IgG2b isotype (McIntyre, 1993). IL-4 directs 
murine IgE and IgGl isotype production by activating transcription factors such as 
STAT6, which bind to and transactivate the germ-line Cs and Cyl promoters (Bacharier 
& Geha, 2000). Finally, IFN-y regulates IgG2a class switching in B cells, in part through
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the transcription factor T-bet (Peng, 2002). These results highlight that antibody isotypes 
sometimes can help to define which T cell phenotype is acting in the course of an 
immune response. Other investigators have also shown the presence of a mixed Thl-Th2 
antibody response after ApaDNA vaccination. Although not examining IL-4 cytokine 
production, Morris and collaborators (2000) obtained a balanced ratio of IgGl and IgG2a 
antibodies after ApaDNA vaccination in C57BL/6, while Garapin and colleagues (2001) 
using a non-secretable ApaDNA vaccine found a high percentage of IgGl and low 
IgG2a, in vaccinating Balb/c mice. In the results obtained here, the titres of IgGl were 
higher than IgG2a after ApaDNA vaccination (fig. 3.10); therefore, although I was not 
able to detect IL-4 production in vitro by immune cells (including purified CD4+ T cells) 
from ApaDNA vaccinated mice, the analysis of the humoral immune responses is 
suggestive that some level of IL-4 production does occur in vivo after ApaDNA 
vaccination. However, the role of IL-4 in tuberculosis is still elusive. Both young (North, 
1998) and old (Turner, 2001b) IL-4 knockout mice are as resistant as the wild type to 
MTB infection.
Some reports support an important role for B cells on protection (Teitelbaum, 
1998; Glatman-Freedman, 2003) or granuloma formation (Bosio, 2000; Turner, 2001b) 
in tuberculosis. Monoclonal antibodies recognising mycobacterial arabinomannan 
(Teitelbaum, 1998), heparin binding hemaglutinin adhesin and MPB83 (Glatman- 
Freedman, 2003), either enhanced survival or/and had effects on granuloma formation. 
Interestingly, similarly to Apa, all molecules discussed are glycosylated and contain 
mannose moieties. B cells and antibodies may have other, not yet investigated roles in 
anti-tuberculous immunity. Similarly to mycobacteria, in Listeria monocytogenes (an 
intracellular bacteria) model, B cells are not required for protective immunity; however,
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the absence of these cells results in increased death of activated CD8+ T cells during the 
contraction phase, leading to a lower level of Ag-specific CD8+ T cell memory in 
infected animals (Shen, 2003). In summary, a role for Apa-specific antibodies in the 
immune response generated after ApaDNA vaccination may deserve further study.
The first data showing protection against M. tuberculosis using naked DNA 
immunisation demonstrated it to be one of the most effective vaccination strategies to be 
able to stimulate T cell responses, both CD4+ and CD8+, and to induce priming of Thl 
immune responses (Tascon, 1996; Huygen, 1996; Huygen, 2003). Several mycobacterial 
antigens such as Mtb8.4, Ag85, Mtb41, Mtb39, MPT63, MPT83, HSP65, PstS3, ESAT- 
6, MPT64, 38-kDa protein and others, delivered as naked DNA have shown to be 
effective at inducing protection in mice following aerosol challenge (reviewed in Reed, 
2003; Huygen, 2003). In addition, most of the antigens tested originated from culture 
filtrate preparations (Orme, 1997). Apa protein is one of such culture filtrate components; 
cells obtained from guinea pigs vaccinated with live (but not dead) BCG recognised this 
protein strongly (Romain, 1993; Romain, 1999), suggesting that mycobacterial Apa 
protein would be a good candidate to test in vaccination experiments against MTB. 
However, regardless the extensive production of IFN-y, C57BL/6 mice vaccinated four 
times with ApaDNA was not better protected than vector-vaccinated animals, after the 
intravenous challenge with M. tuberculosis H37Rv (fig.3.39). Consistent with our results, 
Morris and collaborators (2000) also tested a similar DNA construct in C57BL/6 mice 
obtaining a high frequency of IFN-y-positive cells in the spleens of ApaDNA-vaccinated 
mice, with lack of protection after M. tuberculosis challenge infection. At the same time, 
other researchers had also reported similar findings using this vaccine in M. tuberculosis 
aerosol-infected animals (I. Orme, USA, personal communication). In contrast, Garapin
and colleagues (2001) demonstrated significant protection (0.5 log unit CFU) against 
mycobacterial infection in mice using a DNA construct with the apa gene, subtracted of 
the signal peptide. However, the challenge experiments were performed in mice infected 
with the attenuated M. bovis BCG strain rather than the virulent M. tuberculosis H37Rv 
(Garapin, 2001), making their results difficult to compare with the results obtained here. 
Kumar and colleagues (2003) have also reported recently lack of protection by the 
ApaDNA plasmid injected as a single vaccine, in the guinea pig model.
In developing countries, as many as 40 to 80% of individuals with AIDS will also 
develop tuberculosis, indicating a key role for CD4+ T cells in the immune control of TB 
infection (Dye, 2002; Flynn & Chan, 2001). CD4+ T cells are the main producers of 
IFN-y, which then activates macrophages to control bacterial growth. One of the 
principal anti-mycobacterial mechanisms induced by IFN-y is the expression of the 
enzyme NOS2, responsible for restricting M. tuberculosis replication via nitric oxide 
generation (Chan, 1992; Ehrt, 2001). Recently, another IFN-y-dependent mechanism has 
been identified (MacMicking, 2003), LRG-47, a member of a newly emerging family 47- 
kDa guanosine-triphosphatases, provides a NOS2-independent and functionally separated 
system for the control of MTB replication in macrophages. Supporting the crucial role of 
IFN-y in the control of mycobacterial infections by the host, both mice and humans with 
genetic deficiencies in IFN-y signalling pathways were showed to be highly susceptible 
to severe mycobacterial infections (Casanova & Abel, 2002). Tuberculosis-vaccine 
antigen-candidates have been prioritised based on their ability to stimulate cells from 
healthy PPD+ donors to proliferate and produce IFN-y (Reed, 2003). These data and 
others (Black, 2002) support the use of quantitative assays such as the ELISPOT assay 
for IFN-y responses, as promising tests for correlating protective immunity. The initial
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observations on the increased production of IFN-y by cells from ApaDNA vaccinated 
mice in response to Apa protein in vitro were thus very encouraging (figs.3.12 & 3.13). 
However, after challenge with M. tuberculosis H37Rv, the animals demonstrated lack of 
successful protection in short-term experiments (fig.3.39). Thus, IFN-y production failed 
to correlate with effective protection in this model. The importance of the production of 
IFN-y in mycobacterial immunity is beyond doubt, but as discussed (Kaufmann, 2001), 
in certain instances IFN-y production and protection are not correlated. Interestingly, the 
lack of ESAT-6-induced IFN-y after M. bovis infection in cattle has been found to be 
associated with protective efficacy after BCG vaccination (Vordermeier, 2002). 
Importantly, the timing for detection of IFN-y-producing cells after vaccination may be 
crucial. In summary, one explanation for the lack of protection observed in the ApaDNA 
vaccinated mice would be that the response generated by immune CD4+ T cells was not 
sufficient in quantitative terms to inhibit bacterial replication.
Even if the IFN-y response specifically generated by CD4+ T cells after ApaDNA 
vaccination in mice, could be considered adequate, it is equally possible that other 
components of an effective anti-tuberculous response were missing. The role of 
unconventional T cells in anti-mycobacterial responses in mice has been demonstrated, 
although these cells are not as critical for protection as the conventional T cells 
(Kaufmann, 2001; Flynn & Chan, 2001). Significant roles have has been attributed for 
CD8+ T cells in protection against mycobacteria in both mice and humans (Boom, 2003). 
The IFN-y produced by activated CD8+ T cells would certainly contribute for a more 
concerted protective response against the tubercle bacillus (Tascon, 1998; Lalvani, 1998; 
Smith, 1999). CD8+ T cells from the lungs of MTB-infected old mice produces
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significantly more IFN-y than their counterparts in young mice and are critically involved 
in the early resistance displayed by old mice to aerosol infection (Turner, 2002a). In a 
experimental murine model of latent tuberculosis, depletion of CD8+ T cells or 
neutralisation of IFN-y had greater impact on the increase of pulmonary bacterial 
numbers than anti-CD4 treatment (van Pinxteren, 2000). Successful vaccination 
strategies against mycobacteria aim at inducing a powerful Thl response as well as an 
effective cytotoxic response. When investigating CD8+ T cell responses in ApaDNA 
vaccinated mice, I found that the IFN-y production from these animals were never 
significantly different from the cells originated from animals injected with saline or 
empty vector, when re-stimulated in vitro with RecApa; and in addition, there was no 
specific production of IL-2 in the cultures (fig.3.14). Re-stimulation with the 
glycosylated native Apa protein also resulted in similar findings (not shown). Therefore, 
it is tempting to speculate that a more efficient protective response in this model would 
be induced if an increased number of Apa-specific CD8+ T cells actively secreting IFN-y 
could be present. Kumar and colleagues (2003) have reported recently, increased IFN-y+ 
secretion by Apa-specific human CD8+ T cells from some healthy PPD+ individuals. A 
possible explanation for these contrasting findings would be the natural difference in 
TCR and MHC repertoire between mouse and humans, where the latter, being vaster 
would allow existing Apa-specific precursors to be expanded. Interestingly, Kumar and 
colleagues (2001) had used approximately 8-fold more recombinant Apa/ml of in vitro 
culture. This higher antigen concentration could possibly facilitate the Apa-specific 
primed CD8+ T cells to differentiate and secrete IFN-y (Hecht, 1983). More importantly, 
the lack of CD8+ T cell activation demonstrated by failure to produce IFN-y and lack of 
cytotoxicity has been reported for the C57BL/6 strain (but not for the Balb/c strain)
vaccinated with Ag85A DNA vaccine; protection in this mice was solely mediated by 
CD4+ T cells (D’Souza, 2000). However, despite of the absence of CD8+ T cell response 
in mice, there are several reports demonstrating human CD8+ T cell responses against 
mycobacterial Ag85A (Smith, 2000a; Smith 2000b). Thus, Apa could be behaving in 
similar fashion as Ag85A in the murine system but not in humans.
To explain the lack of protection, a crucial observation is the fact that Apa- 
dependent specific cytotoxicity was not detected (fig.3.16). Although cells such as NKT, 
NK or CD4+ T cells may have cytotoxic properties against mycobacteria, the CD8+ T 
cell sub-population play a determinant role in mycobacterial protection in mice (Flynn & 
Chan, 2001; Kaufmann, 2001). Besides cytokine release, CD8+ T cells can contribute to 
the control of M. tuberculosis infection through other three mechanisms: (1) cytotoxicity 
via granule-dependent exocytosis pathway, (2) cytotoxicity mediated through Fas/Fas 
ligand interaction, and (3) direct microbicidal activity, e.g. granulysin (Lazarevic & 
Flynn, 2002). The first cytotoxic mechanism is perforin-dependent, the second activates a 
cascade of caspase molecules resulting in apoptosis (programmed cell death) of the 
infected cell; to date, the third mechanism has not been detected in mice (Lazarevic & 
Flynn, 2002). Additional evidence for the importance of CD8+ cytotoxic effector 
functions comes from CD4+ T cell deficient mice which succumbed to infection besides 
apparently normal IFN-y responses in the lungs (Scanga, 2000). CD8+ T cells from 
CD4+ T cell deficient mice actually have impaired cytotoxic functions in the lungs of 
MTB-infected mice (Serbina, 2001).
In conclusion, these observations suggest that the lack of an appropriate CD8+ T 
cell response in ApaDNA-vaccinated mice could be more likely responsible for the 
observed failure in protection against M. tuberculosis infection. Thus, strategies of
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vaccination designed to induce increased levels of CD8+ T cell responses would be 
extremely interesting to investigate. ApaDNA vaccination did not elicit improved levels 
of protection compared to BCG. In fact, there are rare occasions where any single antigen 
showed better protection than BCG in rodent models (Reed, 2003). Vaccination of mice 
with one of the single antigens MTB8.4 (Coler, 2001), MTB41 (Skeiky, 2000), HSP65 
(Tascon, 1996; Bonato, 1998), 38-kDa (Zhu, 1997) and PstS-3 (Tanghe, 1999), in DNA 
format, have been reported in the literature to show reductions in MTB bacterial load 
similar to BCG in either lungs or spleen or both. For broader T cell responses, it would 
be necessary for a single antigen to contain a sufficient number of MHC class I and MHC 
class II epitopes to cover the diversity of HLA types in a targeted population. The 
antigenic complexity of BCG is not comparable to a single gene vaccine. Although 
increasing in complexity, it is possible to construct vaccines expressing defined epitopes 
for multiple MHC-class I loci (“polytope vaccines”), which facilitates co-priming of 
CD8+ T cell populations with a diverse repertoire (Schirmbeck, 2003).
4.4 Prime-boost vaccination using DNA and BCG
Prime-boost vaccination appears to be an effective immunisation strategy against 
tuberculosis. Here I demonstrated that intramuscular DNA vaccination of C57BL/6 and 
Balb/c mice with two or three priming doses of a plasmid cocktail encoding the 
mycobacterial antigens Apa, HSP65 and HSP70, followed by one intradermal injection 
boost of BCG one month later resulted in highly significant reductions in M. tuberculosis 
bacterial load from either the lungs, spleen or both, in comparison to either vaccine alone 
(figs. 3.36, 3.37 & 3.38).
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In the model described here, protection was critically dependent on the 
composition of the priming cocktail and the number of priming doses. Priming once was 
not demonstrated to be effective (figs. 3.21 and 3.25). Removal of the Apa plasmid from 
the cocktail resulted in significantly diminished protection in comparison with the 
injection with all components together, although the protection obtained was still 
superior to BCG injected alone (fig.3.37). This result demonstrates the importance of the 
Apa antigen (high IFN-y secretion by CD4+ T cells) in the protective immune response 
generated by the prime-boosting protocol studied here. In this context, mycobacterial 
HSP65 and HSP70 were also critical elements of this plasmid cocktail. These stress 
proteins can chaperone exogenous peptides to MHC class I molecules and thus promote 
antigen specific CD8+ CTL responses, as previously demonstrated in other systems 
(reviewed in Pockley, 2003; Audibert, 2003). More importantly, they can also play a role 
as intercellular signalling molecules, activating innate immune responses: mycobacterial 
HSP70 has been reported to induce several proinflammatory cytokines and the 
maturation of dendritic cells (Wang, 2001; Wang, 2002). Signalling and peptide binding 
in HSP70 are separate entities, localised at the C-terminal domain (MacAry, 2004). 
Intracellular signalling by HSP70 in dendritic cells seems to be independent of the TLR 
pathway (MacAry, 2004) and involves several receptors; CD40 for instance, is one 
important HSP70 receptor (Wang, 2001). Recently, CD40_/' mice has been reported to be 
susceptible to a low-dose aerosol infection with M. tuberculosis due to poor priming of 
IFN-y-producing T cells in the lymph nodes, a result of attenuated IL-12 production 
(Lazarevic, 2003). CD40 activation by mycobacterial HSP70 was implied as the 
alternative ligand in vivo (Lazarevic, 2003). These relevant evidences suggest an 
important adjuvant effect induced by HSP70 DNA vaccination in the activation of
dendritic cells in our model. Although a carrier effect for promoting CTL-induction by 
the HSP vaccines for the Apa protein (produced in vivo after ApaDNA vaccination) is 
difficult to consider since the two vaccines were not mixed and administered in different 
anatomical sites, it is still likely that the APC activation induced by HSP70 proteins, 
promoted effective priming of protective T cells in this model. It would be certainly 
interesting to test the carrier adjuvant effect of mycobacterial HSP70 by the production 
of a fusion protein with Apa, since similar strategies have been described to be very 
successful in promoting potent CTL responses against tumours (Chen, 2000). 
Mycobacterial HSP65 has also been reported to help cross-presentation of soluble, free 
antigen by dendritic cells for CD8+ T cells, although a direct role for DC activation is 
still controversial (Chen, 2004).
The efficacy of the plasmid combination Apa/HSP65/HSP70 plus BCG was 
recently tested in cattle with successful results (Skinner, 2003a). In that model, 
DNA/BCG vaccination resulted in significant enhancement of six pathological and 
microbiological parameters of protection following M. bovis challenge, i.e. number of 
animals with lung lesions, the mean lung lesion score, the number of animals with lymph 
node lesions, the mean lymph node lesion score, the mean number of lymph nodes with 
lesions per animal, and the mean lymph node bacterial count, while BCG alone affected 
only two (Skinner, 2003a). In contrast to HSP65 and HSP70 antigens, ApaDNA 
vaccination has been successful only when combined with a live heterologous boost 
(Skinner, 2003a; Kumar, 2003). Interestingly, prime-boost using single-dose ApaDNA 
vaccine plus BCG boosting did not improve BCG protection against M. tuberculosis in 
C57BL/6 mouse (fig.3.21). However, Kumar and collaborators (2003) had reported 
significant protection with a ApaDNA/ApaMVA combination in the guinea pig model,
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although heterologous viral boosting does not seem suitable for all antigens, as is the 
case of Ag85B (Feng, 2001).
One-dose vaccination priming with ApaDNA or Apa/HSP65/HSP70/MPT83 or 
HSP65/HSP70/MPT70 plasmids followed by BCG boosting did not induce significant 
protection over BCG alone, in the mice strains tested (figs.3.21 and 3.25). Besides the 
apparent increase in humoral (fig.3.19) and Thl responses (fig.3.20A & B and fig.3.23) 
in prime-boost groups, inhibitory cytokines such as IL-4 and IL-10 (figs.3.20C and 3.24) 
were also detected in both groups of mice, either receiving a single dose of one or more 
plasmids, as part of their vaccination regimen. However, the role of these cytokines in 
this and other models (Jung, 2002) is still uncertain. Nonetheless, IL-10 would probably 
not be desirable cytokine in terms of vaccine efficiency. IL-10-producing T cells have 
been found in anergic tuberculous patients; T cells from these patients had defective 
phosphorylation of the zeta-chain of the TCR and failure in activation of ZAP70 kinase 
(Boussiotis, 2000).
Although a single vaccination with DNA can induce both antibody and CTL 
responses in several model systems, both cellular and humoral immune responses are 
increased by one or two additional immunisations (Gurunathan, 2000). HSP65-plasmid 
vaccination against murine tuberculosis increases considerably in efficiency with a 
regimen of four-doses, four weeks apart. Accordingly, in view of the failure in inducing 
protection against murine tuberculosis with one-dose priming of DNA as described 
above, I decided to test whether repeated priming doses of plasmid DNA would result in 
increased protection. The composition of the vaccine cocktail was also altered during the 
course of my experiments. As predicted, a protocol of two or three priming doses of 
Apa/HSP65/HSP70 DNA plasmids (Combo III) followed by a boost with BCG generated
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unprecedented levels of protection over BCG alone, against M. tuberculosis infection in 
C57BL/6 mice (fig. 3.37 & 3.38). To my knowledge, it is the first time that a prime- 
boosted vaccination study against tuberculosis is able to afford such a high degree of 
reduction in bacterial load in both lungs and spleen, in comparison to mice vaccinated 
with empty vector plus BCG. Interestingly, a similar prime-boosting study using a 
priming vaccine expressing the mycobacterial antigens ESAT-6 and Ag85A followed by 
BCG boosting was not successful in obtaining better protection than BCG alone in mice 
(Skinner, 2003b). In comparison to my results, this study brings an immediate 
confirmation of how critical is to obtain a good combination of antigens necessary for 
successful priming. Improved levels of protection over BCG in Balb/c females were 
demonstrated when using three priming doses of DNA cocktail (fig.3.36). However, 
similarly to the experiment with C57BL/6 described in figure 3.37, it is possible that a 
protective effect in Balb/c after a two dose priming plus boosting would be seen more 
clearly once a large number of animals were examined. Nonetheless, numbers of M. 
tuberculosis CFU in the lungs of Balb/c and C57BL/6 mice are non-uniform depending 
on the day of infection (Wakeham, 2000).
The improved protection over BCG seen in Balb/c mice from prime-boost III 
groups, correlated with a very significant increase in the frequency of splenic CD8+ T 
cells secreting IFN-y in response to PPD before challenge (fig.3.32). This increased IFN- 
y secretion was probably dependent on the HSP65 and HSP70 antigens since stimulation 
of the cultures with recombinant Apa did not result in significant number of CD8+ T 
cells producing this cytokine (not shown). Whether this increase explains the successful 
results of protection is however a matter of speculation. Besides the excellent protection 
observed in the C57BL/6 strain, no correlation was obtained in terms of increase in
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CD8+ T cells; only IFN-y+CD4+ cells responding to Apa could be seen differentially 
increased in prime boosted groups (fig.3.33). Importantly, specific IFN-y secretion was 
not predictive of protection in most of the prime-boost experiments with C57BL/6 mice.
DNA vaccination is known to induce a Thl-type of immune response and IFN-y is 
an essential component of the anti-tuberculous response in the host; it seems logical to 
expect that high levels of this cytokine, present immediately before challenge would be a 
sign of successful protective outcome after challenge. However, the levels of this 
cytokine may fluctuate over time and only a kinetic study with a more detailed follow-up 
after vaccination and challenge would determine whether a better correlation with 
protection could be found. No correlation with protection on IFN-y secretion by either 
CD4+ or CD8+ T cells was seen in the lung of prime-boosted groups after challenge at 
the time the bacterial load was assessed (fig.3.34).
Mycobacterial leprae HSP65 plasmid DNA, one of the components of the prime- 
boost cocktail used in this study has been previously demonstrated to be effective against 
experimental tuberculosis when administered prophylatically or immunotherapeutically 
(Tascon, 1996; Lowrie, 1999). Protection associated with this antigen was critically 
associated with CD8+ T cells (Bonato, 1998; Silva, 2000). The natural infection by 
tuberculosis in the murine host indicates that CD8+ T cells would be important but only 
most critical at a later stage of infection (Turner, 2001; Turner, 2002a; Van Pinxteren, 
2001). In this context, a strong CD4+ T cell response is more important, particularly at 
the initial stages and many vaccine strategies have been developed to favour the 
induction of these responses, although none have been more effective than BCG in 
animal models (Lazarevic & Flynn, 2002). It is interesting to observe that successes in 
vaccinology have been mostly obtained stimulating a kind of “unnatural” immunity,
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where paradoxically, specific antibodies or cells are induced but are unlikely to be 
involved in the so called control/clearance of natural infections (Casadevall & Pirosfky, 
2003). As one of several examples, detailed immunological studies showing that CD4+ T 
lymphocytes are critical components of the successful host defence against both 
Blastomyces dermatitides and Hystoplasma capsulatum fungi might have predicted that 
vaccination with a live attenuated B. dermatitides strain or live H. capsulatum would be 
ineffective, considering an eventual CD4+ T cell deficiency; yet surprisingly, CD8+ T 
cells were conclusively shown to mediate protection in the absence of CD4+ T cell 
lymphocytes (Wuthrich, 2003). It would be interesting to study more deeply how highly 
potent and specific CD8+ T cell responses, induced early in animal models by 
vaccination would perform in terms of protection against tuberculosis.
In the current study, the efficacy of BCG priming and DNA boosting was 
assessed in Balb/c and C57BL/6 strains but no significant improvement in protection was 
observed. Several DNA-boosting combinations and doses have been used in this 
strategy: boosting with one dose of ApaDNA or one dose of the combination of 
mycobacterial genes Apa/HSP65/HSP70/MPT83 resulted in protection similar to BCG 
(figs.3.21 and 3.25). Furthermore, no additional improvement has been observed in 
boosting BCG with two doses of HSP65 and HSP70 plasmids (fig.3.40), in contrast with 
the significant protection seen in the reverse combination (fig.3.37). The studies above 
underline the importance of the immunisation order. Although many vector agents are 
able to prime an immune response, not all of them are effective at boosting. Priming the 
response requires induction of specific T cells, including a population that persists as 
antigen-specific memory cells, which then undergoes rapid expansion upon re-exposure 
to the same antigen in a boosting immunisation. Vector agents such as DNA plasmids,
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protein-in-adjuvant formulations, virus-like particles and lipopeptides are excellent 
priming agents but relatively ineffective boosting agents (Dunachie & Hill, 2003). 
Recombinant viruses including MVA, attenuated fowlpox viruses and non-replicating 
adenoviruses appear capable of either priming or boosting, however if used alone or in 
homologous boosting, the increase in cellular immunity is not observed; boosting BCG 
with BCG in mice resulted in no improvement in protection or immunity over a single 
BCG dose (not shown). Priming with MVA vector and boosting with DNA vaccine 
resulted in no improvement in immunogenicity or protection over MVA alone 
(Schneider, 1998). Part of the explanation for these results may be related to an 
immunodominance effect; the overall immunogenicity of a recombinant virus or bacteria 
(BCG) is substantially greater than that of a plasmid DNA vector (Dunachie & Hill, 
2003). In addition, BCG priming may activate undesirable components of the anti- 
tuberculous immunity such as Th2-responses, in contrast to a more focused response 
resulting from a plasmid DNA vaccine. Nonetheless, it is important to remember that the 
majority of the world population has received BCG vaccination at birth and therefore, is 
imperative to develop vaccination strategies able to boost efficiently BCG.
In summary, I have demonstrated that: (1) the mycobacterial apa gene is up- 
regulated during M. tuberculosis infection in the host cell and can be used effectively as a 
component of a plasmid combination vaccine cocktail that was able to induce significant 
protective responses against murine tuberculosis, despite its inability to stimulate IFN-y- 
secreting CD8+ T cells in ApaDNA-vaccinated mice. (2) This DNA-prime BCG-boost 
approach induced statistically better protection than BCG against M. tuberculosis 
infection in mice. In addition (3), I demonstrated the importance of the nature of the 
components of the priming vaccine cocktail and also, the order of vaccination, to the
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successful outcome of immunisation. As the primary route of infection in humans is the 
pulmonary route, further testing using a more relevant aerosol model of M. tuberculosis 
challenge would be of great value.
CD8+ T cells are very likely involved in this high improvement in BCG 
protection, although a more clearly defined answer would be provided by the isolation of 
CD8+ T cell clones from prime-boosted animals as well as testing the prime boosting 
protocol in animals devoid of CD8+ T cell populations (Feng, 2001). Also, it would be 
interesting to employ this effective prime-boost model of protection in search for more 
reliable correlates of protection against TB in mice.
Recently, some reports on potential autoimmune reactions in rodents due to 
vaccination with M. leprae HSP65 DNA have been published in the literature (Turner, 
2000; Taylor, 2003). Despite the fact that, in a decade of research and vaccine testing in 
our laboratory at the NIMR and others around the world, there have not been reports of 
any deleterious reaction with the use of the HSP65 and HSP70 plasmid DNA vaccine in 
mice, it is important that a study investigating these important questions in more detail 
could be carried in animal models before HSP-vaccines could advance for clinical 
testing. Evaluation of alternative antigen combinations may also be carried out 
concomitantly.
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